(2s,5r)-5-(hydroxymethyl)morpholine-2-carboxamides as agonists of somatostatin receptor 4
Novel compounds with specific structural modifications address the issue of selectivity and efficacy in targeting somatostatin receptor 4, improving therapeutic outcomes by enhancing binding and reducing off-target effects.
Patent Information
- Application Number
- SA1120260972
- Authority / Receiving Office
- SA · SA
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2026-02-02
- Publication Date
- 2026-10-06
AI Technical Summary
Current pharmaceutical compounds targeting somatostatin receptor 4 (SSTR4) lack selectivity and efficacy, leading to off-target effects and reduced therapeutic potential.
Development of novel compounds with specific structural modifications, such as those described by formula (I), which enhance binding affinity and selectivity for SSTR4, reducing off-target interactions.
The modified compounds demonstrate improved binding to SSTR4 with reduced affinity for other somatostatin receptors, enhancing therapeutic efficacy and specificity.
Smart Images

Figure 50196A98-1FF7-42D6-A4F8-A27B779B9DDA 
Figure CA93FB16-6CCF-4E24-BFB4-74F46CDEED81
Abstract
Description
Expressions and definitions used General Definitions Undefined expressions in this document should be given the meanings that can be given by someone skilled in the field, in light of the disclosure and context. As used in the specification, however, unless otherwise specified, the following expressions shall have the meaning indicated and shall adhere to the following conventions. In the groups, cleavages, or segments identified below, the number of carbon atoms is usually specified before the group; for example, C1-6-alkyl means an alkyl group or cleavage with 1 to 6 carbon atoms. Generally, in groups like HO, H2N, (O)S, (O)2S, NC (cyano), HOOC, F3C, or similar, a skilled practitioner can identify the radical attachment point(s) to the molecule from the free valence of the group itself. For grouped groups containing two or more subgroups, the subgroup named later is the radical attachment point; for example, the substitution group "aryl-C1-3-alkylene" refers to the aryl group to which the C1-3-alkyl group is attached, and the latter is attached to the nucleus or the group to which the substitution group is attached. If a "-" is explicitly indicated at any end of the substitution group, the point of partial bonding to the molecule is at the (sub)group to which the "-" is immediately adjacent, and the "-" indicates the chemical bond between the (sub)group and the rest of the molecule. If the compound of the present invention is represented by its chemical name and its formula, in case of any discrepancy, the formula shall prevail. A waveform may be used in subforms to indicate the bond attached to the main molecule as specified. For example, the expression "3-carboxypropyl group" represents the following substitution group: The carboxy group on the third carbon atom is bonded to the propyl group. The expressions "1-methylpropyl-", "2,2-dimethylpropyl-", or "cyclopropylmethyl-" represent the following groups: The waveform can be used in subforms to indicate the bond that connects to the nucleus molecule as defined. The expression is replaced by The expression "with substitution," as used in this document, indicates that one or more hydrogen atoms on a given atom are replaced by a selected substitution group from a defined set, provided that the valence of the given atom is not exceeded and that the substitution results in a stable compound. Similarly, the expression "with substitution" can be used in conjunction with a chemical component rather than a single atom, for example, "alkyl with substitution," "aryl with substitution," or the like. The expression "can be substituted using" is used interchangeably with "with selective substitution using." Stereochemistry – Solvates – Hydrates Unless specifically stated, throughout the description and attached protective elements, a given chemical formula or name includes rotamers, tautomers, stereoisomers, optical isomers, geometric isomers (for example, enantiomers, diastereomers, E / ZE / Z isomers, etc.), racemic compounds thereof, as well as mixtures of different proportions of discrete isomers, mixtures of diastereomers, or mixtures of any of the above forms in which these isomers and isomers exist, as well as solutes thereof, such as, for example, hydrates. Unless otherwise indicated, "pharmaceuticalally acceptable salts," as defined in greater detail below, should include their solubility, such as, for example, hydrates. Compounds containing two chiral centers can exist in both isomer and diploid forms. The relative and absolute design of these compounds is often essential for their biological activity and pharmacological properties. When a compound has two chiral centers, this can lead to an increase to four available stereoisomers: two pairs of isomers, each pair consisting of two diploids. Isomers are inverted, non-superimposable images of each other, while stereoisomers are inverted stereoisomers. Pure isomers and diploids exhibit distinct three-dimensional structures, which contribute to their unique pharmacological characteristics. The stereochemistry of chiral compounds can be represented using the Cahn-Ingold-Prelog (CIP) system, where the absolute design of each chiral center is characterized by either R or S. Bi-chiral isomers can be characterized by their opposite designs at both chiral centers, while duplicates have different designs at one chiral center and the same design at the other. In general, high-purity isomers can be obtained according to the principles of synthesis known to a skilled person in the field, for example by chiral analysis of racemic mixtures into their independent isomers, which can be accessed using methods such as the formation of a diastereomeric salt of the racemic compound using optically active acids or optically active bases, the subsequent analysis of the salts and release of the desired compound from the salt, enzymatic resolution, or chiral auxiliary-based resolution.Furthermore, it is known to a skilled practitioner that high-purity isomers can also be obtained by asymmetric synthesis, which involves the direct synthesis of isomorphically pure compounds using chiral catalysts, chiral auxiliaries, chiral pool starting materials, or by the preparation and subsequent separation of suitable isomer molecules that can be separated by known methods (e.g., chromatographic separation or crystallization). Moreover, it is known to a skilled practitioner that high-purity isomers can be obtained by chromatographic separation, for example, using chiral stationary phases, chiral mobile phases, or chiral mobile phase additives. In general, high-purity diastereoselective synthesis can be obtained using one or a combination of several methods known to a skilled person in the field, such as diastereoselective synthesis (e.g., using chiral auxiliaries, chiral catalysts, or chiral reagents), selective crystallization, chromatographic techniques, e.g., column chromatography, high-performance liquid chromatography (HPLC), supercritical fluid chromatography (SFC), or gas chromatography, enzymatic analysis, or derivatization. salts The term "pharmaceuticalally acceptable" is used here to refer to those compounds, substances, formulations, and / or dosage forms which, within the scope of prudent medical judgment, are appropriate for use in contact with human tissues without excessive toxicity, irritation, allergic response, or other problems or complications, and in proportion to a reasonable benefit / risk ratio. As used in this document, "pharmaceuticalally acceptable salt" refers to derivatives of identified compounds where the original compound is modified by the preparation of acid or base salts. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral acid salts or organic acid salts from basic residues such as amines; alkali salts or organic salts from acidic residues such as carboxylic acids; and the like. For example, these salts include salts of benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gentisic acid, hydrobromic acid, hydrochloric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, 4-methyl-benzenesulfonic acid, phosphoric acid, salicylic acid, succinic acid, sulfuric acid, and tartaric acid. Additional pharmaceutically acceptable salts may be formed using cations of ammonia, L-arginine, calcium, 2,2'-iminobisethanol, L-lysine, magnesium, N-methyl-D-glucamine, potassium, sodium and tris(hydroxymethyl)-aminomethane. The pharmaceutically acceptable salts of the present invention may be synthesized from an original compound containing a basic or acidic moiety by conventional chemical methods. Generally, such salts may be prepared by reacting the free acid or base forms of these compounds with a sufficient quantity of a suitable acid or base in water or in an organic diluent such as ether, ethyl acetate (EA), ethanol (EtOH), isopropanol (IPA), acetonitrile (ACN), or a mixture thereof. Salts of acids other than those mentioned above that are useful, for example, for purifying or separating the compounds of the present invention (for example, trifluoroacetate salts) also comprise a part of the invention. halogen The term halogen refers to fluorine, chlorine, brommine and iodine. alkyl The expression "C1-n-alkyl," where n is a selected integer from 2, 3, 4, 5 or 6, preferably 4, 5, or 6, either alone or in combination with another moiety, refers to a hyphenated, saturated, branched or linear hydrocarbon radical with 1 to n C atoms. For example, the expression C1-5-alkyl includes the moieties H3C-, H3C-CH2-CH2-CH2-, H3C-CH(CH3)-, H3C-CH2-CH2-CH2-, H3C-CH2-CH2-CH(CH3)-, H3C-CH2-CH(CH3)-CH2-, H3C-CH2-CH(CH3)-CH2- H3C-CH(CH3)-CH2-CH2-, H3C-CH2-C(CH3)2-, H3C-C(CH3)2-CH2-, H3C-CH(CH3)-CH(CH3)- and H3C-CH2-CH(CH2CH3)-. Alkylene The expression "C1-n-alkyl", where n is a selected integer from 2, 3, 4, 5 or 6, preferably 4, 5 or 6, either alone or in combination with another radical, refers to a saturated, bivalent, bicyclic, branched or linear, divalent alkyl radical containing 1 to n carbon atoms. For example, the expression C1-4-alkyne includes -CH2-, -CH2-CH2-, -CH(CH3)-, -CH2-CH2-CH2-, -C(CH3)2-, -CH(CH2CH3)-, -CH(CH3)-CH2-, -CH2-CH(CH3)-, -CH2-CH2-CH2-CH2-, -CH2-CH2-CH(CH3)-, -CH(CH3)-CH2-CH2-, -CH2-CH(CH3)-CH2-, -CH2-C(CH3)2-, -C(CH3)2-CH2-, -CH(CH3)-CH(CH3)-, -CH2-CH(CH2CH3)-CH2-, -CH(CH2CH2CH3)-, -CH(CH(CH3))2- and -C(CH3)(CH2CH3)-. Alkenyl The expression "C2-m-alkenel" is used for the group "C2-m-alkyl" where m is a selected integer from 3, 4, 5 or 6, preferably 4, 5 or 6, if at least two carbon atoms from a given group are bonded together by a double bond. Alkenylene The expression "C2-m-alkenylne" is used for the group "C2-m-alkene", where m is a selected integer from 3, 4, 5 or 6, preferably 4, 5 or 6, if at least two carbon atoms from a given group are bonded together by a double bond. Alkynyl The expression "C2-m-alkenyl" is used for the "C2-m-alkyl" group, where m is a selected integer from 3, 4, 5 or 6, preferably 4, 5 or 6, if at least two carbon atoms from a given group are bonded together by a triple bond. Alkineln The expression "C2-m-alkynelen" is used for the group "C2-m-alkyne" where m is a selected integer from 3, 4, 5 or 6, preferably 4, 5 or 6, if at least two of these carbon atoms of the group are bonded together by a triple bond. cycloalkyl The expression "C3-k-cycloalkyl", where k is a selected integer from 3, 4, 5, 7 or 8, preferably 4, 5 or 6, either alone or in combination with another moiety, refers to a cyclic, saturated, unbranched hydrocarbon moiety with 3 to k C atoms. For example, the expression C3-7-cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Halo-(alkyl, alkyl or cycloalkyl) The term "halo" added to the group "alkyl," "alkyne," or "cycloalkyl" (saturated or unsaturated) refers to an alkyl, alkyl, or cycloalkyl group in which one or more hydrogen atoms are replaced by a halogen atom chosen from among fluorine, chlorine, or bromine, preferably fluorine and chlorine, and specifically fluorine. Examples include F3C-, H2FC-, and HF2C. Crabocyclyl The term "carboxylate," as used alone or in combination with another molecule, refers to a single-, double-, or triple-ring cyclic structure consisting of 3 to 14 carbon atoms. The term "carboxylate" encompasses fully saturated, partially saturated, and aromatic cyclic systems. It also includes compact, bridging, and spirocyclic systems. heterocyclic aryl The term "heterocyclyl" refers to a monocyclic or polycyclic ring system containing at least one aromatic ring with one or more selected heteroatoms of nitrogen (N), oxygen (O), sulfur (S), SO₂, or SO₂, consisting of 3 to 14 atoms in the ring, where no heteroatom is part of the aromatic ring. The terms "heterocyclyl" or "heterocyclic ring" are intended to encompass all available isomer forms. Therefore, the expression "heterocyclic" or "heterocyclic ring" includes the following typical structures (not pictured as cleavages of each image that are linked by a covalent bond to any atom as long as they preserve the appropriate valence degrees): ﻻ Many of the expressions provided above can be used repeatedly in defining a formula or set, and in each case, they have one of the definitions provided above, independently of each other. The term "dual-ring ring systems" refers to groups consisting of two connected ring structures that include spirocyclic, fused, and bridged ring systems. Favorite incarnations In another embodiment, the invention relates to compounds of formula (I) where the stereocenter is at position 2 of the morpholine in design (S) and where the stereocenter is at position 5 of the morpholine in design (R). In another embodiment, the invention relates to compounds of formula (I) where R5 and R6 together with the carbon atom to which they are attached form C3-6-cycloalkyl; and where A is a phenyl ring, which may be substituted using 1 to 3 substitution groups, chosen independently from among a group consisting of -halogen, -CF3, -C1-4-alkyl, -C3-6-cycloalkyl, -C2-4-alkenyl and -O-C1-4-alkyl; or a salt thereof. In another embodiment, the invention relates to compounds of formula (I) where R5 and R6 together with the carbon atom to which they are attached form C3-6-cycloalkyl; and where A is a phenyl ring, which may be substituted by 1 to 3 substitution groups, chosen independently from a group consisting of -halogen, -CF3, -C1-4-alkyl, -C3-6-cycloalkyl, -C2-4-alkenyl and -O-C1-4-alkyl; and where the skew center is at position 2 of morpholine in design (S) and where the skew center is at position 5 of morpholine in design (R); or a salt thereof. In another embodiment, the invention relates to compounds of formula (I) where R5 and R6 together with the carbon atom to which they are attached form a C3-6-cycloalkyl; and where A is a heterocyclic aryl with 6-10 atoms, which may be substituted using 1 to 3 substitution groups, chosen independently from among a group consisting of -halogen, -CF3, -C1-4-alkyl, and -O-C1-4-alkyl; or a salt thereof. In another embodiment, the invention relates to compounds of formula (I) where R5 and R6 together with the carbon atom to which they are attached form a C3-6-cycloalkyl; where A is a heterocyclic aryl with 6-10 atoms, where it may be substituted using 1 to 3 substitution groups, chosen independently from a group consisting of -halogen, -CF3, -C1-4-alkyl, and -O-C1-4-alkyl; where the steric center is at position 2 of morpholine in design (S) and where the steric center is at position 5 of morpholine in design (R); or a salt thereof. In another embodiment, the invention relates to compounds of formula (I) where R5 is methyl; R6 is C1-4-alkyl or C3-6-cycloalkyl; and A is a phenyl ring, which may be substituted using 1 to 3 substitution groups, chosen independently from a group consisting of -halogen, -CF3, -C1-4-alkyl, -C3-6-cycloalkyl, -C2-4-alkenyl and -O-C1-4-alkyl; or a salt thereof. In another embodiment, the invention relates to compounds of formula (I) where R5 is a methyl; R6 is a C1-4-alkyl or C3-6-cycloalkyl; and A is a phenyl ring, which may be substituted by 1 to 3 substitution groups, chosen independently from a group consisting of -halogen, -CF3, -C1-4-alkyl, -C3-6-cycloalkyl, -C2-4-alkenyl and -O-C1-4-alkyl; and where the steric center at position 2 is morpholine in design (S) and where the steric center at position 5 is morpholine in design (R); or a salt thereof. In another embodiment, the invention relates to compounds of formula (I) where R5 is a methyl; R6 is a C1-4-alkyl or C3-6-cycloalkyl; and A is a heterocyclic aryl with 6-10 atoms, which may be substituted using 1 to 3 substitution groups, chosen independently from a group consisting of -halogen, -CF3, -C1-4-alkyl, and -O-C1-4-alkyl; or a salt thereof. In another embodiment, the invention relates to compounds of formula (I) where R5 is a methyl; R6 is a C1-4-alkyl or C3-6-cycloalkyl; and A is a heterocyclic aryl with 6-10 atoms, which may be substituted using 1 to 3 substitution groups, chosen independently from a group consisting of -halogen, -CF3, -C1-4-alkyl, and -O-C1-4-alkyl; and where the steric center is at position 2 with morpholine in design (S) and where the steric center is at position 5 with morpholine in design (R); or a salt thereof. In another embodiment, the invention relates to compounds of formula (I) where R5 and R6 are methyl; and where A is a phenyl ring, which may be substituted using 1 to 3 substitution groups, chosen independently from a group consisting of -halogen, -CF3, -C1-4-alkyl, -C3-6-cycloalkyl, -C2-4-alkenyl and -O-C1-4-alkyl; or a salt thereof. In another embodiment, the invention relates to compounds of formula (I) where R5 and R6 are methyl; and where A is a phenyl ring, which may be substituted using 1 to 3 substitution groups, chosen independently from a group consisting of -halogen, -CF3, -C1-4-alkyl, -C3-6-cycloalkyl, -C2-4-alkenyl and -O-C1-4-alkyl; where the steric center at position 2 is morpholine in design (S) and where the steric center at position 5 is morpholine in design (R); or a salt thereof. In another embodiment, the invention relates to compounds of formula (I) where R5 and R6 are methyl; and where A is a heterocyclic aryl with 6-10 atoms, which may be substituted using 1 to 3 substitution groups, chosen independently from a group consisting of -halogen, -CF3, -C1-4-alkyl, and -O-C1-4-alkyl; or a salt thereof. In another embodiment, the invention relates to compounds of formula (I) where R5 and R6 are methyl; and where A is a heterocyclic aryl with 6-10 atoms, which may be substituted using 1 to 3 substitution groups, chosen independently from a group consisting of -halogen, -CF3, -C1-4-alkyl, and -O-C1-4-alkyl; where the steric center is at position 2 with morpholine in design (S) and where the steric center is at position 5 with morpholine in design (R); or a salt thereof. In another embodiment, the invention relates to compounds of formula (Ia) where R1 is chosen from a group consisting of -H, -F, -Cl, -Br, -CF3, -C1-4-alkyl, -C3-6-cycloalkyl and -O-C1-4-alkyl; where R2 is chosen from a group consisting of -H, -F, -Cl, -Br, and -C1-4-alkyl; where R3 is chosen from a group consisting of -H, -F, -Cl, -Br, -C1-4-alkyl, -C3-6-cycloalkyl and -C2-4-alkenyl; where R4 is chosen from a group consisting of -H, -F, -Cl, -Br, and -C1-4-alkyl; where R5 is a methyl; and where R6 is a methyl; or a salt thereof. In another embodiment, the invention relates to compounds of formula (Ia) where R1 is chosen from a group consisting of -H, -F, -Cl, -Br, -CF3, -C1-4-alkyl, -C3-6-cycloalkyl and -O-C1-4-alkyl; where R2 is chosen from a group consisting of -H, -F, -Cl, -Br, and -C1-4-alkyl; where R3 is chosen from a group consisting of -H, -F, -Cl, -Br, -C1-4-alkyl, -C3-6-cycloalkyl and -C2-4-alkenyl; where R4 is chosen from a group consisting of -H, -F, -Cl, -Br, and -C1-4-alkyl; where R5 is a methyl; and where R6 is a methyl. Where the spatial center is at position 2 with morpholine in design (S) and where the spatial center is at position 5 with morpholine in design (R); or a salt thereof. In another embodiment, the invention relates to compounds of formula (Ia) where R1 is chosen from a group consisting of -H, -halogen, -CF3, -C1-2-alk yl, cyclopropyl, and -O-C1-2-alkyl; where R2 is chosen from a group consisting of -H, -halogen and -C1-2-alkyl; where R3 is chosen from a group consisting of -H, -halogen, -C1-2-alkyl, cyclopropyl and C2-4-alkenyl; where R4 is chosen from a group consisting of -H, -halogen and methyl; where R5 is methyl; where R6 is methyl; or a salt thereof. In another embodiment, the invention relates to compounds of formula (Ia) where R1 is chosen from a group consisting of -H, -halogen, -CF3, -C1-2-alkyl, cyclopropyl, and -O-C1-2-alkyl; where R2 is chosen from a group consisting of -H, -halogen, and -C1-2-alkyl; where R3 is chosen from a group consisting of -H, -halogen, -C1-2-alkyl, cyclopropyl, and C2-4-alkenyl; where R4 is chosen from a group consisting of -H, -halogen, and methyl; where R5 is methyl; where R6 is methyl; where the steric center is at position 2 of morpholine in design (S), and where the steric center is at position 5 of morpholine in design (R); or a salt thereof. In another embodiment, the invention relates to compounds of formula (Ia) where R1 is chosen from a group consisting of -H, -F, -Cl, -Br, -CF3, -C1-2-alkyl, cyclopropyl, and -O-C1-2-alkyl; where R2 is chosen from a group consisting of -H, -F, -Cl, -Br, and -C1-2-alkyl; where R3 is chosen from a group consisting of -H, -F, -Cl, -Br, -C1-2-alkyl, cyclopropyl, and C2-4-alkenyl; where R4 is chosen from a group consisting of -H, -F, -Cl, -Br, and methyl; where R5 is a methyl; and where R6 is a methyl; or a salt thereof. In another embodiment, the invention relates to compounds of formula (Ia) where R1 is chosen from a group consisting of -H, -F, -Cl, -Br, -CF3, -C1-2-alkyl, cyclopropyl and -O-C1-2-alkyl; where R2 is chosen from a group consisting of -H, -F, -Cl, -Br, and -C1-2-alkyl; where R3 is chosen from a group consisting of -H, -F, -Cl, -Br, -C1-2-alkyl, cyclopropyl and C2-4-alkenyl; where R4 is chosen from a group consisting of -H, -F, -Cl, -Br, and methyl; where R5 is methyl; where R6 is methyl and where the steric center is at position 2 of morpholine in design (S) and where the steric center is at position 5 of morpholine in design (R); Or salt from it. In another embodiment, the invention relates to compounds of formula (I) where A is chosen from a set consisting of , , , and, each where it can be substituted using 1 to 3 substitution groups, chosen independently from a set consisting of -halogen, -CF3, -C1-4-alkyl, and -O-C1-4-alkyl; where R5 is methyl; and where R6 is C1-4-alkyl or C3-6-cycloalkyl; or a salt thereof. In another embodiment, the invention relates to compounds of formula (I) where A is chosen from a set consisting of , , , and, each where it can be substituted using 1 to 3 substitution groups, independently chosen from a set consisting of -halogen, -CF3, -C1-4-alkyl, and -O-C1-4-alkyl; where R5 is methyl; where R6 is C1-4-alkyl or C3-6-cycloalkyl; where the steric center is at position 2 of morpholine in design (S) and where the steric center is at position 5 of morpholine in design (R); or a salt thereof. In another embodiment, the invention relates to compounds of formula (I) where A is chosen from a set consisting of , , , and Each can be replaced using 1 to 3 substitution groups, independently selected from a group consisting of -halogen, -CF3, -C1-4-alkyl, and -O-C1-4-alkyl; where R5 and R6 together with the carbon atom to which they are bonded form C3-6-cycloalkyl; or a salt thereof. In another embodiment, the invention relates to compounds of formula (I) where A is chosen from a set consisting of , , , and; Where each can be substituted using 1 to 3 substitution groups, independently selected from a group consisting of -halogen, -CF3, -C1-4-alkyl, and -O-C1-4-alkyl; where R5 and R6 together with the carbon atom to which they are bonded form C3-6-cycloalkyl; where the skew center is at position 2 of the morpholine in design (S) and where the skew center is at position 5 of the morpholine in design (R); or a salt thereof. In another embodiment, the invention relates to compounds of formula (I) where A is chosen from a set consisting of , , , and; Where each can be substituted using 1 to 3 substitution groups, independently chosen from a set consisting of -halogen, -CF3, -C1-4-alkyl; where R5 is methyl; where R6 is methyl; or a salt thereof. In another embodiment, the invention relates to compounds of formula (I) where A is chosen from a set consisting of , , , and; Where it can have substitutions using 1 to 3 substitution groups, independently selected from a set consisting of -halogen, -CF3, -C1-4-alkyl; where R5 is methyl; where R6 is methyl; where the steric center is at position 2 with morpholine in design (S) and where the steric center is at position 5 with morpholine in design (R); or a salt thereof. In another embodiment, the invention relates to compounds of formula (I). Where A is chosen from a group consisting of , , , and; Where R1 is chosen from a group consisting of -H, -halogen, -CF3, -C1-4-alkyl, and -O-C1-4-alkyl; where R2, R3, R4, R7, R8 and R9 are chosen independently from a group consisting of -H, -halogen and -C1-4-alkyl; where R10 is -H or -C1-4-alkyl; where R5 is methyl; and where R6 is a methyl or a salt thereof. In another embodiment, the invention relates to compounds of formula (I) where A is chosen from a set , Axon{d1f26795-1d47-48fa-b828-ca1b9430f35f} Renderer|Marvin 21.15.8.115" / >, , and; Where R1 is chosen from a group consisting of -H, -halogen, -CF3, -C1-4-alkyl, and -O-C1-4-alkyl; where R2, R3, R4, R7, R8 and R9 are chosen independently from a group consisting of -H, -halogen and -C1-4-alkyl; where R10 is -H or -C1-4-alkyl; where R5 is methyl; where R6 is methyl; where the steric center is at position 2 of morpholine in design (S) and where the steric center is at position 5 of morpholine in design (R); or a salt thereof. In another embodiment, the invention relates to compounds of formula (I) where A is chosen from a set , , and; Where R1 is chosen from a group consisting of -H, -halogen, -CF3, -C1-4-alkyl, and -O-C1-4-alkyl; where R2, R3, R4, R7, R8 and R9 are chosen independently from a group consisting of -H, -halogen and -C1-4-alkyl; where R5 is a methyl; and where R6 is a methyl; or a salt thereof. In another embodiment, the invention relates to compounds of formula (I) where A is chosen from a set , , and; Where R1 is chosen from a group consisting of -H, -halogen, -CF3, -C1-4-alkyl, and -O-C1-4-alkyl; where R2, R3, R4, R7, R8 and R9 are chosen independently from a group consisting of -H, -halogen and -C1-4-alkyl; where R5 is a methyl; where R6 is a methyl; where the steric center is at position 2 of morpholine in design (S) and where the steric center is at position 5 of morpholine in design (R); or a salt thereof. In another embodiment, the invention relates to compounds of form (I), where A is; and Where R7, R8 and R9 are independently selected from a group consisting of -H, -halogen and -C1-4-alkyl; where R10 is -H; where R5 is methyl; and where R6 is methyl; or a salt thereof. In another embodiment, the invention relates to compounds of form (I), where A is; and Where R7, R8 and R9 are independently selected from a group consisting of -H, -halogen and -C1-4-alkyl; where R10 is -H; where R5 is methyl; where R6 is methyl; where the steric center is at position 2 of morpholine in design (S) and where the steric center is at position 5 of morpholine in design (R); or a salt thereof. In another embodiment, the invention relates to compounds of formula (I) where A is chosen from a set , , , and; Where R1 is chosen from a group consisting of -H, -F, -Cl, -Br, -CF3, -C1-4-alkyl, and -O-C1-4-alkyl; where R2, R3, R4, R7, R8 and R9 are chosen independently from a group consisting of -H, -F, -Cl, -Br and -C1-4-alkyl; where R10 is -C1-4-alkyl; where R5 is methyl; where R6 is methyl; or a salt thereof. In another embodiment, the invention relates to compounds of formula (I) where A is chosen from a set , , , and; Where R1 is chosen from a group consisting of -H, -F, -Cl, -Br, -CF3, -C1-4-alkyl, and -O-C1-4-alkyl; where R2, R3, R4, R7, R8 and R9 are chosen independently from a group consisting of -H, -F, -Cl, -Br and -C1-4-alkyl; where R10 is -C1-4-alkyl; where R5 is methyl; where R6 is methyl; where the steric center is at position 2 of morpholine in design (S) and where the steric center is at position 5 of morpholine in design (R); or a salt thereof. In another embodiment, the invention relates to compounds of formula (I) where A is chosen from a set , , and; Where R1 is chosen from a group consisting of -H, -F, -Cl, -Br, -CF3, -C1-4-alkyl, and -O-C1-4-alkyl; where R2, R3, R4, R7, R8 and R9 are chosen independently from a group consisting of -H, -F, -Cl, -Br and -C1-4-alkyl; where R5 is a methyl; and where R6 is a methyl; or a salt thereof. In another embodiment, the invention relates to compounds of formula (I) where A is chosen from a set , , and; Where R1 is chosen from a group consisting of -H, -F, -Cl, -Br, -CF3, -C1-4-alkyl, and -O-C1-4-alkyl; where R2, R3, R4, R7, R8 and R9 are chosen independently from a group consisting of -H, -F, -Cl, -Br and -C1-4-alkyl; where R5 is a methyl; where R6 is a methyl; where the steric center is at position 2 of the morpholine in design (S) and where the steric center is at position 5 of the morpholine in design (R); or a salt thereof. In another embodiment, the invention relates to compounds of form (I), where A is; and Where R7, R8 and R9 are independently selected from a group consisting of -H, -F, -Cl, -Br and -C1-4-alkyl; where R10 is -H; where R5 is methyl; and where R6 is methyl; or a salt thereof. In another embodiment, the invention relates to compounds of form (I), where A is; and Where R7, R8, and R9 are independently selected from a group consisting of -H, -F, -Cl, -Br, and -C1-4-alkyl groups; where R10 is -H; where R5 is methyl; where R6 is methyl; where the steric center is at position 2 of the morpholine in design (S) and where the steric center is at position 5 of the morpholine in design (R) ="ar-SA">); or salt from it. In another embodiment, the invention relates to compounds of formula (Ia) where R1 is chosen from a group consisting of -H, -halogen, -CF3, -C1-4-alkyl, -C3-6-cycloalkyl and -O-C1-4-alkyl; where R2 is chosen from a group consisting of -H, -halogen and -C1-4-alkyl; where R3 is chosen from a group consisting of -H, -halogen, -C1-4-alkyl, -C3-6-cycloalkyl and C2-4-alkenyl; where R4 is chosen from a group consisting of -H, -halogen and -C1-4-alkyl; where R5 and R6 together with the carbon atom to which they are bonded form a cyclopropyl; or a salt thereof. In another embodiment, the invention relates to compounds of formula (Ia) where R1 is chosen from a group consisting of -H, -halogen, -CF3, -C1-4-alkyl, -C3-6-cycloalkyl and -O-C1-4-alkyl; where R2 is chosen from a group consisting of -H, -halogen and -C1-4-alkyl; where R3 is chosen from a group consisting of -H, -halogen, -C1-4-alkyl, -C3-6-cycloalkyl and C2-4-alkenyl; where R4 is chosen from a group consisting of -H, -halogen and -C1-4-alkyl; where R5 and R6 together with the carbon atom to which they are bonded form a cyclopropyl; or a salt thereof; Where the spatial center is at position 2 with morpholine in design (S) and where the spatial center is at position 5 with morpholine in design (R); or a salt thereof. In another embodiment, the invention relates to selected compounds from a group consisting of , , , , , , , , , , , , , , and; Or a salt that is pharmaceutically acceptable from it. In another embodiment, the invention relates to selected compounds from a group consisting of , , , , and ; Or a salt that is pharmaceutically acceptable from it. Biological experiments Abbreviations: AUC Area under the curve BSA Bovine Serum Albumin cAMP adenosine monophosphate CHO Chinese Hamster Egg CL Disposal CTL Sample Comparison DMEM Dulbecco's Modified Eagle's Medium DMSO Dimethyl Sulfoxide EC50 Test compound concentration means half of the maximum response EDTA (ethylenediaminetetraacetic acid) FC Ultimate Focus FCS calf fetal serum HBSS Hanks Balanced Salt Solution HEPES hydroxyethyl-piperazine ethane-sulfonic acid HPLC (High-Efficiency Liquid Chromatography) HPLC-MS / MS High-performance liquid chromatography with tandem mass spectrometry IBMX 3-Isobutyl-1-methylxanthine MDCK Madin-Darby Animal College MDR1 is a multidrug-resistant protein. P-gp P-glycoprotein PBS is a phosphate buffered solution QH Hepatic blood flow An experiment to determine the binding to the somatostatin receptor 4 Describe the method for performing binding assays with human somatostatin receptors using Chinese hamster ovary (CHO) cell membranes expressing recombinant human somatostatin receptor 4: In competition experiments, unlabeled test compounds compete with the radiolabeled binding molecule for binding to the target receptor. Displacement of the labeled binding molecule by the test compound results in a decrease in signal strength. Procedure: For the binding experiments, 200 microliters of membrane homogenate components of one of the following protein quantities were used: human somatostatin receptor 4 (0.5 picograms / eye). The homogeneous components were incubated with 0.05 nM of a radioactive binding molecule ([3-125I-Tyr]-somatostatin-14)) in addition to increasing the concentrations of the test compound or carrier (100% binding) to a total volume of 250 μL using a buffer solution of hydroxyethyl-piperazineethane-sulfonic acid (HEPES) (10 mM), ethylenediaminetetraacetic acid (EDTA) (1 mM), magnesium chloride (MgCl2) (5 mM), pH 7.6, bovine serum albumin (BSA) (0.5%) and dimethyl sulfoxide (DMSO) (1%) for 180 mins at room temperature. Incubation was stopped by filtering the membrane suspension through GF / C glass fiber filters, which had been pretreated with polyethyleneimine (0.3% dissolved in 0.9% saline solution was used in a cell harvester, followed by four washes using 250 μL of 0.9% buffered saline. To interpret the nonspecific binding of the ligand, the radioactive ligand was assessed in the presence of a substantial excess (1 μM) of unlabeled somatostatin-14 during the incubation period. Protein-bound radioactivity was measured using a Top Count radioactivity meter. Binding concentration curves were analyzed using computer-aided nonlinear curve matching, employing a single-receptor binding site model. An experiment to determine selectivity against somatostatin receptor 1, somatostatin receptor 2, somatostatin receptor 3 and somatostatin receptor 5 Selectivity data are obtained using radioligand binding assays, as described above, with membrane preparations from recombinant cell lines expressing the relevant somatostatin receptors. Briefly, recombinant cells overexpressing human somatostatin receptor 1, 2, 3, or 5 are incubated with varying concentrations of the experimental compound in the presence of radiolabeled 125I Tyr11-somatostatin-14 for different time periods at 25°C. After the incubation period, washing steps are performed, and the amount of remaining radiolabeled binding molecule is determined. Based on the amount of remaining radiolabeled binding molecule, the inhibition constants (Ki) of the experimental compound against somatostatin receptor 1, 2, 3, and 5 are determined. The trials are: 282510 (Somastatin sst1), 282700 (Somastatin sst2), 282530 (Somastatin sst3) and 283010 (Somastatin sst5) (Eurofins Panlabs Discovery Services). The compounds, according to the invention, bind to the somatostatin 4 receptor and are selective against somatostatin 1, 2, 3, and 5 receptors in the experiments described in this document above. Cellular experiment to determine the stimulatory activity on the somatostatin 4 receptor (test compound concentration means half of the maximum response) (cyclic adenosine monophosphate experiment) Activation of the somatostatin 4 (Gi-conjugated) receptor leads to inhibition of intracellular cyclic adenosine monophosphate (cAMP) following stimulation with forskolin, and this can be quantified using a suitable assay kit and instrument. Reading appropriate panels. This technique is used to characterize the pharmacological effects of somatostatin 4 receptor agonists using human H4H4 cells expressing somatostatin 4 receptors. Material for cell culture: Cell culture medium: Dulbecco's Modified Eagle's Medium (DMEM), high glucose, GlutaMAX™ Fetal calf serum (FCS): Heat inactivated Antibiotics: Hygromycin B Washing buffer solution: Phosphate buffered saline (PBS) solution, without calcium chloride (CaCl2) and magnesium chloride. Separation reagent: Versene freezing medium: Recovery cell culture freezing medium Cryo Tubes: Nunc CryTubes 1.8 ml Additional material: The LANCE Ultra cAMP 50,000-test-point detection kit was purchased from PerkinElmer. The stimulant is Sigma SST14 somatostatin, in addition to Forskolin. The 384-cell white microplate is Greiner. The 10-fold HanksHanks balanced salt solution (HBSS) is from Invitrogen, in addition to a 1 M hydroxyethylpiperazine ethanesulfonic acid solution. The 3-isobutyl-1-methylxanthine (IBMX) is from Sigma, and the BSA stabilizer is from PerkinElmer. The buffer solution for the experiment was prepared as follows: A 10-fold Hanks equilibrium salt solution and 1 mM hydroxyethyl-piperazine ethane-sulfonic acid solution were diluted to a final concentration of 1-fold Hanks equilibrium salt solution and 5 mM hydroxyethyl-piperazine ethane-sulfonic acid in distilled water; 0.1% bovine serum albumin and 3-isobutyl-1-methylxanthine (0.5 mM final concentration) were added and adjusted to a pH of 7.4 using sodium hydroxide (NaOH). Method: H4-somatostatin 4 receptor cells were cultured in Dulbecco+GlutaMAX™ modified Eagle medium supplemented with 10% calf fetal serum and 250 micrograms / ml hygromycin B. Cells were divided 1:8 twice a week by washing twice with a phosphate-buffered buffer (minus calcium chloride / magnesium chloride) and separating by adding Versene for 5–10 minutes. Cells were only divided when they reached at least 80% cohesion. When preparing frozen stocks, cells were washed and separated as described above, then centrifuged at 160 × g for 5 minutes and resuspended in freezing medium. The cells were then counted and adjusted to 3 × 10⁶ cells / ml. One milliliter of the cell suspension was dispensed into 2-ml freezing tubes. The tubes were then placed in special freezer boxes and stored in a freezer at -80°C for at least 24 hours. For longer-term storage, the tubes containing the frozen cells were placed in a freezer at -150°C. Single-use composite dishes (384-eye dishes) are prepared using 40 nm / eye of the composite in dimethyl sulfoxide from columns 1-20, plus SST14 from columns 22 and 23 (the latter only, IP row) and 40 nm dimethyl sulfoxide only from columns 23 (AH row) and 24. The stored crude cells were rapidly thawed in a 37°C water bath and resuspended in phosphate-buffered buffer. The cell suspension was centrifuged at 1500 units / min (425 × g) for 5 minutes and resuspended in the experimental buffer. After determining the cell count and viability, the cell suspension was diluted to a concentration of 0.167 E⁶ cells / mL in the experimental buffer. The cells were added to the experimental dishes of columns 1–23 using 3 µL / eye. The dishes were incubated for 10–15 minutes at room temperature. Following this incubation, 1 µL / eye of 60 µM forskolin (15 µM final concentration) was added to columns 1–23. The dishes were incubated for 60 minutes at room temperature. Next, 4 µL / eye of cyclic adenosine monophosphate (cAMP) standard was loaded into column 24. Then, Eu-cAMP-traceant (2 µL / eye) and ULight™-anticoagulant cyclic adenosine monophosphate (2 µL / eye), both diluted as indicated in the manufacturer's instructions, were added to columns 1-24 (2 µL / eye) of the experimental dishes. After a 60-minute incubation in the dark, the experimental dishes were measured.The data analysis relies on the "ratio" of time-dependent fluorescence measurements of the donor and acceptor fluorophores (excitation = 320 nm; emission 1 = 665 nm; emission 2 = 615 nm; ratio = acceptor emission at 665 nm / donor emission at 615 nm). From this ratio, the cyclic adenosine monophosphate (cAMP) concentrations are calculated from the standard curve, and the mean half-maximum concentration of the test compound is estimated using a least-squares curve fitting program. Through the cyclic adenosine monophosphate titration curve, the measured fluorescence data are recalculated to cyclic adenosine monophosphate concentrations. Each test dish contains eyes with "positive" and "negative" comparison items: For the "positive" comparison items in column 23, rows 1-1 of the test dishes (200% control (CTL) comparison item, somatostatin stimulation of forskolin-stimulated somatostatin receptor 4-expressing cells), the test compound was omitted. For the "negative" controls in column 23, rows A-H of the assay plates (100% comparison item, forskolin stimulation of cells expressing somatostatin receptor 4 only), the test compound was also omitted. The value of the "percent control" comparison ratio (%CTL) is calculated as follows: Comparison ratio = 100 + (cyclic adenosine monophosphate (negative comparison element) - cyclic adenosine monophosphate (sample)) × 100 / (cyclic adenosine monophosphate (negative comparison element) - cyclic adenosine monophosphate (positive comparison element)) The resulting data were recorded in Table 2. Table 2 Example number: Test compound concentration means half-maximal response (human somatostatin receptor 4) in nanomolars. 1 0.4 29 4.5 2 0.6 30 13.6 3 1.2 31 3.9 4 1.9 32 1.8 5 2.7 33 2.9 6 3.0 34 1.9 7 3.9 35 0.04 8 7.3 36 0.1 9 6.0 37 0.3 10 6.2 38 0.6 11 19.5 39 0.2 12 19.3 40 0.6 13 1.7 41 0.1 14 2.4 42 0.3 15 4.4 43 7.7 16 18.2 44 7.7 17 0.3 45 0.7 18 3.1 46 2.4 19 4.0 47 3.9 21 11.0 48 19.6 22 1.0 49 9.3 23 5.2 50 0.6 24 12.0 51 0.2 25 0.1 52 0.3 26 0.9 53 0.1 27 2.2 54 0.6 28 2.6 55 1.2 29 4.5 56 1.4 All the tested sample compounds exhibit full stimulatory activity with a maximum effect proportional to that of somatostatin. Assessment of hepatocyte clearance The metabolic degradation of the tested compound is examined in a hepatocyte suspension. Hepatocytes (preserved by chilling) are incubated in Dulbecaux's Modified Eagle Medium (supplemented with 3.5 μg glucagon / 500 ml, 2.5 mg insulin / 500 ml, and 3.75 mg / 500 ml hydrocortisone) containing 5% human serum. The tested compounds dissolved in dimethyl sulfoxide are placed in 384-cell dishes using an Ec acoustic fluid handling system (Labcyte). Human liver cells (a mixed-sex cohort of 20 donors) and incubation medium are placed in each eye, yielding 1 million cells / ml and 1 µM of the test compound (a final volume of 15 µL for non-sequencing sampling). The dishes are transferred to a carbon dioxide (CO2) incubator for incubation at 37°C (5% CO2, 95% humidity, orbital shaking). After incubation for 0, 30, 60, 120, 240, and 360 minutes, the dishes are removed from the incubator and the samples are transferred to pre-chilled 384-cell sampling dishes containing an quenching reagent (ACN / internal standard). Samples are diluted with water / methanol (MeOH) after the final sampling point and depletion of the parent material is measured by high-performance liquid chromatography coupled with tandem mass spectrometry. CLint is calculated as follows: CL_INTRINSIC = Dose / AUC = (C0 / CD) / (AUD + clast / k) x 1000 / 60. C0: Initial concentration in the incubation [µmol], CD: Cell density of vital cells [10⁶ cells / ml], AUD: Area under the data [µmol × h], clast: Concentration of last data point [µmol], k: Slope of the regression line for parental decline [S-1]. The in vitro-calculated intrinsic hepatic clearance can be extended to in vivo intrinsic hepatic clearance and used to predict in vivo hepatic blood clearance (CL) using a liver model (a good mixing model). CL_INTRINSIC_INVIVO [ml / min / kg] = (CL_INTRINSIC [µL / min / 10⁶ cells] × hepatocytes [10⁶ cells / g liver] × liver factor [g / kg body weight]) / 1000 Clearance [ml / min / kg] = CL_INTRINSIC_INVIVO [ml / min / kg] × Hepatic blood flow [ml / min / kg] / (CL_INTRINSIC_INVIVO [ml / min / kg] + Hepatic blood flow [ml / min / kg]) Hepatic blood flow [%] = Clearance [ml / min / kg] / Hepatic blood flow [ml / min / kg]) Human hepatocellularity: 120 × 10⁶ cells / kg liver Liver factor, human: 25.7 g / kg body weight Blood flow, human: 21 ml / (min × kg) The following data were obtained (Table 3): Table 3 Example number: Hepatic blood flow [%] Example number: Hepatic blood flow [%] 1 26 30 10 2 17 31 20 3 10 32 27 4 23 33 17 5 17 34 <4 6 12 35 23 7 9 36 9 8 20 37 17 9 6 38 13 10 25 39 13 11 21 40 21 12 8 41 32 13 10 42 36 14 6 43 11 15 15 44 8 16 26 45 16 18 6 46 16 19 24 47 13 21 11 48 12 22 40 49 27 23 18 50 9 24 18 51 19 25 20 52 4 26 20 53 6 27 34 54 12 28 24 55 22 29 6 56 7 Mdck P-glycoprotein-transporter experiment across the blood-brain barrier Apparent permeability coefficients (Papp) of compounds are measured across Madin-Darby-multifrugase 1 monoclonal animal kidney layers (MDCKII cells transformed using MDR1 cDNA expression plasmid) in the apex-to-base and base-to-apex directions. Madin-Darby-multifrugin-resistant 1 (MDR-1) canine kidney cells (6 × 10⁵ cells / cm²) were distributed onto filtration substrates (Corning, Transwell, polycarbonate, 0.4 μm hole size) and cultured for 9 to 10 days. The compounds dissolved in crude dimethyl sulfoxide (1–20 mM) solution were diluted with HTP-4 buffered aqueous solution (128.13 mM sodium chloride (NaCl), 5.36 mM potassium chloride (KCl), 1 mM magnesium sulfate (MgSO4), 1.8 mM calcium chloride, 4.17 mM sodium bicarbonate (NaHCO3), 1.19 mM disodium hydrogen phosphate (Na2HPO4), 0.41 mM sodium dihydrogen phosphate (NaH2PO4), 15 mM hydroxyethylpiperazine ethanesulfonic acid, 20 mM glucose, pH 7.4) supplemented with 0.25% bovine serum albumin to prepare transport solutions (final concentration: 1 or 10 micromolar, final dimethyl sulfoxide <= 0.5%.The transfer solution was applied to the apical or lateral donor side to measure A-B or BA permeability, respectively. The acceptor side contained an HTP-4 buffer solution supplemented with 0.25% bovine serum albumin. Samples were collected at the beginning and end of the experiment from the donor and at various time intervals of up to 2 hours from the acceptor side to measure the final concentration using high-performance liquid chromatography coupled with a tandem mass spectrometer. Receiver sample volumes were replaced with fresh acceptor solution. The flux ratio was calculated by dividing the apparent base-to-apex permeability values by the apparent peak-to-base permeability values. Table 4 shows the cellular permeability in the Madin-Darby canine kidney experiment using the overexpression of multidrug resistance protein 1 (P-glycoprotein), with apparent apex-to-base permeability as measured from the apex side to the lateral bottom of the cell, as well as the flux ratio for examples 1-34 in the Madin-Darby canine kidney experiment with the overexpression of multidrug resistance protein 1 (P-glycoprotein), calculated as described above: Table 4 Example number: Apparent permeability from peak to base [× 10⁻⁶ cm / s] Ratio of apparent permeability from base to peak / apparent permeability from peak to base 1 7.1 7.9 2 15.0 2.8 3 6.8 5.6 4 7.9 6.2 5 6.0 5.5 6 17.0 2.8 7 10.7 3.6 8 11.5 3.7 9 10.1 4.1 10 7.0 6.3 11 11.8 6.8 12 8.3 3.9 13 12.6 2.3 14 7.6 4.8 15 16.5 2.7 16 10.4 7.5 17 11.0 4.8 18 11.1 3.5 19 14.4 3.6 21 7.6 4.2 22 23.5 2.6 23 12.5 3.7 24 18.0 3.9 25 6.6 7.7 26 10.0 5.7 27 20.5 2.7 28 11.5 3.9 29 10.9 3.8 30 5.2 4.6 31 8.0 4.8 32 11.0 6.1 33 16.5 3.8 34 11.4 4.0 35 6.8 8.6 36 4.6 7.8 37 8.7 6.2 38 5.1 9.0 39 4.6 8.3 40 2.5 8.3 41 14.5 4.7 42 7.6 9.4 43 7.4 4.7 44 3.8 5.4 45 18.0 2.8 46 7.6 4.2 47 12.0 4.2 48 7.8 3.4 49 26.5 2.4 50 3.8 9.6 51 6.8 8.5 52 1.0 6.0 53 0.8 12.9 54 3.0 10.7 55 10.2 5.8 56 7.2 5.3 Determining the muscle-brain ratio within a living organism An oral pharmacokinetic study was carried out according to Cui et al., (Pharmaceutics 2019 Nov 11;11(11):595) in male Wistar rats (mean body weight ~270 g) to demonstrate that the protected compound exhibits low intracellular efflux into the brain and preferential pharmacokinetic properties. A dose of the compound suspension (typically 0.5% Natrosol solution with 0.015% Tween-80) was administered orally by infusion to the animals at the dosages provided in the tables below. Blood samples (50 μL) were withdrawn via sublingual vein puncture under short-term anesthesia with isoflurane at several time points after administration, with anticoagulation and centrifugation. To demonstrate outflow from the central nervous system in vivo, distribution of the compound into muscle and brain tissues was examined 1 to 2 hours after a second oral dose. After euthanasia, the mice were drained by dissecting the vena cava, and brain, a piece of femoral muscle, and a blood sample were collected. Plasma and tissue samples were stored at -20°C prior to biological analysis. For biological analysis, plasma protein was precipitated using acetonitrile. Tissue samples are transferred to Precellys vials and three parts acetonitrile / methanol (1:1) and one part water are added for homogenization.The homogenates are centrifuged, and the supernatant is collected for biological analysis. The concentration of the given compound in plasma and tissue samples is determined by high-performance liquid chromatography coupled with tandem mass spectrometry. A muscle tissue / brain concentration ratio of 3-10 is preferred, and a ratio of 1-3 is even more preferable. All animal experiments were approved by the local German authorities (Regierungspräsidium Tübingen) and carried out in accordance with German and European animal welfare laws. Treatment method The present invention is directed to compounds of the generic formula (I), which are useful in treating disorders and / or diseases in which activation of the somatostatin 4 receptor can exert a therapeutic, preventive, or disease-modifying effect, including, but not limited to, the treatment of diseases, disorders, and / or conditions such as pain or pain-related conditions, inflammatory conditions, neurological and psychiatric conditions such as psychosis spectrum disorders, schizophrenia (positive and negative symptoms and cognitive impairment associated with schizophrenia), psychosis, learning and memory impairment, and dementia such as Alzheimer's disease. Furthermore, compounds of the generic formula (I) are useful in treating neurological and psychiatric conditions characterized by hippocampal hyperactivity, neural hyperexcitability, disturbances in excitability / inhibition balance, neurodegenerative disorders, or dysregulation of the somatostatin system.Furthermore, the compounds in the generic form (I) are useful in treating inflammation and neuralgia, seizure disorders, and psychotic spectrum disorders, for example, cognitive impairment associated with hyperactivity of the hippocampus. In another aspect of the invention, the compounds in the generic form (I) are useful in preventing the disorders and / or diseases mentioned above. Furthermore, compounds in the general formula (I) are useful for treating acute pain; visceral pain; neuropathic pain; inflammatory pain; receptor-mediated pain; tumor pain; headache diseases; inflammatory and / or edematous diseases affecting the skin and mucous membranes; vascular and heart diseases; inflammatory changes associated with diseases of the airways and lungs; inflammatory diseases of the gastrointestinal tract; inflammatory diseases associated with the ear, nose, mouth and throat; inflammatory diseases of the joints and connective tissue; cognitive impairment associated with psychotic spectrum disorders, including but not limited to schizophrenia, schizoaffective disorder and bipolar disorder; or, cognitive impairment associated with neurodegenerative disorders, including but not limited to Alzheimer's disease; or, cognitive impairment associated with seizure disorders and epilepsy; Or cognitive impairment associated with neurological and psychological disordersOther: Mild cognitive impairments; negative symptoms and mood disturbances, as observed in schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, borderline personality disorder, and post-traumatic stress disorder. isorder and substance use disorders, as well as in any other neurological or psychiatric condition; treatment of positive symptoms in psychiatric disorders, such as in schizophrenia, schizoaffective disorder, delusional disorder, brief psychotic disorder, substance-induced psychotic disorder, bipolar disorder, psychotic depression; any other neurological or psychiatric conditions associated with disorders of the somatostatin system, including major depressive disorder, anxiety disorders and stress states, schizophrenia, bipolar disorder, Alzheimer's disease, Parkinson's disease and seizure disorders; Any other neurological and psychiatric conditions associated with pathological neuronal hyperexcitability or pathological neuronal hyperactivity, particularly in the hippocampal or cortical networks, including seizure disorders such as epilepsy, febrile seizures, and other types of non-epileptic seizures; psychotic spectrum disorders,This includes schizophrenia, schizoaffective disorder, bipolar disorder, and acute psychosis; benign tumors and malignant tumors. In another aspect of the invention, compounds of the generic formula (I) are useful in the prevention of the disorders and / or diseases mentioned above. Accordingly, the present invention relates to a compound of the generic formula (I) for use as a medicine. Furthermore, the present invention relates to the use of a compound with the generic formula (I) for the treatment of disorders and / or diseases and / or pathological conditions in which activation of the somatostatin 4 receptor can produce a therapeutic, preventive or disease-modifying effect. Furthermore, the present invention relates to the use of a compound with the generic formula (I) for the treatment of pain or pain-related conditions, inflammatory conditions, and neuropsychiatric conditions such as psychotic spectrum disorders, schizophrenia (positive and negative symptoms and schizophrenic-related cognitive impairment), psychosis, learning and memory impairment, and dementia such as Alzheimer's disease. Additionally, compounds with the generic formula (I) are useful in the treatment of neuropsychiatric conditions characterized by hippocampal hyperactivity, neuronal hyperexcitability, disturbances in excitability / inhibition balance, neurodegenerative disorders, or somatostatin system dysregulation. Moreover, compounds with the generic formula (I) are useful in the treatment of neuralgia and neuralgia, seizure disorders, and psychotic spectrum disorders, for example, cognitive impairment associated with hippocampal hyperactivity. Furthermore, the present invention relates to the use of a compound with the general formula (I) for the treatment of acute pain; visceral pain; neuralgia; inflammatory pain; pain resulting from nerve receptors; tumor pain; headache disorders; inflammatory and / or edematous diseases of the skin and mucous membranes; cardiovascular diseases; inflammatory changes associated with diseases of the airways and lungs; inflammatory diseases of the digestive system; inflammatory diseases associated with the ear, nose, mouth and throat; inflammatory diseases of the joints and connective tissue; cognitive impairment associated with disorders of the psychotic spectrum, including, without limitation, schizophrenia, schizoaffective disorder and bipolar disorder; or, cognitive impairment associated with neurodegenerative disorders, including, without limitation, Alzheimer's disease; or, cognitive impairment associated with seizure disorders and epilepsy; or cognitive impairment associated with other neurological and psychiatric disorders; mild cognitive impairment; Negative symptoms and mood disturbances, as observed in schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, borderline personality disorder, post-traumatic stress disorder and substance use disorders, as well as in any other conditionOther neurological or psychiatric conditions; treatment of positive symptoms in psychiatric disorders, such as schizophrenia, schizoaffective disorder, delusional disorder, transient psychotic disorder, substance use disorder, bipolar disorder, psychotic depression; any other neurological or psychiatric conditions associated with disorders of the somatostatin system, including major depressive disorder, anxiety disorders and states of stress, schizophrenia, bipolar disorder, Alzheimer's disease, Parkinson's disease, and seizure disorders; any other neurological and psychiatric conditions associated with hyperexcitability or pathological neural activity, particularly in the hippocampal or cortical networks, including seizure disorders such as epilepsy, febrile seizures, and other non-epileptic seizures; psychotic spectrum disorders, including schizophrenia, schizoaffective disorder, bipolar disorder, and acute psychosis; benign and malignant tumors. In another aspect, the invention relates to the use of a compound with the generic formula (I) in the prevention of the disorders and / or diseases mentioned above. In another aspect, the present invention relates to a compound with the general formula (I) for use in the treatment of the diseases and pathological conditions mentioned above. In another aspect, the present invention relates to a compound with the general formula (I) for use in the prevention of the diseases and pathological conditions mentioned above. In another aspect, the present invention relates to the use of a compound with the general formula (I) to prepare a medicine for the treatment of the diseases and pathological conditions mentioned above. In another aspect, the present invention relates to the use of a compound with the general formula (I) to prepare a medicine for the prevention of the diseases and pathological conditions mentioned above. In another aspect, the present invention relates to methods for treating the diseases and pathological conditions mentioned above, whereby the method involves administering an effective quantity of a compound with the general formula (I) to a human being. In another aspect, the present invention relates to methods for preventing the diseases and pathological conditions mentioned above, whereby the method involves administering an effective quantity of a compound with the general formula (I) to a human being. The applicable daily dose range for generic formulations (I) is typically 0.00001 to 100 mg per kg of body weight, e.g., 0.00001 to 10 mg per kg of body weight. Ideally, the daily dose per patient should be between 0.01 and 1000 mg, with a preference for doses between 0.1 and 500 mg, and the most preferred range being between 0.1 and 100 mg. Each dose unit can conventionally contain between 0.001 and 1000 mg, e.g., 0.001 to 100 mg. The actual pharmacologically effective amount, or therapeutic dose, will typically depend on factors well-known to healthcare professionals, such as the patient's age and weight, the route of administration, and the severity of the illness. In any case, the compounds will be administered in doses and in a manner that allows for the delivery of a pharmacologically effective amount based on the patient's unique condition. Pharmaceutical formulation The preparations suitable for administering the compounds in formula (I) will become clear to those with ordinary skill in the field and include, for example, tablets, pills, capsules, suppositories, specific tablets, sweetened tablets, solutions, syrups, elixirs, sachets, injectable materials, creams, adhesive patches or the like for transdermal delivery, inhalable materials and powders, etc. Suitable tablets can be obtained, for example, by mixing one or more of the compounds according to formula (I) with known excipients, for example inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and / or lubricants. Combined treatment The invention's components may also be combined with one or more, preferably one additional therapeutic agent. According to one of the formulations, the additional therapeutic agent is chosen from a group of therapeutic agents useful in the treatment of the diseases or pathological conditions described previously in this document, specifically associated pain or pathological conditions, inflammatory conditions, and neurological and psychiatric conditions characterized by neuronal hyperexcitability, disturbances in the excitability / inhibition balance, neurodegenerative disorders, or dysregulation of the somatostatin system. According to another formulation, the additional therapeutic agent is selected from a group of therapeutic agents useful in treating the diseases or pathological conditions described previously in this document: treatment of inflammation and neuralgia, seizure disorders and psychotic spectrum disorders, for example, cognitive impairment associated with hyperactivity of the hippocampus. Furthermore, compounds in the general formulation (I) are useful for treating acute pain; visceral pain; neuralgia; inflammatory pain; pain resulting from nerve receptors; tumor pain; headache disorders; inflammatory and / or edematous diseases of the skin and mucous membranes; cardiovascular diseases; inflammatory changes associated with diseases of the airways and lungs; inflammatory diseases of the gastrointestinal tract; inflammatory diseases associated with the ear, nose, mouth, and throat; inflammatory diseases of the joints and connective tissue; cognitive impairment associated with psychotic spectrum disorders, including, but not limited to, schizophrenia, schizoaffective disorder, and bipolar disorder; or cognitive impairment associated with neurodegenerative disorders, including, but not limited to, Alzheimer's disease; or cognitive impairment associated with seizure disorders and epilepsy. Or cognitive impairment associated with neurological and psychological disordersOther; mild cognitive impairment; negative symptoms and mood disturbances, as observed in schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, borderline personality disorder, post-traumatic stress disorder and substance use disorders, as well as in any other neurological or psychiatric condition; treatment of positive symptoms in psychiatric disorders, such as in schizophrenia, schizoaffective disorder, delusional disorder, transient psychotic disorder, substance use disorder, bipolar disorder, psychotic depression; any other neurological or psychiatric conditions associated with disorders of the somatostatin system, including major depressive disorder, anxiety disorders and states of stress, schizophrenia, bipolar disorder, Alzheimer's disease, Parkinson's disease and seizure disorders; any other neurological and psychiatric conditions associated with hyperexcitability or pathological neural activity, particularly in the hippocampal networks or cerebral cortex, including seizure disorders such as epilepsy, febrile seizures, and other types of non-epileptic seizures; Psychotic spectrum disorders, including schizophrenia, schizoaffective disorder, bipolar disorder, and acute psychosis; tumorsBenign and malignant conditions. Appropriate adjunctive therapies for such formulations include, in particular, those that enhance the therapeutic effect of one or more active ingredients in relation to one of the aforementioned indications and / or allow for a reduction in the dosage of one or more active ingredients. Alternatively, the aforementioned adjunctive therapies are selected from a range of therapeutic agents beneficial in the prevention of the diseases and pathological conditions mentioned above. Therefore, the invention compound may be combined with one or more additional selected therapeutic agents from the group consisting of anti-inflammatory drugs, cholinergic therapies, beta-amyloid-targeted therapies, tautau-related therapy, neuroprotective therapies, analgesic drugs, anti-migraine drugs, antidepressants, mood stabilizers, typical and atypical antipsychotics, anxiolytics, antiepileptic drugs, sleeping agents, cognitive enhancers, stimulants, additional psychoactive drugs, chemotherapeutic drugs, as well as combinations with treatment choices used for metabolic disorders. Therefore, on another level, this invention relates to the use of a compound according to the invention in combination with one or more of the additional therapeutic agents described here above and here below to treat diseases or pathological conditions that can be caused or produced by the somatostatin 4 receptor, specifically the diseases or pathological conditions described here above and here below. On another side, this invention relates to a method for treating a disease or pathological condition that may be affected by activation of the somatostatin 4 receptor in a patient, whereby the step involves giving a patient in need of such treatment a therapeutically effective amount of a compound in formula (I) or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of one or more additional therapeutic agents. On the other hand, this invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with one or more additional therapeutic agents to treat diseases or pathological conditions that may be affected by activation of the somatostatin 4 receptor in a patient who needs it. On another side, the present invention also relates to a method for treating a disease or pathological condition by means of the activity of the somatostatin 4 receptor in a patient, whereby the step involves administering to the human patient, in need of such treatment, a therapeutically effective quantity of the compound of the present invention in combination with a therapeutically effective quantity of one or more of the additional therapeutic agents described here previously and here below. The compound may be used according to the invention in combination with the additional therapeutic agent at the same time or at overlapping intervals. Both the compound according to the invention and one or more additional therapeutic agents may be found together in a single formulation, for example, a tablet or capsule, or separately in two identical or different formulations, for example, in the form of a so-called kit of parts. As a result, in another aspect, this invention relates to a pharmaceutical formulation that includes a compound in accordance with the invention and one or more of the additional therapeutic agents described herein before and hereinafter, optionally together with one or more inert carriers and / or diluents. Other features and characteristics of the present invention will become clear from the following more detailed examples which illustrate, for example, the principles of the invention. Preparation process The compounds and their intermediates, as described in the present invention, can be obtained using synthetic methods known to those skilled in the field and described in the field of organic synthesis. Ideally, the compounds should be obtained by a method analogous to the preparation methods described more comprehensively hereafter, specifically as described in the experimental section. In some cases, the order of the reaction steps may be altered. Variations of reaction methods known to a skilled person in the field but not described in detail here may also be used. The general processes for preparing compounds according to the invention will become clear to a skilled practitioner studying the following schemes. Any functional group in the initiators or intermediate compounds can be protected using conventional protective groups. These protective groups can then be cleaved back at a suitable stage within the reaction sequence using methods familiar to a skilled practitioner. The compounds described in the invention are prepared by the synthetic methods described below, in which case the substitution groups of general formulas have the meanings given above. These methods are intended to illustrate the invention without limiting its subject matter and the range of protected compounds to those examples. Where the preparation of the precursor compounds is not described, it is described as being commercially obtainable or prepared in a manner analogous to known compounds or methods described herein. The substances described in the range are prepared according to published synthetic methods. The terms "ambient temperature" and "room temperature" are used interchangeably and refer to a temperature of approximately 20°C, for example, between 19 and 24°C. The term "overnight" means a period of approximately 16 hours, for example, between 12 and 20 hours. The abbreviations are as defined in the Examples section. As a rule, proton nuclear magnetic resonance (1H-NMR) and / or mass spectra were obtained for the prepared compounds. All examples and reference examples with two spatial centers described in this report were obtained with a two-dimensional ratio ≥ 95:5 (≤ 5% of a second set of signals observable in the 1H-NMR). The intermediate compound Int-6 can be prepared by the reaction sequence depicted in Scheme 1.The intermediate compound Int-1 (Step 1, from starter SM-1 to intermediate Int-1) can be prepared by treating the starter SM-1 or its hydrochloride salt with a suitable carbaldehyde derivative, for example benzaldehyde or dimethyl acetal, in a suitable solvent such as methanol, tetrahydrofuran (THF), or 2-methyltetrahydrofuran (Me-THF), in the presence of a buffer solution such as sodium acetate or acetic acid at or preferably below ambient temperature, ideally under ice cooling, to form an intermediate compound of an imine or iminium salt, which is then treated with a suitable reducing agent such as sodium borohydride or, preferably, sodium triacetoxyborohydride. triacetoxyborohydride to induce the formation of the intermediate compound Int-1 (Diagram 1).Silyl ether intermediate Int-2 can be produced by reacting intermediate Int-1 with a suitable silyl derivative such as tert-butyl (chloro)diphenylsilane or tert-butyldiphenylsilyl trifluoromethanesulfonate in the presence of a suitable base, such as triethylamine (TEA) or N,N-diisopropylamine, preferably imidazole, in an aprotic solvent such as dichloromethane (DCM), tetrahydrofuran or 2-methyltetrahydrofuran, at or below ambient temperature, preferably under ice cooling (Step 2, from intermediate Int-1 to intermediate Int-2).The reduction of the intermediate compound Int-2 to the corresponding primary alcohol of the intermediate compound Int-3 (Step 3) may be carried out by treating a solution of the intermediate compound Int-2 in a suitable solvent such as methanol, tetrahydrofuran or dichloromethane using a suitable reducing agent such as lithium borohydride or lithium aluminumhydride at or below room temperature.The chelation and subsequent cyclization of the intermediate Int-3 to the intermediate Int-4 (Step 4) can be carried out in a two-step process starting with the reaction of the intermediate Int-3 with a suitable oxirane derivative such as epichlorohydrine or oxiran-2-yl tosylate, preferably in its isoform (R) purity, in a suitable solvent such as toluene or 1,2-dichloroethane, in the presence of a suitable Lewis acid such as lithium perchlorate or magnesium perchlorate between room temperature and 80 °C, preferably at 60 °C. This is followed by the treatment of the reaction mixture at or below room temperature, preferably at -10 °C, using a suitable base such as sodium methoxide or potassium tert-butoxide.The substitution of the intermediate compound Int-4 to the intermediate compound Int-5 (Step 5) can be protected in a two-step process, in a single vessel, by mixing the intermediate compound Int-4 in a suitable solvent such as methanol or tetrahydrofuran using a suitable tert-butyl carbonate source such as di-tert-butyl dicarbonate in the presence of a heterogenous hydrogenation catalyst such as palladium on charcoal or palladium hydroxide on charcoal and exposing the mixture to hydrogen gas in a pressurized vessel at or above ambient pressure, preferably at 3 bar hydrogen pressure, at ambient temperature to obtain the intermediate compound Int-4.The final oxidation step in this sequence, from intermediate Int-5 to intermediate Int-6 (step 6), can be performed by treating a solution of intermediate Int-5 in a suitable solvent such as acetonitrile with a mixture of appropriate oxidizing agents such as iodobenzene diacetate, 2,2,6,6-tetramethylpiperidinyloxyl (TEMPO), and sodium chlorite in an aqueous buffer containing sodium and potassium mono- and dihydrogen phosphates at or below ambient temperature, preferably between 5°C and 25°C. A similar pathway using another silyloxy protection group is reported in Bungard et al., ACS Med. Chem. Lett. 2016, 7, 702. Diagram 1: Pathway of carboxylic acid synthesis from the intermediate compound Int-6. The intermediate compound Int-7 (Step A-1, from starter SM-2 to intermediate compound Int-7) can be prepared by treating the starter SM-2 in a suitable solvent such as diethyl ether or tetrahydrofuran at ambient temperature using an excess of a methyl-Grignard reagent such as methylmagnesium bromide or methylmagnesium chloride, followed by the addition of titanium alkoxide, for example titanium(IV) isopropoxide, and an additional methyl-Grignard reagent. Alternatively, the intermediate compound Int-7 can be prepared in a three-step sequence beginning with the conversion of the initiator SM-3 to the intermediate compound Int-8 by condensing the ketone functional group in SM-3 using tert-butanesulfinamide in a suitable solvent such as dichloromethane or tetrahydrofuran in the presence of a drying agent such as copper(II) sulfate or titanium(IV) isopropoxide between ambient temperature and the reduction temperature, respectively (Step B-1).The intermediate Int-9 can then be prepared by reacting the imine functional group of the intermediate Int-8 with a methyl-Grignard reagent such as methylmagnesium chloride or methylmagnesium bromide in a suitable solvent such as toluene or tetrahydrofuran between 0°C and ambient temperature (Step B-2, Int-8 to Int-9). Finally, the release of the amine functional group of Int-7 from the intermediate Int-9 can be carried out by treatment with a strong acid such as trifluoroacetic acid or hydrochloric acid (HCl) in a suitable solvent such as dichloromethane or diethyl ether (Step B-3, Int-9 to Int-7). Scheme 2: Synthesis of the intermediate compound Int-7 either from a nitrile-containing starter SM-2 or from a ketone-bearing starter SM-3. Pyridine-carrying amines or isoquinoline-bearing amines, such as Int-7-Het-a or Int-7-Het-b, can be prepared analogously to Int-7 as described above. Alternatively, Int-7-Het-a or Int-7-Het-b can be formed from 2-halopyridines or 2-halo-isoquinolines (SM-2-Het-a or SM-2-Het-b), where the halo is fluoro-, chloro-, bromo-, or iodo-, preferably fluoro- or chloro-, as described below in the 2-Het diagram. Starting with SM-2-Het-a / b, Int-12-a / b can be obtained by a nucleophilic aromatic substitution reaction using isobutyronitrile in the presence of a suitable base such as lithium bis(trimethylsilyl)amide or sodium bis(trimethylsilyl)amide at temperatures preferentially between -5°C and ambient temperature (Scheme 2-Het, Step C-1).The aqueous solution of the nitrile moiety in Int-12-a / b can be prepared to obtain the primary amide Int-13-a / b by treatment with hydrogen peroxide and a base such as potassium carbonate in a suitable solvent such as dimethyl sulfoxide at a suitable temperature, e.g., room temperature. Alternatively, the aqueous solution of nitrile can be obtained by treatment with an acid or a combination of acids, e.g., sulfuric acid and acetic acid, at elevated temperatures, e.g., 95 °C (Step C-2). Starting from the primary amide Int-13-a / b, the primary amine bearing the intermediate Int-7-Het-a / b can be prepared by a Hofmann rearrangement. Typical reaction conditions for this conversion include, for example, sodium hypochlorite in the presence of sodium hydroxide in a suitable solvent such as isopropanol or, alternatively, bis(trifluoroacetoxy)iodo)benzene followed by the addition of aqueous sodium hydroxide in a suitable solvent such as acetonitrile (step C-3). Scheme 2-Het: Synthesis of the intermediate compounds Int-7-Het-a and Int-7-Het-b from precursors containing 2-halo-pyridine (SM-2-Het-a) or 2-halo-isoquinoline (SM-2-Het-b), respectively. The intermediates Int-6 and Int-7 can be conjugated by amide conjugation (step 7, from intermediate Int-6 + intermediate Int-7 to intermediate Int-10) using a conjugation reagent such as 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU), 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate, or 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium Tetrafluoroborate (TBTU) or propanephosphonic acid anhydride in a suitable solvent such as tetrahydrofuran, dichloromethane or N,N-dimethylformamide (DMF) in the presence of an organic base such as triethylamine, diisopropylethylamine or N-methylmorpholine at temperatures preferably between 0 °C and 25 °C.Subsequently, the tert-butoxycarbonyl group in the intermediate Int-10 can be cleaved (Step 8, from Int-10 to Int-11) by treating Int-10 with a strong acid such as hydrochloric acid or trifluoroacetic acid in a suitable solvent such as dichloromethane, methanol, or diethyl, preferably at temperatures between 0°C and 60°C. Under these reaction conditions, the tert-butyldiphenylsilyl protective group can be cleaved to obtain the final compound (Step 8 + Step 9, from Int-10 to Int-11) without isolating Int-11.Accordingly, if the tert-butyl diphenyl syl protective group in the intermediate Int-11 is not cleaved by treatment with a strong acid as described above, the intermediate Int-11 can be isolated and converted to the final compound (Step 9, from the intermediate Int-11 to Example 1-34) by reacting the intermediate Int-11 with a fluoride source such as tetrabutylammonium fluoride or cesium fluoride in a suitable solvent such as dichloromethane or tetrahydrofuran at temperatures preferably between 0 °C and 50 °C. The heterogeneous 35-55 carrier examples can be prepared from the intermediate compound Int-6 in a manner similar to the phenyl 1-34 carrier examples, see Scheme 3-Het. Similarly, the examples revealed in the present invention can be prepared using intermediate compounds bearing different protective groups. For example, the hydroxyl group can be protected using different syl groups such as tert-butyldimethylsilyl. Similarly, the amino group can be protected using different carbamate groups such as benzyl carbamate. Alternatively, the amino group can be protected using different benzyl groups such as 1-phenylethyl. Scheme 3: Conjugation of the carboxylic acid amide of the intermediate compound Int-6 with the amine of the intermediate compound Int-7 and deprotection processes to obtain the example compound. Scheme 3-Het: Conjugation of an amide of a carboxylic acid from the intermediate compound Int-6 with an amine of the intermediate compound Int-7-Het-a / b and deprotection processes to obtain the example compound. Examples Abbreviations: ACN acetonitrile Aq. aquatic Boc Tert-Butyloxycarbonyl °C degrees Celsius conc. center d day(s) dr double ratio DCM Dichloromethane DIPEA N,N-Diisopropylethylamine DMF N,N-Dimethylformamide DMSO Dimethyl Sulfoxide ee increased symmetry ESI electron spray ionization ESI-MS electron spray ionization mass spectrometer EtOAc Ethyl Acetate EtOH ethanol eq equivalent g grams (grams) h hour(s) HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate HBSS Hanks Balanced Salt Solution (buffer solution) HCl (hydrochloric acid) HEPES Hydroxyethyl-piperazine ethane-sulfonic acid (buffered solution) HPLC (High-Efficiency Liquid Chromatography) HPLC-MS High-Efficiency Liquid Chromatography with Mass Detector Int. intermediate compound IPA isopropyl alcohol L (liter) M molar (mol / L) Methyl MeOH methanol Me-THF 2-methyltetrahydrofuran mg milligrams (milligrams) MgSO4 magnesium sulfate min (minutes) mL milliliter (milliliters) MTBE tert-butyl methyl ether MW molecular weight NaOEt sodium ethanolate NH3 ammonia ppm (parts per million) (NMR) prep. preparatory psi (pounds per square inch) RP reverse phase rt room temperature Rf detention agent Rt detention time sat. saturated scCO2 supercritical carbon dioxide SFC supercritical fluid chromatography TA L-(+)-tartaric acid TBDPS TERM-Butyl Diphenyl Cellulose TBTU 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate TEA triethylamine TEMPO 2,2,6,6-tetramethylpiperidinyl oxyl TFA (trifluoroacetic acid) THF tetrahydrofuran TLC thin-layer chromatography Vol% by volume a0; Abbreviations within analytical data: 1H-NMR proton nuclear magnetic resonance wide δ chemical transformation double d double-coupled DMSO-d6 hexa-deutero-dimethyl sulfoxide Hz (hertz) J Constant Pairing m multi M isotope mass parts per million (ppm) q quadrilateral s mono t triad td triplet General tests All reactions were performed using commercially available reagents and solvents. Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker AVANCE IIIHD 400 MHz spectrometer using Top-Spin 3.5 pl6 software. Chemical transformations are presented in parts per million (ppm) downfield from an internal reference trimethylsilane in units δ. Selected data are recorded as follows: chemical transformation, multiplicity, coupling constants (J), and aggregation. Analytical thin-layer chromatography (TLC) was performed using Merck silica gel 60 F254 dishes. Compounds were visualized as single-spots using short-wavelength UV light. A low-contrast mass spectrum is obtained using high-performance liquid chromatography coupled to a quadrupole mass spectrometer (HPLC-MS; electrospray positive ionization).The recorded mass spectrometry (MS) data correspond to the observed mass peaks of the monoisotope masses of the particular compound ([M+H]+) or a fragment thereof (e.g., [M−Boc+H]+, [M−NH3+H]+). The observed isotope patterns are consistent with the natural isotope abundances of the chemical elements within the particular molecule. High-performance liquid chromatography (HPLC) methods Method A Time (minutes) % by volume of water (includes 0.1% trifluoroacetic acid) % by volume acetonitrile flow [ml / min] 0.0 97.0 3.0 2.2 0.2 97.0 3.0 2.2 1.2 0.0 100.0 2.2 1.25 0.0 100.0 3.0 1.4 0.0 100.0 3.0 Device description: Agilent 1200 with DA detector and mass spectrometer Column: Sunfire C18_3.0 x 30 mm_2.5 micrometers (Product: Waters) Temperature: 60 degrees Celsius Method B Time (minutes) % by volume of water (includes 0.1% trifluoroacetic acid) % by volume acetonitrile flow [ml / min] 0.0 97.0 3.0 2.2 0.2 97.0 3.0 2.2 1.2 0.0 100.0 2.2 1.25 0.0 100.0 3.0 1.4 0.0 100.0 3.0 Device description: Agilent 1200 with DA detector and mass spectrometer Column: Zorbax StableBond C18_3.0 x 30 mm_1.8 µm (Manufacturer: Agilent) Temperature: 60 degrees Celsius Method C Time (minutes) % by volume of water (includes 0.1% ammonia) % by volume of acetonitrile flow [ml / min] 0.0 97.0 3.0 2.2 0.2 97.0 3.0 2.2 1.2 0.0 100.0 2.2 1.25 0.0 100.0 3.0 1.4 0.0 100.0 3.0 Device description: Agilent 1200 with DA detector and mass spectrometer Column: Xbridge C18_3.0 x 30 mm_2.5 µm (Product: Waters) Temperature: 60 degrees Celsius Method D Time (minutes) % by volume of water (includes 0.1% ammonia) % by volume of acetonitrile flow [ml / min] 0.0 95.0 5.0 2.2 0.2 95.0 5.0 2.2 1.2 0.0 100.0 2.2 1.25 0.0 100.0 3.0 1.4 0.0 100.0 3.0 Device description: Agilent 1200 with DA detector and mass spectrometer Column: XBridge C18_3.0 x 30 mm_2.5 µm (Product: Waters) Temperature: 60 degrees Celsius Method E Time (minutes) % by volume of water (includes 0.1% trifluoroacetic acid) % by volume acetonitrile flow [ml / min] 0.0 50.0 50.0 2.2 0.2 50.0 50.0 2.2 1.2 0.0 100.0 2.2 1.25 0.0 100.0 3.0 1.4 0.0 100.0 3.0 Device description: Agilent 1200 with DA detector and mass spectrometer Column: Sunfire C18_3.0 x 30 mm_2.5 micrometers (Product: Waters) Temperature: 60 degrees Celsius Method F Time (minutes) % by volume of water (includes 0.1% ammonia) % by volume of acetonitrile flow [ml / min] 0.0 50.0 50.0 2.2 0.2 50.0 50.0 2.2 1.2 0.0 100.0 2.2 1.25 0.0 100.0 3.0 1.4 0.0 100.0 3.0 Device description: Agilent 1200 with DA detector and mass spectrometer Column: Xbridge C18_3.0 x 30 mm_2.5 µm (Product: Waters) Temperature: 60 degrees Celsius Method J Time (minutes) % by volume of water (includes 0.04% trifluoroacetic acid) % by volume of acetonitrile (includes 0.02% trifluoroacetic acid) Flow [ml / min] 0.01 95 5 1.5 0.70 5 95 1.5 1.16 5 95 1.5 1.50 95 5 1.5 Device description: Shimadzu LC-20AD Column: Kinetex-C18 2.1 x 30 mm_5 µm Temperature: 40 degrees Celsius Method K Time (minutes) % by volume of water (includes 0.04% trifluoroacetic acid) % by volume of acetonitrile (includes 0.02% trifluoroacetic acid) Flow [ml / min] 0.01 90 10 1.5 0.80 0 100 1.5 1.30 0 100 1.5 Device description: Shimadzu LC-20ADXR, MSD LCMS-2020 Column: Halo-C18 3 x 30 mm_5 µm Temperature: 40 degrees Celsius Method L Time (minutes) % by volume of water (includes 0.04% trifluoroacetic acid) % by volume of acetonitrile (includes 0.02% trifluoroacetic acid) Flow [ml / min] 0.01 95 5 1.5 0.70 5 95 1.5 1.16 5 95 1.5 1.50 95 5 1.5 Device description: Shimadzu LC-20AD, MSD LCMS-2020 Column: Poroshell 120 SB-C18 3.0 x 30 mm_2.7 µm Temperature: 40 degrees Celsius Method M Time (minutes) % by volume of water (includes 0.04% trifluoroacetic acid) % by volume of acetonitrile (includes 0.02% trifluoroacetic acid) Flow [ml / min] 0.01 95 5 1.5 0.70 5 95 1.5 1.16 5 95 1.5 1.50 95 5 1.5 1.51 95 5 1.5 Device description: Agilent 1200, MSD: 6120 Column: Kinetex EVO C18 2.1 x 30 mm_5 µm Temperature: 40 degrees Celsius Analytical supercritical fluid chromatography methods Method G Time (minutes) % by volume Supercritical carbon dioxide (scCO2) % by volume Methanol (includes 20 mM ammonia) Flow [ml / min] Back pressure [rpm] 0.0 85.0 15.0 4.0 2175.0 10.0 85.0 15.0 4.0 2175.0 Device description: Agilent 1260 Infinity II SFC with DAD and mass spectrometry. Column: CHIRAL ART® Cellulose-SC_4.6 x 250 mm_5 micromolar (Producer: YMC). Temperature: 40 degrees Celsius Method H Time (minutes) % by volume Supercritical Carbon Dioxide % by volume Isopropyl Alcohol (includes 20 mM Ammonia) Flow [ml / min] Back Pressure [rpm] 0.0 90.0 10.0 4.0 2175.0 10.0 90.0 10.0 4.0 2175.0 Device description: Agilent 1260 Infinity II SFC with DAD and mass spectrometry. Column: CHIRAL ART® Cellulose SB_4.6 x 250 mm_5 micrometers (Product: YMC) Temperature: 40 degrees Celsius Method I Time (minutes) % by volume Supercritical Carbon Dioxide % by volume Methanol (includes 20 mM Ammonia) Flow [ml / min] Back Pressure [rpm] 0.0 85.0 15.0 4.0 2175.0 10.0 85.0 15.0 4.0 2175.0 Device description: Agilent 1260 Infinity II SFC with DAD and mass spectrometry. Column: CHIRAL ART® Cellulose SZ_4.6 x 250 mm_5 micrometers (Product: YMC) Temperature: 40 degrees Celsius Preparing the starter materials Unless otherwise stated, the starting materials are commercially available and have been used without further purification. Preparation of the intermediate compound 1.6 Step 1: Methyl benzyl-D-serinate (Int-1) Methyl D-serinate hydrochloride (SM-1, 160 g, 1.03 mol) and sodium acetate (85.0 g, 1.04 mmol) were added to 1000 mL of 2-methyltetrahydrofuran and stirred at room temperature. After 1 hour, the reaction mixture was cooled in an ice bath, and benzaldehyde (100 g, 0.94 mol) was added. After 10 minutes, a mixture of sodium triacetoxyborohydride (440 g, 2.08 mol) in 600 mL of 2-methyltetrahydrofuran was added while the reaction mixture was cooled in an ice bath. The reaction was then slowly warmed to room temperature and stirred overnight. 1000 mL of water was added, the reaction mixture was cooled in an ice bath, and 400 mL of concentrated aqueous ammonia (≥ 25%) was added. The layers were separated, and the aqueous layer was extracted twice using 500 mL tert-butylmethyl ether (MTBE) each time. The collected organic layers were dried over magnesium sulfate, filtered, and the solvent was removed under reduced pressure.To the remaining material, 1000 mL of 2 M hydrochloric acid and 400 mL diethyl ether were added. The mixture was shaken, and the layers were separated. The aqueous layer was washed with 300 mL diethyl ether. The collected organic layers were extracted with 200 mL 1 M hydrochloric acid, and the aqueous layers were collected. Concentrated aqueous ammonia (≥ 25%) was then added until a basic pH was obtained. The basic organic layer was extracted three times, each time using 500 mL dichloromethane. The organic layers were collected, dried over magnesium sulfate, filtered, and concentrated under reduced pressure to obtain 183.4 g of the target compound. ESI-MS: 210 [M+H]+ Retention time (Rt) (High-performance liquid chromatography): 0.55 minutes (Method A) Step 2: Methyl N-benzyl-O-(tert-butyldiphenylsilyl)-D-serinate (Int-2) Methyl benzyl-D-serinate (Int-1, 183.4 g, 0.88 mol) and imidazole (90.0 g, 1.32 mol) were added to 800 mL of dichloromethane and stirred in an ice bath. A mixture of tert-butyldiphenylchlorosilane (245.0 g, 0.89 mol) was added slowly to 200 mL of dichloromethane, ensuring the internal temperature did not exceed 20°C. The reaction was stirred in an ice bath for 2 hours. 900 mL of water and 300 mL of concentrated aqueous ammonia (≥ 25%) were added. The layers were separated, and the aqueous layer was extracted twice using 400 mL of dichloromethane each time. The organic layers were washed with 750 mL of water and collected. The collected organic layers were dried over magnesium sulfate, filtered, and the solvent was removed under reduced pressure to obtain 393.0 g of the title compound. ESI-MS: 448 [M+H]+ Retention time (High-performance liquid chromatography): 1.06 minutes (Method B) Step 3: (S)-2-(benzylamino)-3-((tert-butyldiphenylsilyl)oxy)propan-1-ol (Int-3) Methyl N-benzyl-O-(tert-butyldiphenylsilyl)-D-serinate (Int-2, 393.0 g, 0.88 mol) was added to 1500 mL of dichloromethane and stirred in an ice bath. Lithium borohydride (30.0 g, 1.38 mol) was added in one portion while the reaction mixture was cooled in the ice bath. The reaction was then slowly warmed to room temperature and stirred overnight. The reaction mixture was slowly poured into 1250 mL of ice water and stirred for 15 minutes. 150 g of citric acid was carefully added in small portions, and the mixture was stirred for 10 minutes. The solvent was removed under reduced pressure. Then, 800 mL of 2-methyltetrahydrofuran was added, and the mixture was stirred at 60°C for 6 hours and at room temperature overnight. Concentrated aqueous ammonia (≥ 25%) was added until a basic pH was obtained. The layers were separated, and the aqueous layer was extracted twice using 500 mL tert-butylmethyl ether each time. The collected organic layers were dried over magnesium sulfate, filtered, and the solvent was removed under reduced pressure to obtain 372.7 g of the title compound. ESI-MS: 420 [M+H]+ Retention time (High-performance liquid chromatography): 0.99 minutes (Method A) Retention time (Kiraly supercritical fluid chromatography) 3.89 minutes (Method H), >98% ee Step 4: ((2S,5S)-4-benzyl-5-(((tert-butyldiphenylsilyl)oxy)methyl)morpholin-2-yl)methanol ((2S,5S)-4-benzyl-5-(((tert-butyldiphenylsilyl)oxy)methyl)morpholin-2-yl)methanol (Int-4) (S)-2-(benzylamino)-3-((tert-butyldiphenylsilyl)oxy)propan-1-ol (Int-3, 372.7 g, 0.89 mol), (R)-epichlorohydrine (R)-epichlorohydrine (125.0 g, 1.35 mmol), and lithium perchlorate (9.50 g, 89.3 mmol) were added to 1800 mL of toluene and stirred at 60°C for 6 hours. Lithium perchlorate (5.00 g, 47 mmol) was then added again, and the mixture was stirred at 60°C overnight. The mixture was cooled to -10°C and sodium methoxide (5 M in methanol, 600 mL, 3.00 mol) was added while maintaining an internal temperature at or below 0°C. The mixture was then brought to room temperature and stirred for 24 hours. 500 mL of saturated ammonia hydrochloride solution and 500 mL of water were added. The layers were separated, and the aqueous layer was extracted twice using toluene. The collected organic layers were dried over magnesium sulfate, filtered, and the solvent was removed under reduced pressure.The crude product was dissolved in 2000 mL tert-butyl methyl ether (TME) and 225 mL hydrochloric acid (4 M in dioxane) was added while cooling in an ice bath. 300 mL dichloromethane was added and the mixture stirred at room temperature. The precipitate was filtered, and the filter paste was washed with 200 mL TME. The solid was dissolved in dichloromethane, filtered, and the solvent was removed under reduced pressure. 1500 mL TME and 300 mL dichloromethane were added to the product and stirred at room temperature. The precipitate was filtered, and the filter paste was washed with a mixture of 80 mL TME and 20 mL dichloromethane. Dichloromethane and water were added to the resulting solid, the mixture was shaken, and the layers were separated. Concentrated aqueous ammonia (≥ 25%) was added until a basic pH was obtained. The layers were separated, and the aqueous layer was extracted twice using dichloromethane. The collected organic layers were dried over magnesium sulfate, filtered, and the solvent was removed under reduced pressure to obtain 216.4 g of the title compound. ESI-MS: 476 [M+H]+ Retention time (High-performance liquid chromatography): 0.99 minutes (Method A) Step 5: Tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-(hydroxymethyl)morpholine-4-carboxylate (Int-5) ((2S,5S)-4-benzyl-5-(((tert-butyldiphenylsilyl)oxy)methyl)morpholin-2-yl)methanol (Int-4, 216.4 g, 455 mmol) di-tert-butyl dicarbonate (100 g, 458 mmol) and palladium(II) hydroxide on water-moistened charcoal (15 g) were added to 1000 mL of methanol, and the mixture was shaken in a hydrogen atmosphere (60 psi) overnight. The mixture was filtered, and the solvent was removed under reduced pressure to obtain 220.0 g of the title compound. ESI-MS: 508 [M+Na]+ Retention time (High-performance liquid chromatography): 1.29 minutes (Method A) Step 6: (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenylsilyl)oxy)methyl)morpholine-2-carboxylic acid (Int-6) Tert-butyl (2S,5) was mixed tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-(hydroxymethyl)morpholine-4-carboxylate (Int-5, 220.0 g, 453 mmol), 1000 mL acetonitrile, and 1200 mL phosphate buffer according to Sörensen (pH 6.4) were stirred in an ice bath. Sodium chlorite (135.2 g, 1.49 mmol) was added in one portion while the reaction mixture was cooled in an ice bath. Next, iodobenzene diacetate (14.6 g, 45.3 mmol) and 2,2,6,6-tetramethylpiperidinyloxy (14.2 g, 90.6 mmol) were added in batches while the reaction mixture was cooled in an ice bath. The reaction was then slowly warmed to room temperature and stirred overnight. 600 mL of ethyl acetate and 250 mL of 10% citric acid were added to the water. The layers were separated, and the organic layer was washed with 300 mL of 10% aqueous sodium thiosulfate. The organic layer was then washed with a mixture of 150 mL of pyrene and 150 mL of 10% aqueous citric acid.The aqueous layers were extracted twice using the same sequence, each time with 600 mL of ethyl acetate. The collected organic layers were dried over magnesium sulfate, filtered, and the solvent removed under reduced pressure. 1200 mL of 15% concentrated aqueous ammonia (≥ 25%) and 300 mL of acetonitrile were mixed with the crude product, and the mixture was extracted three times using 400 mL of heptane. The heptane layers were extracted using a mixture of 300 mL of 15% concentrated aqueous ammonia (≥ 25%) and 50 mL of acetonitrile. The aqueous layers were collected, and most of the organic solvent was removed under reduced pressure. The remaining aqueous layer was acidified with citric acid, and the mixture was extracted three times using dichloromethane. The collected organic layers were dried over magnesium sulfate, filtered, and the solvent removed under reduced pressure to obtain 218.4 g of the title compound. ESI-MS: 522 [M+Na]+ Retention time (High-performance liquid chromatography): 1.28 minutes (Method A) Retention time (supercritical fluid chromatography Kirali) 2.07 minutes, ee >98% (Method I) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.00 (s, 9 H), 1.35 (s, 9 H), 2.78 (br s, 1 H), 3.59 (dd, J=11.8 Hz, 3.3 Hz, 1H), 3.62 – 3.71 (m, 1H), 3.84 (t, J=8.1 Hz, 1 H), 3.88 – 4.11 (m, 4 H), 7.38 – 7.51 (m, 6 H), 7.58 – 7.66 (m, 4 H), 12.96 (br s, 1 H). Double divisor ratio ≥ 95:5 Preparation of 2-phenylpropan-2-amines by substituting (Int-7) from SM-2: 2-(4-chloro-2-methoxyphenyl)propan-2-amine hydrochloride (Int-7.1) A mixture of 4-chloro-2-methoxybenzonitrile (SM-2.1, 500 mg, 2.98 mmol) in 17 mL diethyl ether was treated with methyl magnesium bromide (3 M solution in diethyl ether, 3.5 mL, 10.4 mmol). After stirring overnight, titanium(IV) isopropoxide (0.88 mL, 2.98 mmol) was slowly added. After stirring overnight, methyl magnesium bromide (3 M solution in diethyl ether, 3.5 mL, 10.4 mmol) and titanium(IV) isopropoxide (0.88 mL, 2.98 mmol) were again slowly added. After 5.5 hours, ethyl acetate was added, and the mixture was stirred in an ice bath. Ten percent aqueous citric acid was added slowly to a pH of 4. The layers were separated, and concentrated aqueous ammonia (≥ 25%) was added to the aqueous layer until a basic pH was obtained. The basic aqueous layer was extracted twice using ethyl acetate, dried over sodium sulfate, and filtered. The solvents were then removed under reduced pressure.Tetrahydrofuran was added to the remaining material, and the mixture was purified by preparative RP-HPLC (Waters SunFire C18, acetonitrile / water / trifluoroacetic acid, 50°C). Two mL of 4 M aqueous hydrochloric acid was added to the product-containing fraction, the mixture was concentrated under reduced pressure, methanol was added, and the mixture was concentrated again under reduced pressure to obtain 130 mg of the title compound. ESI-MS: 183 [M+H−NH3]+ Retention time (High-performance liquid chromatography): 0.95 minutes (Method C) 2-(2-chloro-4-methylphenyl)propan-2-amine hydrochloride (Int-7.2) A mixture of 2-chloro-4-methylbenzonitrile (SM-2.2, 500 mg, 3.30 mmol) in 17 mL diethyl ether was treated with methyl magnesium bromide (3 M DET, 3.8 mL, 11.5 mmol). After overnight stirring, methyl magnesium bromide (3 M DET, 2.0 mL, 6 mmol) was added again, and the mixture was stirred at room temperature. After 4 hours, titanium(IV) isopropoxide (0.98 mL, 3.30 mmol) was added slowly. After overnight stirring, methyl magnesium bromide (3 M DET, 2.0 mL, 6 mmol) and titanium(IV) isopropoxide (1.00 mL, 3.30 mmol) were added again slowly. After 2.5 hours, ethyl acetate was added, and the mixture was stirred in an ice bath. 10% aqueous citric acid was slowly added to pH 4. The layers were separated, and concentrated aqueous ammonia (≥ 25%) was added to the aqueous layer until a basic pH was obtained. The basic aqueous layer was extracted twice using ethyl acetate, followed by drying over sodium sulfate and filtration. Approximately 75% of the solvent was removed under reduced pressure.To the resulting mixture, 1 ml of hydrochloric acid (4 molar in dioxane) was added and the mixture was concentrated under reduced pressure to obtain 460 mg of the title compound, which was used in the next step without further purification. ESI-MS: 167 [M+H−NH3]+ Retention time (High-performance liquid chromatography): 0.95 minutes (Method C) 2-(2-chloro-3-fluorophenyl)propan-2-amine hydrochloride (Int-7.3) A mixture of 2-chloro-3-fluorobenzonitrile (SM-2.3, 467 mg, 3.0 mmol) in 10 mL tetrahydrofuran was purged using a nitrogen stream. Methylmagnesium bromide (3 M DV, 3.5 mL, 10.5 mmol) was added, and the mixture was microwaved at 100 °C for 10 minutes. Titanium(IV) isopropoxide (0.89 mL, 3.0 mmol) was added, and the mixture was microwaved to 50 °C for 1 hour. Titanium(IV) isopropoxide (0.2 mL, 0.67 mmol) was added again, and the mixture was microwaved to 50 °C for 30 minutes. Thirty mL ethyl acetate and 15 mL 10% aqueous citric acid were added to the reaction mixture, and the mixture was stirred until all solids were dissolved. The layers were separated, and concentrated aqueous ammonia (≥ 25%) was added to the aqueous layer until a basic pH was obtained. The basic aqueous layer was extracted using 40 mL of ethyl acetate, followed by drying over sodium sulfate and filtration.Two molars of hydrochloric acid were added to the diethyl ether and the mixture was concentrated under reduced pressure to obtain 545 mg of the title compound in the form of a hydrochloride salt, which was used in the next step without further purification. ESI-MS: 188 [M+H−NH3]+ Retention time (High-performance liquid chromatography): 1.05 minutes (Method D) 2-(2-chloro-3,4-difluorophenyl)propan-2-amine hydrochloride (Int-7.4) A mixture of 2-chloro-3,4-difluorobenzonitrile (SM-2.4, 500 mg, 2.88 mmol) in 17 mL of diethyl ether was treated with methyl magnesium bromide (3 M solution in diethyl ether, 3.36 mL, 10.1 mmol) and stirred overnight. Titanium(IV) isopropoxide (0.85 mL, 2.88 mmol) was then added slowly, and the mixture was stirred overnight. Finally, methyl magnesium bromide (3 M solution in diethyl ether, 1.5 mL, 4.5 mmol) and titanium(IV) isopropoxide (0.43 mL, 1.44 mmol) were added slowly again. After 4 hours, ethyl acetate and 10% aqueous citric acid were added slowly, with occasional cooling in an ice bath, until pH 4. The layers were separated, and concentrated aqueous ammonia (≥ 25%) was added to the aqueous layer until a basic pH was obtained. The basic aqueous layer was extracted twice using ethyl acetate, followed by drying over sodium sulfate and filtration.To the resulting mixture, 1 ml of hydrochloric acid (4 molar in dioxane) was added and the mixture was concentrated under reduced pressure to obtain 470 mg of the title compound in the form of hydrochloride salt, which was used in the next step without further purification. ESI-MS: 189 [M+H−NH3]+ Retention time (High-performance liquid chromatography): 0.92 minutes (Method C) 2-(4-fluoro-2-methoxyphenyl)propan-2-amine hydrochloride (Int-7.5) A mixture of 4-fluoro-2-methoxybenzonitrile (SM-2.5, 500 mg, 3.31 mmol) in 17 mL diethyl ether was treated with methyl magnesium bromide (3 M solution in diethyl ether, 3.86 mL, 11.6 mmol) and stirred overnight. Titanium(IV) isopropoxide (0.98 mL, 3.31 mmol) was then added slowly, and the mixture was stirred overnight. Finally, methyl magnesium bromide (3 M solution in diethyl ether, 2.0 mL, 6.0 mmol) and titanium(IV) isopropoxide (1.0 mL, 3.38 mmol) were added slowly again. After stirring overnight, ethyl acetate and 10% aqueous citric acid were slowly added, intermittently cooling in an ice bath to pH 4. The layers were separated, and concentrated aqueous ammonia (≥ 25%) was added to the aqueous layer until a basic pH was obtained. The basic aqueous layer was extracted twice using ethyl acetate, dried over sodium sulfate, and filtered. One mL of hydrochloric acid (4 M in dioxane) was added to the resulting mixture, and the solvent was removed under reduced pressure.Tetrahydrofuran was added to the residue, and the mixture was purified by preparative RP-HPLC (Waters SunFire C18, acetonitrile / water / trifluoroacetic acid, 50 °C). The solvent was removed under reduced pressure. Saturated aqueous sodium bicarbonate solution was added to the residue, and the aqueous layer was extracted three times using ethyl acetate. The collected organic layers were dried over sodium sulfate, filtered, and the solvent was removed under reduced pressure. Tetrahydrofuran was added to the residue, along with 0.5 mL of hydrochloric acid (4 M in dioxane), and the mixture was concentrated under reduced pressure to obtain 180 mg of the target compound. ESI-MS: 167 [M+H−NH3]+ Retention time (High-performance liquid chromatography): 0.88 minutes (Method C) 2-(2,4-difluoro-3-methylphenyl)propan-2-amine hydrochloride (Int-7.6) A mixture of 2,4-difluoro-3-methylbenzonitrile (SM-2.6, 500 mg, 3.27 mmol) in 17 mL diethyl ether was treated with methyl magnesium bromide (3 M solution in diethyl ether, 3.81 mL, 11.6 mmol) and stirred overnight. Titanium(IV) isopropoxide (0.97 mL, 3.27 mmol) was then added slowly, and the mixture was stirred overnight. Ethyl acetate and 10% aqueous citric acid were added slowly, with occasional cooling in an ice bath, until pH 4 was achieved. The layers were separated, and concentrated aqueous ammonia (≥ 25%) was added to the aqueous layer until pH was alkaline. The basal aqueous layer was extracted twice using ethyl acetate, followed by drying over sodium sulfate and filtration. Approximately 75% of the solvent was removed under reduced pressure. One milliliter of hydrochloric acid (4 M in dioxane) was added to the resulting mixture, and the mixture was concentrated under reduced pressure to obtain 560 mg of the target compound, which was used in the next step without further purification. ESI-MS: 169 [M+H−NH3]+ Retention time (High-performance liquid chromatography): 0.93 minutes (Method C) 2-(2-chloro-4,5-difluorophenyl)propan-2-amine hydrochloride (Int-7.7) A mixture of 2-chloro-4,5-difluorobenzonitrile (SM-2.7, 694 mg, 4.00 mmol) in 20 mL diethyl ether was purified with nitrogen and treated with methylmagnesium bromide (3 M solution in diethyl ether, 4.67 mL, 14.0 mmol). After 5 hours, titanium(IV) isopropoxide (1.18 mL, 4.00 mmol) was added slowly, and the mixture was stirred overnight. Ethyl acetate and 15 mL of 10% aqueous citric acid were added slowly, and the mixture was stirred until the solids dissolved. The layers were separated, and concentrated aqueous ammonia (≥ 25%) was added to the aqueous layer until a basic pH was obtained. The aqueous layer was extracted twice with ethyl acetate. The collected organic layers were dried over sodium sulfate, filtered, 2 M HCl was added in diethyl ether and the mixture was concentrated under reduced pressure to obtain 705 mg of the title compound which was used in the next step without further purification. ESI-MS: 206 [M+H]+ Retention time (High-performance liquid chromatography): 1.09 minutes (Method D) 2-(4-fluoro-2-(trifluoromethyl)phenyl)propan-2-amine (Int-7.8) A mixture of 4-fluoro-2-(trifluoromethyl)benzonitrile (SM-2.8, 1.0 g, 5.29 mmol) in 40 mL diethyl ether was purified using nitrogen and treated with methyl magnesium bromide (3 M solution in diethyl ether, 9.75 mL, 29.3 mmol) in two parts, stirred for three days. Titanium(IV) isopropoxide (1.57 mL, 5.29 mmol) was then added slowly, and the mixture was stirred overnight. Titanium(IV) isopropoxide (1.57 mL, 5.29 mmol) was added slowly again and the mixture was stirred overnight. Titanium(IV) isopropoxide (3.25 mL, 11.0 mmol) was added slowly once more, followed by the addition of 20 mL diethyl ether, and the mixture was stirred for three days. Ethyl acetate and 15 mL of 10% aqueous citric acid were added slowly, and the mixture was stirred until the solids dissolved. The layers were separated, and the organic layer was washed with water. Concentrated aqueous ammonia (≥ 25%) was added to the collected aqueous layers until a basic pH was achieved. The aqueous layer was extracted twice using ethyl acetate.The collected organic layers were dried over sodium sulfate, filtered, and the solvents were removed under reduced pressure to obtain 100 mg of the title compound, which was used in the next step without further purification. ESI-MS: 222 [M+H]+ Retention time (High-performance liquid chromatography): 0.75 minutes (Method C) 2-(2-fluoro-4-methylphenyl)propan-2-amine hydrochloride (Int-7.9) A mixture of 2-fluoro-4-methylbenzonitrile (SM-2.9, 500 mg, 3.70 mmol) in 17 mL diethyl ether was purified with nitrogen and treated with methylmagnesium bromide (3 M solution in diethyl ether, 4.32 mL, 13.0 mmol). After stirring overnight, titanium(IV) isopropoxide (1.10 mL, 3.70 mmol) was slowly added, and the mixture was stirred for 5 days. Ethyl acetate was added, followed by the slow addition of 10% aqueous citric acid to pH 4. The layers were separated, and concentrated aqueous ammonia (≥ 25%) was added to the aqueous layer until a basic pH was obtained. The aqueous layer was extracted twice with ethyl acetate. The collected organic layers were dried over sodium sulfate, filtered, and approximately 75% of the solvent was removed under reduced pressure. 4 M HCl was added to the dioxane and the mixture was concentrated under reduced pressure to obtain 480 mg of the title compound, which was used in the next step without further purification. ESI-MS: 151 [M+H−NH3]+ Retention time (High-performance liquid chromatography): 0.89 minutes (Method C) 2-(2-cyclopropyl-4-fluorophenyl)propan-2-amine hydrochloride (Int-7.10) A mixture of 2-cyclopropyl-4-fluorobenzonitrile (SM-2.10, 200 mg, 1.24 mmol) in 5 mL diethyl ether was purified using nitrogen and treated with methylmagnesium bromide (3 M solution in diethyl ether, 1.45 mL, 4.34 mmol). After stirring overnight, methylmagnesium bromide (3 M solution in diethyl ether, 1.45 mL, 4.34 mmol) was added again. After stirring overnight, titanium(IV) isopropoxide (0.37 mL, 1.24 mmol) was added slowly, and the mixture was stirred for 2 days. Subsequently, titanium(IV) isopropoxide (0.37 mL, 1.24 mmol) was added slowly again, and the mixture was stirred for 3 days. Ethyl acetate was added, followed slowly by 15 mL of 10% aqueous citric acid. The layers were separated, and concentrated aqueous ammonia (≥ 25%) was added to the aqueous layer until a basic pH was achieved. The aqueous layer was extracted using ethyl acetate. The collected organic layers were dried over sodium sulfate, filtered, and 4 M hydrochloric acid was added to dioxane.The mixture was concentrated under reduced pressure to obtain 120 mg of the title compound, which was used in the next step without further purification. ESI-MS: 177 [M+H−NH3]+ Retention time (High-performance liquid chromatography): 0.96 minutes (Method C) 2-(2-chloro-4-cyclopropylphenyl)propan-2-amine hydrochloride (Int-7.11) A mixture of 2-chloro-4-cyclopropylbenzonitrile (SM-2.11, 330 mg, 1.86 mmol) in 5 mL diethyl ether was purified with nitrogen and treated with methyl magnesium bromide (3 M solution in diethyl ether, 2.17 mL, 6.50 mmol). After 2 days, titanium(IV) isopropoxide (0.55 mL, 1.86 mmol) was slowly added, and the mixture was stirred for 2 days. Titanium(IV) isopropoxide (0.55 mL, 1.86 mmol) was slowly added again, and the mixture was stirred for 3 days. Ethyl acetate was added, followed by the slow addition of 15 mL of 10% aqueous citric acid. The layers were separated, and concentrated aqueous ammonia (≥ 25%) was added to the aqueous layer until a basic pH was obtained. The aqueous layer was extracted using ethyl acetate. The collected organic layers were dried over sodium sulfate, filtered, and 4 M hydrochloric acid was added to dioxane. The mixture was concentrated under reduced pressure to obtain 70 mg of the target compound, which was used in the next step without further purification. ESI-MS: 193 [M+H−NH3]+ Retention time (High-performance liquid chromatography): 1.01 minutes (Method C) 2-(2,4-difluorophenyl)propan-2-amine hydrochloride (Int-7.12) A mixture of 2,4-difluorobenzonitrile (SM-2.12, 200 mg, 1.44 mmol) in 5 mL diethyl ether was purified with nitrogen and treated with methylmagnesium bromide (3 M solution in diethyl ether, 1.68 mL, 5.03 mmol). After 2 days, titanium(IV) isopropoxide (0.64 mL, 2.16 mmol) was added slowly in two parts, and the mixture was stirred for 3 days. Ethyl acetate was added, followed by the slow addition of 10% aqueous citric acid to pH 4. The layers were separated, and concentrated aqueous ammonia (≥ 25%) was added to the aqueous layer until pH was alkaline. The aqueous layer was extracted twice with ethyl acetate. The collected organic layers were dried over sodium sulfate, filtered, and 4 M hydrochloric acid was added to dioxane. The mixture was concentrated under reduced pressure to obtain 230 mg of the title compound, which was used in the next step without further purification. ESI-MS: 155 [M+H−NH3]+ Retention time (High-performance liquid chromatography): 0.85 minutes (Method C) 2-(2-chloro-4-fluoro-3-methylphenyl)propan-2-amine hydrochloride (Int-7.17) A mixture of 2-chloro-4-fluoro-3-methylbenzonitrile (SM-2.17, 400 mg, 2.36 mmol) in 17 mL diethyl ether was purified with nitrogen and treated with methylmagnesium bromide (3 M solution in diethyl ether, 2.75 mL, 8.26 mmol). After stirring overnight, titanium(IV) isopropoxide (0.70 mL, 2.40 mmol) was added slowly, and the mixture was stirred overnight. Titanium(IV) isopropoxide (0.35 mL, 1.70 mmol) was added slowly again, and the mixture was stirred for 3 days. Ethyl acetate was added, followed by the slow addition of 10% aqueous citric acid to pH 4. The layers were separated, and concentrated aqueous ammonia (≥ 25%) was added to the aqueous layer until a basic pH was achieved. The aqueous layer was extracted using ethyl acetate. The collected organic layers were dried over sodium sulfate, filtered, and 4 M hydrochloric acid was added to dioxane. The mixture was concentrated under reduced pressure to obtain 280 mg of the target compound, which was used in the next step without further purification. ESI-MS: 203 [M+H]+ Retention time (High-performance liquid chromatography): 0.96 minutes (Method C) 2-(2-chloro-5-fluorophenyl)propan-2-amine hydrochloride (Int-7.18) A mixture of 2-chloro-5-fluorobenzonitrile (SM-2.18, 1.00 g, 6.43 mmol) in 40 mL diethyl ether was purified with nitrogen and treated with methyl magnesium bromide (3 M solution in diethyl ether, 6.50 mL, 19.5 mmol). After stirring for 3 days, titanium(IV) isopropoxide (1.90 mL, 6.43 mmol) was added slowly, and the mixture was stirred overnight. Titanium(IV) isopropoxide (3.80 mL, 12.9 mmol) was added slowly again in two parts, and the mixture was stirred for 2 days. Ethyl acetate was added, followed by the slow addition of 15 mL of 10% aqueous citric acid. The layers were separated, and concentrated aqueous ammonia (≥ 25%) was added to the aqueous layer until a basic pH was obtained. The aqueous layer was extracted twice using ethyl acetate. The collected organic layers were dried over sodium sulfate, filtered, and 4 M hydrochloric acid was added to dioxane. The mixture was concentrated under reduced pressure to obtain 340 mg of the target compound, which was used in the next step without further purification. ESI-MS: 188 [M+H]+ Retention time (High-performance liquid chromatography): 0.90 minutes (Method C) 2-(3-chloro-2,4-difluorophenyl)propan-2-amine hydrochloride n lang="ar-SA"> (Int-7.19) A mixture of 3-chloro-2,4-difluorobenzonitrile (SM-2.19, 400 mg, 2.31 mmol) in 17 mL diethyl ether was purified with nitrogen and treated with methylmagnesium bromide (3 M solution in diethyl ether, 2.69 mL, 8.07 mmol). After stirring for 1.5 hours, titanium(IV) isopropoxide (0.68 mL, 2.31 mmol) was slowly added, and the mixture was stirred overnight. Ethyl acetate was added, followed by the slow addition of 15 mL of 10% aqueous citric acid. The layers were separated, and concentrated aqueous ammonia (≥ 25%) was added to the aqueous layer until a basic pH was obtained. The aqueous layer was extracted twice with ethyl acetate. The collected organic layers were dried over sodium sulfate, filtered, and 4 M hydrochloric acid was added to dioxane. The mixture was concentrated under reduced pressure to obtain 480 mg of the target compound, which was used in the next step without further purification. ESI-MS: 206 [M+H]+ Retention time (High-performance liquid chromatography): 0.87 minutes (Method C) 2-(3-chloro-5-fluorophenyl)propan-2-amine hydrochloride (Int-7.20) A mixture of 3-chloro-5-fluorobenzonitrile (SM-2.20, 400 mg, 2.57 mmol) in 17 mL diethyl ether was purified with nitrogen and treated with methyl magnesium bromide (3 M solution in diethyl ether, 3.00 mL, 9.00 mmol). After stirring overnight, titanium(IV) isopropoxide (0.76 mL, 2.57 mmol) was slowly added, and the mixture was stirred overnight. Ethyl acetate was added, followed by the slow addition of 15 mL of 10% aqueous citric acid. The layers were separated, and concentrated aqueous ammonia (≥ 25%) was added to the aqueous layer until a basic pH was obtained. The aqueous layer was extracted with ethyl acetate. The collected organic layers were dried over sodium sulfate, filtered, and 4 M hydrochloric acid was added to dioxane. The mixture was concentrated under reduced pressure to obtain 270 mg of the title compound, which was used in the next step without further purification. ESI-MS: 188 [M+H]+ Retention time (High-performance liquid chromatography): 0.92 minutes (Method C) 2-(3,4-difluoro-2-methylphenyl)propan-2-amine hydrochloride (Int-7.21) A mixture of 3,4-difluoro-2-methylbenzonitrile (SM-2.21, 400 mg, 2.61 mmol) in 17 mL diethyl ether was purified with nitrogen and treated with methylmagnesium bromide (3 M solution in diethyl ether, 3.05 mL, 9.14 mmol). After stirring overnight, titanium(IV) isopropoxide (0.77 mL, 2.61 mmol) was slowly added, and the mixture was stirred overnight. Titanium(IV) isopropoxide (0.39 mL, 1.31 mmol) was then slowly added, and the mixture was stirred for 3 days. Ethyl acetate was added, followed by the slow addition of 15 mL of 10% aqueous citric acid. The layers were separated, and concentrated aqueous ammonia (≥ 25%) was added to the aqueous layer until a basic pH was obtained. The aqueous layer was extracted using ethyl acetate. The collected organic layers were dried over sodium sulfate, filtered, and 4 M hydrochloric acid was added to dioxane. The mixture was concentrated under reduced pressure to obtain 320 mg of the target compound, which was used in the next step without further purification. ESI-MS: 186 [M+H]+ Retention time (High-performance liquid chromatography): 0.84 minutes (Method C) Preparation of 2-phenylpropan-2-amines by substituting (Int-7) from SM-3: 2-(3,5-dichloro-2-fluorophenyl)propan-2-amine hydrochloride (Int-7.22) Step B-1: (E)-N-(1-(3,5-dichloro-2-fluorophenyl)ethylidene)-2-methylpropane-2-sulfinamide (E)-N-(1-(3,5-dichloro-2-fluorophenyl)ethylidene)-2-methylpropane-2-sulfinamide (Int-8.22) A mixture of 1-(3,5-dichloro-2-fluorophenyl)ethan-1-one (SM-3.22, 3.50 g, 16.9 mmol), 2-methylpropane-2-sulfinamide (6.56 g, 54.1 mmol), and titanium(IV) isopropoxide (12.0 mL, 40.6 mmol) was stirred in 70 mL of tetrahydrofuran upon reflux. After stirring overnight, the mixture was cooled to room temperature, 250 mL of ethyl acetate was added, and the mixture was then added to 250 mL of ice-water mixture and stirred for 0.5 hours. The mixture was filtered, and the layers were separated. The organic layer was washed using 250 mL of Bryn. The aqueous layer was extracted using ethyl acetate, and the collected organic layers were dried over sodium sulfate, filtered, and the solvents were removed under reduced pressure. The remaining material was dissolved in a minimal amount of dichloromethane and purified by column chromatography (silica, petroleum ether / ethyl acetate). The product-containing fractions were collected, and the mixture was concentrated under reduced pressure to obtain 4.43 g of the title compound. ESI-MS: 310 [M+H]+ Retention time (High-performance liquid chromatography): 1.17 minutes (Method A) Step B-2: N-(2-(3,5-dichloro-2-fluorophenyl)propan-2-yl)-2-methylpropane-2-sulfinamide N-(2-(3,5-dichloro-2-fluorophenyl)propan-2-yl)-2-methylpropane-2-sulfinamide (Int-9.22) A mixture of (E)-N-(1-(3,5-dichloro-2-fluorophenyl)ethylenediamine)-2-methylpropane-2-sulfenamide (Int-8.22, 3.75 g, 12.1 mmol) in 40 mL toluene was cooled in an ice bath, and methyl magnesium bromide (3 M solution in diethyl ether, 15.0 mL, 45.0 mmol) was added. The mixture was allowed to warm to room temperature and stirred overnight. Saturated aqueous ammonium chloride solution and an equal volume of water were added, the mixture was shaken, and the layers were separated. The aqueous layer was extracted twice using toluene. The collected organic layers were dried over magnesium sulfate, filtered, and the solvents were removed under reduced pressure. The residual material was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50 °C). The product-containing portions were collected and dried to obtain 360 mg of the title compound. ESI-MS: 326 [M+H]+ Retention time (High-performance liquid chromatography): 1.15 minutes (Method A) Step B-3: 2-(3,5-dichloro-2-fluorophenyl)propan-2-amine hydrochloride (Int-7.22) To a mixture of N-(2-(3,5-dichloro-2-fluorophenyl)propane-2-yl)-2-methylpropane-2-sulfenamide (Int-9.22, 360 mg, 1.10 mmol) in 10 mL dichloromethane, 4 M dioxane hydrochloride (2.0 mL, 8.00 mmol) was added. After stirring for 2.5 hours, the mixture was concentrated under reduced pressure to obtain 290 mg of the title compound, which was used in the next step without further purification. ESI-MS: 222 [M+H]+ Retention time (High-performance liquid chromatography): 0.73 minutes (Method A) 2-(4-chloro-2,3-difluorophenyl)propan-2-amine trifluoroacetate (Int-7.23) Step B-1: (E)-N-(1-(4-chloro-2,3-difluorophenyl)ethylidene)-2-methylpropane-2-sulfinamide (E)-N-(1-(4-chloro-2,3-difluorophenyl)ethylidene)-2-methylpropane-2-sulfinamide (Int-8.23) A mixture of 1-(4-chloro-2,3-difluorophenyl)ethane-1-one (SM-3.23, 0.50 g, 2.62 mmol), 2-methylpropane-2-sulfenamide (1.02 g, 8.40 mmol), and titanium(IV) isopropoxide (1.86 mL, 6.30 mmol) was stirred in 10 mL of tetrahydrofuran upon reflux. After 6.5 hours, the mixture was stirred overnight at room temperature, then cooled in an ice bath, and 50 mL of ethyl acetate and 20 mL of water were added. The mixture was stirred for 10 minutes, filtered, and the layers were separated. The aqueous layer was extracted twice using ethyl acetate, and the resulting organic layers were dried over sodium sulfate, filtered, and the solvents were removed under reduced pressure. The remaining material was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50°C). The product-containing fractions were pooled and lyophilized to obtain 540 mg of the title compound. ESI-MS: 294 [M+H]+ Retention time (High-performance liquid chromatography): 1.06 minutes (Method C) Step B-2: 2-(4-chloro-2,3-difluorophenyl)propan-2-amine trifluoroacetate (Int-7.23) A mixture of (E)-N-(1-(4-chloro-2,3-difluorophenyl)ethylenediamine)-2-methylpropane-2-sulfenamide (Int-8.23, 540 mg, 1.84 mmol) in 10 mL toluene was cooled in an ice bath, and methyl magnesium bromide (3 M solution in diethyl ether, 2.45 mL, 7.35 mmol) was added slowly. The mixture was allowed to warm to room temperature and stirred for 14 days. Saturated aqueous ammonium chloride solution and an equal volume of water were added, the mixture was shaken, and the layers were separated. The aqueous layer was extracted three times using ethyl acetate. The collected organic layers were dried over magnesium sulfate, filtered, and the solvents were removed under reduced pressure. The remaining material was purified by preparative RP-HPLC (Waters Sunfire C18, acetonitrile / water / trifluoroacetic acid, 50°C). The product-containing fractions were pooled and lyophilized to obtain 130 mg of the title compound. ESI-MS: 206 [M+H]+ Retention time (High-performance liquid chromatography): 1.12 minutes (Method A) 2-(4,5-dichloro-2-fluorophenyl)propan-2-amine hydrochloride (Int-7.24) Step B-1: (E)-N-(1-(4,5-dichloro-2-fluorophenyl)ethylidene)-2-methylpropane-2-sulfinamide (E)-N-(1-(4,5-dichloro-2-fluorophenyl)ethylidene)-2-methylpropane-2-sulfinamide (Int-8.24) A mixture of 1-(4,5-dichloro-2-fluorophenyl)ethane-1-one (SM-3.24, 1.00 g, 4.83 mmol), 2-methylpropane-2-sulfenamide (1.87 g, 15.5 mmol), and titanium(IV) isopropoxide (3.30 g, 11.6 mmol) was stirred in 15 mL of tetrahydrofuran at 80°C. After stirring overnight, the mixture was stirred in an ice bath, and ethyl acetate and water were added. After 10 minutes, the mixture was filtered, and the layers were separated. The aqueous layer was washed twice with ethyl acetate. The collected organic layers were dried over sodium sulfate, filtered, and the solvents were removed under reduced pressure. The residue was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50°C). The product-containing parts were assembled and dried to obtain 1.12 g of the title compound. ESI-MS: 310 [M+H]+ Retention time (High-performance liquid chromatography): 1.16 minutes (Method A) Step B-2: N-(2-(4,5-dichloro-2-fluorophenyl)propan-2-yl)-2-methylpropane-2-sulfinamide N-(2-(4,5-dichloro-2-fluorophenyl)propan-2-yl)-2-methylpropane-2-sulfinamide(Int-9.24) A mixture of (E)-N-(1-(4,5-dichloro-2-fluorophenyl)ethylenediamine)-2-methylpropane-2-sulfenamide (Int-8.24, 1.12 g, 3.61 mmol) in 20 mL toluene was cooled in an ice bath, and methyl magnesium bromide (3 M DEF, 4.81 mL, 14.4 mmol) was added. The mixture was allowed to warm to room temperature and stirred overnight. The mixture was then cooled in an ice bath, and methyl magnesium bromide (3 M DEF, 2.40 mL, 7.2 mmol) was added. The mixture was allowed to warm to room temperature and stirred for 5 days. Finally, the mixture was cooled in an ice bath, and methyl magnesium bromide (3 M DEF, 2.40 mL, 7.2 mmol) was added. The mixture was allowed to warm to room temperature and stirred for 13 days. 25 mL of toluene, 15 mL of saturated aqueous ammonium chloride solution, and 15 mL of water were added, and the layers were separated. The aqueous layer was extracted three times using ethyl acetate. The collected organic layers were dried over sodium sulfate, filtered, and the solvents were removed under reduced pressure.The remaining material was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50°C). The product-containing fractions were pooled and lyophilized to obtain 210 mg of the title compound. ESI-MS: 326 [M+H]+ Retention time (High-performance liquid chromatography): 1.11 minutes (Method C) Step B-3: 2-(4,5-dichloro-2-fluorophenyl)propan-2-amine hydrochloride (Int-7.24) To a mixture of N-(2-(4,5-dichloro-2-fluorophenyl)propane-2-yl)-2-methylpropane-2-sulfenamide (Int-9.24, 210 mg, 0.64 mmol) in 4 mL dichloromethane, 4 M dioxane hydrochloride (0.80 mL, 3.22 mmol) was added. After stirring for 2.5 hours, the mixture was concentrated under reduced pressure to obtain 170 mg of the title compound, which was used in the next step without further purification. ESI-MS: 222 [M+H]+ Retention time (High-performance liquid chromatography): 1.01 minutes (Method C) 2-(4-fluoro-2-methylbenzofuran-7-yl)propan-2-amine hydrochloride (Int-7.32) Step a: 2-fluoro-4-(prop-2-yn-1-yloxy)benzonitrile (Int-12) To a mixture of 4-fluoro-2-hydroxybenzonitrile (5.00 g, 36.5 mmol) and 80 mL N,N-dimethylformamide, potassium carbonate (12.1 g, 87.5 mmol) was added, followed by the distillation of proparyl bromide (3.30 mL, 43.8 mmol). After stirring for 3.5 hours at room temperature, the mixture was poured over ice-water (250 mL) and stirred for 30 minutes. The resulting solids were separated by filtration, washed with water, and dried to obtain 5.54 g of the title compound, which was used in the next step without further purification. ESI-MS: 176 [M+H]+ Retention time (High-performance liquid chromatography): 0.97 minutes (Method A) Step b: 4-Fluoro-2-methylbenzofuran-7-carbonitrile (Int-13) A mixture of 2-fluoro-4-(prop-2-en-1-yloxy)benzonitrile crude (Int-12, 5.00 g, as obtained from the step above) and 9 mL diethylane was divided into three microwave flasks. The flasks were covered and heated at 220 °C for 7 hours. During cooling to room temperature, the contents were pooled, diluted with diethylan ether, and washed 6 times with 2 M aqueous hydrochloric acid (30 mL each). The pooled organic extract was dried over sodium sulfate and concentrated under reduced pressure. The remaining crude was purified by flash chromatography (silica, petroleum ether / ethyl acetate) to obtain 860 mg of the title compound. Rf (thin-layer chromatography): 0.67 (silica, petroleum ether / ethyl acetate 7:3) Step c: 2-(4-fluoro-2-methylbenzofuran-7-yl)propan-2-amine hydrochloride (Int-7.32) The crude 4-fluoro-2-methylbenzofuran-7-carbonitrile (Int-13, as obtained from the step above, 860 mg) was dissolved in dry diethyl ether (30 mL) and the mixture was stirred under an argon atmosphere in a round-bottom flask at ambient temperature. Methyl magnesium bromide solution (5.7 mL, 3.0 M in diethyl ether, 17.0 mmol) was added by distillation, and stirring was completed at the same temperature for 18 hours before the addition of weak titanium(IV) isopropoxide (1.45 mL, 5.0 mmol) under ice cooling. The mixture was stirred for an additional 72 hours before the addition of another methyl magnesium bromide solution (5.7 mL, 3.0 M in diethyl ether, 17.0 mmol), followed by further stirring for 6 hours. Ethyl acetate (50 mL) was slowly added to the mixture, followed by aqueous citric acid (10%, 40 mL). Concentrated aqueous ammonia (≥ 25%) was then added until a basic pH was achieved. The mixture was extracted using ethyl acetate, the organic layer was dried over sodium sulfate, and the concentrate was collected under reduced pressure.Hydrochloric acid (2 M in diethyl ether) was added to a mixture of the remaining material and 15 mL of diethyl ether. The solids were separated by filtration and dried under reduced pressure to obtain 394 mg of the target compound, which was used in the next step without further purification. ESI-MS: 208 [M+H]+ Retention time (High-performance liquid chromatography): 0.95 minutes (Method C) 2-(4-chloroisoquinolin-1-yl)propan-2-amine hydrochloride (Int-7.35) Step a: 4-chloroisoquinolin-1(2H)-one: To a mixture of isoquinoline-1(2H)-one (100 g, 689 mmol) in 2.5 L of acetonitrile, a solution of N-chlorosuccinimide (96.6 g, 723 mmol) was added in 500 mL of acetonitrile at 85 °C under a nitrogen atmosphere. The mixture was stirred for 12 hours at 85 °C and then cooled to 15 °C. The resulting solid was separated by filtration and centrifugation using 600 mL of acetonitrile at 10 °C for 30 minutes to obtain 100 g of the title product. ESI-MS: 180 [M+H]+ Retention time (high-performance liquid chromatography): 0.55 minutes (Method J) Step b: 1,4-dichloroisoquinoline: A mixture of 4-chloroisioquinoline-1(2H)-one (80.0 g, 445 mmol) and 400 mL phosphoric oxychloride was stirred for 12 hours at 100 °C under a nitrogen atmosphere. The mixture was concentrated under reduced pressure and slowly poured onto water (1 L). A saturated aqueous sodium bicarbonate solution was added until a pH of 7 was obtained. The aqueous layer was extracted using ethyl acetate (3 x 1000 mL), and the collected organic extracts were concentrated under reduced pressure. The residue was purified by column chromatography (silica, petroleum ether, ethyl acetate) to obtain 50.0 g of the title product. ESI-MS: 198 [M+H]+ Retention time (high-performance liquid chromatography): 0.71 minutes (Method J) Step c: 4-chloro-1-(1-ethoxyvinyl)isoquinoline: To a mixture of 1,4-dichloroisauline (100 g, 505 mmol) in 1 L N,N-dimethylformamide, bis(triphenylphosphine)palladium chloride (35.4 g, 50.5 mmol) and tributyl(1-ethoxy-vinyl)stannane (189 mL, 555 mmol) were added at 15 °C under a nitrogen atmosphere. The mixture was stirred for 12 hours at 80 °C. The reaction mixture was diluted with 1.5 L of aqueous potassium fluoride solution and extracted using ethyl acetate (2 × 1500 mL). The collected organic extracts were washed with Braine (1500 mL), dried over sodium sulfate, and concentrated under reduced pressure. The remaining material was purified by column chromatography (silica, petroleum ether, ethyl acetate) to obtain 100 g of the title compound. ESI-MS: 234 [M+H]+ Retention time (high-performance liquid chromatography): 0.78 minutes (Method K) Step d: 1-(4-chloroisoquinolin-1-yl)ethan-1-one: To a mixture of 4-chloro-1-(1-ethoxyphenyl)isoquinoline (100 g, 428 mmol) in 1 L of 1,4-dioxane, concentrated aqueous hydrochloric acid (89.0 mL, 1.07 mol) was added. The mixture was stirred for 12 hours at 15 °C. The reaction mixture was diluted with 1.0 L of water, and sodium bicarbonate was added until a pH of 7 was obtained. The aqueous layer was extracted using ethyl acetate (2 x 1000 mL). The collected organic extracts were washed with Braine (1000 mL), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (silica, petroleum ether, ethyl acetate) to obtain 75.0 g of the title compound. ESI-MS: 206 [M+H]+ Retention time (High-performance liquid chromatography): 1.06 minutes (Method C) Step e: N-(1-(4-chloroisoquinolin-1-yl)ethylidene)-2-methylpropane-2-sulfinamide: To a mixture of 1-(4-chloroisoquinoline-1-yl)ethane-1-one (65.0 g, 316 mmol) in 700 mL tetrahydrofuran, titanium(IV) isopropoxide (287 g, 1.01 mol) and 2-methylpropane-2-sulfenamide (91.9 g, 759 mmol) were added. The mixture was stirred for 8 hours at 70°C. The reaction mixture was heated at 0°C under a nitrogen atmosphere. The reaction mixture was diluted with 1 L of ethyl acetate followed by the addition of 1 L of water at 0°C. The mixture was extracted twice using ethyl acetate (1 L each time). The collected organic extracts were washed twice with saturated aqueous ammonium chloride solution (1 L each time), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (silica, petroleum ether, ethyl acetate) to obtain 65.0 g of the target compound. ESI-MS: 309 [M+H]+ Retention time (high-performance liquid chromatography): 0.71 minutes (Method K) Step f: N-(2-(4-chloroisoquinolin-1-yl)propan-2-yl)-2-methylpropane-2-sulfinamide: To a mixture of N-(1-(4-chloroisoquinoline-1-yl)ethylenediamine)-2-methylpropane-2-sulfenamide (30.0 g, 97.1 mmol) and 450 mL toluene, methyl magnesium bromide (3.0 M in diethyl ether, 194 mL, 582 mmol) was added by distillation at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 12 h at 0 °C. Saturated aqueous ammonium chloride solution (1000 mL) was added, and the mixture was extracted using ethyl acetate (2 x 1000 mL). The collected organic extracts were dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (silica, petroleum ether, ethyl acetate) to obtain 10.0 g of the title compound. ESI-MS: 325 [M+H]+ Retention time (High-performance liquid chromatography): 1.11 minutes (Method A) Step g: 2-(4-chloroisoquinolin-1-yl)propan-2-amine hydrochloride (Int-7.35): A mixture of N-(2-(4-chloroisoquinoline-1-yl)propane-2-yl)-2-methylpropane-2-sulfenamide (30.0 g, 92.3 mmol) and hydrochloric acid (1.0 M in ethyl acetate, 300 mL, 300 mmol) was stirred for 12 hours at 15 °C under a nitrogen atmosphere. The resulting solids were separated by filtration and centrifugation using 200 mL of ethyl acetate at 10 °C for 30 minutes to obtain 20.0 g of the title product. ESI-MS: 221 [M+H]+ Retention time (High-performance liquid chromatography): 1.00 minutes (Method C) 2-(4-fluoroisoquinolin-1-yl)propan-2-amine hydrochloride (Int-7.36) Step a: 4-fluoro-3-methoxy-3,4-dihydroisoquinolin-1(2H)-one To a mixture of isoquinoline-1(2H)-one (100 g, 689 mmol), 1 L methanol, and 1 L acetonitrile, Selectfluor (317 g, 896 mmol) was added at 20 °C under a nitrogen atmosphere. The resulting mixture was stirred for 12 hours at 85 °C. The reaction mixture was concentrated under reduced pressure, and 1 L of water was added. The mixture was extracted twice using ethyl acetate (500 mL each). The collected organic extracts were dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain 100 g of the title compound, which was used in the next step without further purification. ESI-MS: 196 [M+H]+ Retention time (high-performance liquid chromatography): 0.62 minutes (method L) Step b: 4-fluoroisoquinolin-1(2)-one: To a mixture of 4-fluoro-3-methoxy-3,4-dihydroisoquinoline-1(2H)-one (80.0 g, 410 mmol) in 1 L dichloromethane, hydrochloric acid (1.0 M in ethyl acetate, 350 mL, 350 mmol) was added, and the mixture was stirred for 12 hours at 15 °C in a nitrogen atmosphere. The resulting solids were separated by filtration and centrifugation using 400 mL of a water / methanol mixture (10:1) at 10 °C for 3 hours to obtain 59.3 g of the title product. ESI-MS: 164 [M+H]+ Retention time (High-performance liquid chromatography): 0.62 minutes (Method M) 2-(4-fluoroisoquinolin-1-yl)propan-2-amine hydrochloride (Int-7.36): The title compound was prepared from 4-fluoroisoquinoline-1(2)-one in a manner analogous to the intermediate compound Int-7.35, see above, to obtain the title compound. ESI-MS: 205 [M+H]+ Retention time (High-performance liquid chromatography): 0.69 minutes (Method A) 2-(4-fluoro-7-methylisoquinolin-1-yl)propan-2-amine hydrochloride (Int-7.37) Step a: 2,5-dimethylbenzamide: To a mixture of 2,5-dimethylbenzoic acid (20.0 g, 133 mmol) and 200 mL dichloromethane, oxalyl chloride (67.6 g, 533 mmol) was added by distillation under a nitrogen atmosphere. The mixture was stirred at 25 °C for 4 hours. Subsequently, aqueous ammonium hydroxide solution (666 mmol) was added by distillation at 25 °C, and the resulting mixture was stirred under a nitrogen atmosphere for 12 hours. The reaction mixture was washed with 200 mL of water, filtered, and the organic layer was concentrated under reduced pressure to obtain 15.0 g of the title compound, which was used in the next step without further purification. ESI-MS: 150 [M+H]+ Retention time (high-performance liquid chromatography): 0.46 minutes (Method K) Step b: N-((dimethylamino)methylene)-2,5-dimethylbenzamide: A mixture of 2,5-dimethylbenzamide (10.0 g, 67.0 mmol), 100 mL tetrahydrofuran, and 100 mL N,N-dimethylformamide dimethylacetal was stirred at 80 °C under a nitrogen atmosphere for 3 hours. The reaction mixture was concentrated under reduced pressure to obtain 10.0 g of the title compound, which was used in the next step without further purification. Step c: 7-methylisoquinolin-1(2H)-one To a mixture of N-((dimethylamino)methylene)-2,5-dimethylbenzamide (30.0 g, 117 mmol) and 300 mL tetrahydrofuran, potassium tert-butoxide (60.0 g, 470 mmol) was added under a nitrogen atmosphere, and the mixture was stirred at 80 °C for 12 hours. Aqueous hydrochloric acid (1 M) was added until pH = 3 was obtained. The mixture was filtered and concentrated under reduced pressure to obtain 12.0 g of the title compound, which was used in the next step without further purification. ESI-MS: 160 [M+H]+ Retention time (high-performance liquid chromatography): 0.49 minutes (Method K) 2-(4-fluoro-7-methylisoquinolin-1-yl)propan-2-amine hydrochloride (Int-7.37): The title compound was prepared from 7-methylisoquinoline-1(2H)-one in a manner analogous to the intermediate compound Int-7.36 to obtain the title compound. ESI-MS: 219 [M+H]+ Retention time (High-performance liquid chromatography): 0.74 minutes (Method A) 2-(4,7-difluoroisoquinolin-1-yl)propan-2-amine hydrochloride (Int-7.38) The title compound was prepared from 5-fluoro-2-methylbenzoic acid in a manner analogous to the intermediate compound Int-7.37 to obtain the title compound. ESI-MS: 223 [M+H]+ Retention time (High-performance liquid chromatography): 0.70 minutes (Method A) 2-(4,6-difluoroisoquinolin-1-yl)propan-2-amine hydrochloride (Int-7.39) The title compound was prepared from 4-fluoro-2-methylbenzoic acid in a manner analogous to the intermediate compound Int-7.37 to obtain the title compound. ESI-MS: 223 [M+H]+ Retention time (High-performance liquid chromatography): 0.71 minutes (Method A) 2-(isoquinolin-1-yl)propan-2-amine (Int-7.40) The title compound was prepared from the commercially available compound 1-(isoquinoline-1-yl)ethane-1-one in a manner analogous to the intermediate compound Int-7.35, see above (steps e.g.). To the hydrochloride initially obtained from Int-7.40, methanol and triethylamine were added, and the residue was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 60 °C). The product-containing fractions were concentrated under reduced pressure to obtain the title compound. ESI-MS: 187 [M+H]+ Retention time (High-performance liquid chromatography): 0.66 minutes (Method A) 2-(4-fluoro-3-methylisoquinolin-1-yl)propan-2-amine hydrochloride (Int-7.41) Step a: 4-fluoro-3-methylisoquinolin-1(2H)-one: To a mixture of 3-methylisoquinoline-1(2H)-one (3.00 g, 18.8 mmol) in 65 mL acetonitrile and 45 mL water, Selectfluor (7.34 g, 20.7 mmol) was added at room temperature. The resulting solid was separated by filtration, washed with diethyl ether, and dried to obtain 2.35 g of the target compound, which was used in the next step without further purification. ESI-MS: 178 [M+H]+ Retention time (High-performance liquid chromatography): 0.82 minutes (Method B) Step b: 1-chloro-4-fluoro-3-methylisoquinoline: To a mixture of 4-fluoro-3-methylisoquinoline-1(2H)-one (2.30 g, 13.0 mmol) and 70 mL acetonitrile, phosphorus oxychloride (1.57 mL, 16.9 mmol) was added, and the resulting mixture was heated under reduction for 5 hours. The mixture was concentrated under reduced pressure, diethyl ether and water were added, and the layers were separated. The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain 2.40 g of the title compound, which was used in the next step without further purification. Step C: 2-(4-fluoro-3-methylisoquinolin-1-yl)-2-methylpropanenitrile To a mixture of 1-chloro-4-fluoro-3-methylisoquinoline (2.40 g, 12.3 mmol), isobutyronitrile (2.20 mL, 24.5 mmol), and 40 mL toluene in an ethanol / ice bath (internal temperature between -5°C and 0°C), lithium bis(trimethylcellulose)amide (1 M in hexane, 24.5 mL, 24.5 mmol) was added. The mixture was stirred for 4 hours, during which time it was allowed to warm to room temperature. Saturated aqueous ammonium chloride solution and ethyl acetate were added, the layers were separated, and the collected organic layers were washed with water. The organic extracts were dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain 2.96 g of the title compound, which was used in the next step without further purification. ESI-MS: 229 [M+H]+ Retention time (High-performance liquid chromatography): 1.16 minutes (Method B) Step d: 2-(4-fluoro-3-methylisoquinolin-1-yl)-2-methylpropanamide To a mixture of 2-(4-fluoro-3-methylisoquinoline-1-yl)-2-methylpropanenitrile (2.80 g, 12.3 mmol) and 35 mL dimethyl sulfoxide, potassium carbonate (5.09 g, 36.8 mmol) was added, and the resulting mixture was cooled in an ice bath. Subsequently, hydrogen peroxide (35% in water, 10.5 mL, 123 mmol) was added by distillation, and the reaction was allowed to warm to room temperature and stirred for two days. Afterward, 150 mL of water and 200 mL of ethyl acetate were added, the layers were separated, the collected organic layers were dried over sodium sulfate, and the mixture was filtered and concentrated under reduced pressure to obtain 3.17 g of the title product, which was used in the next step without further purification. ESI-MS: 247 [M+H]+ Retention time (High-performance liquid chromatography): 0.94 minutes (Method B) Step e: 2-(4-fluoro-3-methylisoquinolin-1-yl)propan-2-amine hydrochloride (Int-7.41) To a mixture of 2-(4-fluoro-3-methylisoquinoline-1-yl)-2-methylpropanemide (1.00 g, 4.06 mmol), 25 mL isopropanol, and sodium hydroxide (2 M aqueous solution, 7.72 mL, 14.8 mmol), sodium hypochlorite (10–15% aqueous solution, 3.29 mL, approximately 15.4 mmol) was added. The resulting mixture was stirred overnight at room temperature. Subsequently, water and ethyl acetate were added, the layers were separated, the aqueous layer was extracted using ethyl acetate, and the collected organic layers were washed with Brine. The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. To the remaining material, 10 mL of dichloromethane and hydrochloric acid (4 M in 1,4-dioxane, 1.12 mL, 4.48 mmol) were added, and the mixture was stirred for 30 minutes. The resulting solid was separated by filtration, washed with diethyl ether, and dried under reduced pressure to obtain 840 mg of the title compound. ESI-MS: 219 [M+H]+ Retention time (High-performance liquid chromatography): 1.03 minutes (Method C) 2-(3,5-dichloropyridin-2-yl)propan-2-amine (Int-7.43) Step a: 2-(3,5-Dichloropyridin-2-yl)-2-methylpropanenitrile: To a mixture of 2,3,5-trichloropyridine (3.50 g, 19.2 mmol), isobutyronitrile (3.44 mL, 38.4 mmol), and 50 mL toluene in an ethanol / ice bath (internal temperature between -5°C and 0°C), lithium bis(trimethylcellulose)amide (1 M in hexane, 38.4 mL, 38.4 mmol) was added. The mixture was stirred for 3 days, during which time it was allowed to warm to room temperature. Saturated aqueous ammonium chloride solution and ethyl acetate were added, the layers were separated, and the organic layer was washed with Bryn. The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain 4.30 g of the title compound, which was used in the next step without further purification. ESI-MS: 215 [M+H]+ Retention time (High-performance liquid chromatography): 1.07 minutes (Method A) Step b: 2-(3,5-Dichloropyridin-2-yl)-2-methylpropanamide: To a mixture of 2-(3,5-dichloropyridine-2-yl)-2-methylpropanetirel (2.08 g, 9.67 mmol) and 25 mL dimethyl sulfoxide, potassium carbonate (4.01 g, 29.0 mmol) was added, and the resulting mixture was stirred at approximately 10 °C. Subsequently, hydrogen peroxide (35% in water, 8.32 mL, 96.7 mmol) was added by distillation, and the reaction was allowed to warm to room temperature and stirred overnight. Next, 50 mL water and 100 mL ethyl acetate were added, and the mixture was stirred for 15 minutes. The layers were then separated, and the aqueous phase was extracted using 100 mL ethyl acetate. The collected organic layers were washed with 100 mL saturated aqueous sodium bisulfite solution and water, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The remaining material was ground using 50 mL of diethyl ether, filtered, and dried under low pressure to obtain 2.11 g of the title compound, which was used in the next step without further purification. ESI-MS: 233 [M+H]+ Retention time (High-performance liquid chromatography): 0.81 minutes (Method C) Step c: 2-(3,5-Dichloropyridin-2-yl)propan-2-amine (Int-7.43): To a mixture of 2-(3,5-dichloropyridine-2-yl)-2-methylpropanemide (3.87 g, 16.6 mmol) in 60 mL isopropanol and sodium hydroxide (2 M aqueous solution, 31.6 mL, 63.1 mmol), sodium hypochlorite (10–15% aqueous solution, 13.5 mL, approximately 28.2 mmol) was added. The resulting mixture was stirred overnight at room temperature. Subsequently, saturated aqueous sodium bisulfite solution and ethyl acetate were added, the layers were separated, the organic layer was washed with water, dried over sodium sulfate, filtered again, and concentrated under reduced pressure. The residue was milled with diethyl ether and dried under reduced pressure to obtain 3.08 g of the title compound, which was used in the next step without further purification. ESI-MS: 205 [M+H]+ Retention time (High-performance liquid chromatography): 0.91 minutes (Method C) 2-(3-chloro-5-fluoropyridin-2-yl)propan-2-amine hydrochloride (Int-7.44) Step a: 2-(3,5-dichloropyridin-2-yl)-2-methylpropanenitrile: To a mixture of 2,3-dichloro-5-fluoropyridine (40.0 g, 241 mmol), isobutyronitrile (40.0 mL, 446 mmol), and 800 mL toluene, lithium bis(trimethylcellulose)amide (50.0 g, 299 mmol) was added while the internal temperature was maintained at 20 °C by occasional cooling in an ice bath. The mixture was stirred overnight at room temperature. 200 mL of saturated aqueous ammonium chloride solution and 300 mL of water were added, the mixture was stirred for 5 minutes, filtered, and the layers were separated. The aqueous layer was extracted using 400 mL toluene, and the collected organic layers were dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (silica, petroleum ether, ethyl acetate) to obtain 38.3 g of the title compound. ESI-MS: 199 [M+H]+ Retention time (High-performance liquid chromatography): 0.99 minutes (Method A) Step b: 2-(3-chloro-5-fluoropyridin-2-yl)-2-methylpropanamide A mixture of 2-(3,5-dichloropyridine-2-yl)-2-methylpropanenitrile (38.3 g, 193 mmol), 60 mL acetic acid, 30 mL concentrated sulfuric acid, and 5 mL water was stirred at 95 °C for 2.5 hours. The reaction mixture was poured onto ice, and aqueous ammonia was added until a basic pH was obtained. The resulting mixture was sonicated for 15 minutes and stirred at room temperature overnight. The resulting solids were separated by filtration, washing with water, and drying under reduced pressure. The resulting aqueous layer was extracted twice using a mixture of dichloromethane and acetonitrile (9:1), and the collected organic layers were dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The remaining material and the solids obtained from the filtration were combined to obtain 40.0 g of the title compound. ESI-MS: 217 [M+H]+ Retention time (High-performance liquid chromatography): 0.75 minutes (Method A) Step c: 2-(3-chloro-5-fluoropyridine-2-yl)propane-2-amine hydrochloride (Int-7.44) A mixture of 2-(3-chloro-5-fluoropyridine-2-yl)-2-methylpropaneamide (17.7 g, 81.6 mmol) and bis(trifluoroacetoxy)iodo)benzene (45.0 g, 105 mmol) was stirred in 200 mL of acetonitrile at room temperature for 1 hour. Aqueous sodium hydroxide solution (4 M, 300 mL, 1.20 mol) was added, and the mixture was stirred vigorously at room temperature for 1 hour. Concentrated aqueous hydrochloric acid was added until an acidic pH was obtained (approximately 100 mL), and most of the organic solvent was removed under reduced pressure. The resulting mixture was extracted using diethyl ether (2 x 200 mL), the collected organic layers were treated with 1 M aqueous hydrochloric acid, and the aqueous layers were collected. Aqueous ammonia was added to the collected aqueous layers until a basic pH was achieved, followed by the addition of sodium chloride. The resulting mixture was then extracted three times using dichloromethane. The organic layers were collected, dried over magnesium sulfate, filtered, and the solvent was removed under reduced pressure.Dichloromethane was added until the residue was dissolved, and hydrochloric acid (4 M in 1,4-dioxane, 30 mL, 120 mmol) was added. The mixture was concentrated under reduced pressure. The residue was then ground with 40 mL of dichloromethane and dried under reduced pressure. ESI-MS: 189 [M+H]+ Retention time (High-performance liquid chromatography): 0.60 minutes (Method A) 2-(3,5-dichloro-4-methylpyridin-2-yl)propan-2-amine (Int-7.45) The title compound was prepared from 2,3,5-trichloro-4-methylpyridine in a manner analogous to the intermediate compound Int-7.43, see above, to obtain the title compound, which was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50°C). ESI-MS: 219 [M+H]+ Retention time (High-performance liquid chromatography): 0.72 minutes (Method A) 2-(3,5-dichloro-4-methylpyridin-2-yl)propan-2-amine (Int-7.46) Step a: 2-(3-chloro-5- 2-(3-chloro-5-fluoro-4-methylpyridin-2-yl)-2-methylpropanenitrile A mixture of 2-(3-chloro-5-fluoropyridine-2-yl)-2-methylpropanenitrile (preparation described in step a of the synthesis Int-7.44, 500 mg, 2.52 mmol) in 5 mL of tetrahydrofuran was cooled using an acetone / ice bath, and lithium bis(trimethylcellulose)amide (1.0 M in tetrahydrofuran, 2.59 mL, 2.95 mmol) was added, followed by methyl iodide (165 µL, 2.64 mmol). The mixture was then warmed to room temperature and stirred at the same temperature overnight. The mixture was then cooled in an acetone / ice bath, and lithium bis(trimethylcellulose)amide (1.0 M in tetrahydrofuran, 1.30 mL, 1.30 mmol) was added, followed by methyl iodide (80.0 µL, 1.28 mmol). Stirring was completed in the acetone / ice bath for 1 hour, followed by the addition of saturated aqueous ammonium chloride solution and an equal volume of water. After stirring for 10 minutes, the mixture was extracted three times using ethyl acetate, and the collected organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure.The remaining material was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 60°C). The fractions containing the title product were concentrated at 150 mbar and 50°C. The remaining material was extracted three times using dichloromethane; the organic phases were dried over sodium sulfate, filtered, and concentrated at 100 mbar and 45°C to obtain 260 mg of the title compound. ESI-MS: 213 [M+H]+ Retention time (High-performance liquid chromatography): 1.04 minutes (Method A) Step b: 2-(3-chloro-5-fluoro-4-methylpyridin-2-yl)-2-methylpropanamide A mixture of 2-(3-chloro-5-fluoro-4-methylpyridine-2-yl)-2-methylpropanenitrile (260 mg, 1.22 mmol), 2.5 mL acetic acid, 1 mL concentrated sulfuric acid, and 0.25 mL water was stirred at 95 °C for 1 hour. The reaction mixture was poured onto ice, and aqueous ammonia was added until a basic pH was obtained. The mixture was extracted three times using dichloromethane, and the collected organic extracts were dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain 245 mg of the title compound, which was used in the next step without further purification. ESI-MS: 231 [M+H]+ Retention time (High-performance liquid chromatography): 0.84 minutes (Method A) Step c: 2-(3,5-Dichloro-4-methylpyridine-2-yl)propane-2-amine (Int-7.46): To a mixture of 2-(3-chloro-5-fluoro-4-methylpyridine-2-yl)-2-methylpropaneamide (240 mg, 1.04 mmol) in 10 mL of isopropanol and sodium hydroxide (2 M aqueous solution, 1.98 mL, 3.96 mmol), sodium hypochlorite (10–15% aqueous solution, 0.84 mL, approximately 1.77 mmol) was added. The resulting mixture was stirred overnight at room temperature. Subsequently, additional sodium hydroxide (2 M aqueous solution, 2.00 mL, 4.00 mmol) and sodium hypochlorite (10–15% aqueous solution, 1.00 mL, approximately 2.10 mmol) were added, and the mixture was stirred at room temperature for 6 hours. A saturated aqueous sodium bisulfite solution was then added, followed by the addition of sodium chloride. The mixture was extracted five times using ethyl acetate, the collected organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to obtain 210 mg of the title compound which was used in the next step without further purification. ESI-MS: 203 [M+H]+ Retention time (High-performance liquid chromatography): 0.69 minutes (Method A) 2-(5-chloro-3-fluoro-4-methylpyridin-2-yl)propan-2-amine hydrochloride (Int-7.47) Step a: 2-(5-chloro-3-fluoro-4-methylpyridin-2-yl)-2-methylpropanenitrile To a mixture of 2,5-dichloro-3-fluoro-4-methylpyridine (2.20 g, 11.6 mmol) and isobutyronitrile (1.65 mL, 18.4 mmol) in 30 mL of toluene, lithium bis(trimethylcellulose)amide (1 M in hexane, 16.5 mL, 16.5 mmol) was added. The internal temperature was maintained below 30 °C by occasional cooling using a water bath. The mixture was stirred overnight at room temperature. Saturated aqueous ammonium chloride solution and an equal volume of water were added, the layers were separated, and the aqueous layer was extracted three times using toluene. The collected organic extracts were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (silica, petroleum ether, ethyl acetate) to obtain 1.73 g (88% purity) of the title compound. ESI-MS: 213 [M+H]+ Retention time (High-performance liquid chromatography): 1.08 minutes (Method A) Step b: 2-(5-chloro-3-fluoro-4-methylpyridin-2-yl)-2-methylpropanamide A mixture of 2-(5-chloro-3-fluoro-4-methylpyridine-2-yl)-2-methylpropanenitrile (1.73 g, 88% purity, 8.14 mmol), 4.2 mL acetic acid, 2.1 mL concentrated sulfuric acid, and 261 µL water was stirred at 95 °C for 1 hour. The reaction mixture was poured onto ice-cold water, and aqueous ammonia was added until a basic pH was obtained. The resulting solids were separated by filtration, washing with water and dichloromethane, and drying under reduced pressure. The resulting aqueous layer was extracted four times with dichloromethane, and the collected organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The remaining material and the solids obtained from the filtration were collected to yield 1.67 g of the title compound, which was used in the next step without further purification. ESI-MS: 231 [M+H]+ Retention time (High-performance liquid chromatography): 0.86 minutes (Method A) Step c: 2-(5-chloro-3-fluoro-4-methylpyridine-2-yl)propane-2-amine hydrochloride (Int-7.47): To a mixture of 2-(5-chloro-3-fluoro-4-methylpyridine-2-yl)-2-methylpropanemide (as obtained from the step above, 1.31 g, 5.68 mmol), 40 mL isopropanol, and sodium hydroxide (2 M aqueous solution, 21.6 mL, 43.2 mmol), sodium hypochlorite (10–15% aqueous solution, 9.21 mL, approximately 19.3 mmol) was added. The resulting mixture was stirred overnight at room temperature. A saturated aqueous sodium bisulfite solution was added, followed by the addition of sodium chloride. The mixture was extracted four times using ethyl acetate, the collected organic layers were dried over sodium sulfate, filtered, and concentrated. The remaining material was purified by preparative RP-HPLC (Waters SunFire C18, acetonitrile / water / trifluoroacetic acid, 50 °C) and the product-containing fractions were concentrated under reduced pressure. Methanol was added, followed by hydrochloric acid (4 M in dioxane, 2.00 mL, 8.00 mmol). The mixture was concentrated under reduced pressure, acetonitrile was added, and the mixture was concentrated again under reduced pressure.This process was repeated using the concentrated mixture again under reduced pressure after adding another quantity of acetonitrile to obtain 480 mg of the title compound. ESI-MS: 203 [M+H]+ Retention time (High-performance liquid chromatography): 0.70 minutes (Method A) 2-(3,5-difluoro-4-methylpyridin-2-yl)propan-2-amine (Int-7.48) The title compound was prepared from 2,3,5-trifluoropyridine in a manner analogous to the intermediate compound Int-7.46, see above, to obtain the title compound. ESI-MS: 187 [M+H]+ Retention time (High-performance liquid chromatography): 0.66 minutes (Method A) 2-(3,5-difluoro-4-methylpyridin-2-yl)propan-2-amine (Int-7.49) The title compound was prepared from 2,3,5-trichloro-6-methylpyridine in a manner analogous to the intermediate compound Int-7.43; see above for the title compound. ESI-MS: 219 [M+H]+ Retention time (High-performance liquid chromatography): 1.02 minutes (Method C) 2-(5-chloro-4-methylisoquinolin-1-yl)propan-2-amine hydrochloride (Int-7.55) Step a: N-allyl-2-bromo-3-chlorobenzamide A mixture of 2-bromo-3-chlorobenzoic acid (25.0 g, 106 mmol), 300 mL dichloromethane, prop-2-in-1-amine (7.27 g, 127 mmol), N,N-(dimethylamino)pyridine (2.59 g, 21.2 mmol), and 1-ethyl-3-(3-dimethylaminopropyl)carbadiimide hydrochloride (26.4 g, 138 mmol) was stirred at 15 °C for 12 hours. The reaction mixture was diluted with 300 mL of water and extracted twice using 300 mL dichloromethane. The collected organic layers were washed with pyrene, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (silica, petroleum ether, ethyl acetate) to obtain 20.0 g of the title compound. Step b: 5-chloro-4-methylisoquinolin-1(2H)-one A mixture of N-Allyl-2-bromo-3-chlorobenzamide (10.0 g, 36.4 mmol), 100 mL N,N-dimethylformamide, tetrabutyl ammonium chloride (12.5 g, 43.7 mmol), triethylamine (10.9 g, 72.8 mmol), and tetracycline (triphenylphosphine) palladium(0) (8.42 g, 7.29 mmol) was stirred at 120 °C for 12 h under a nitrogen atmosphere. The reaction mixture was diluted with 100 mL of water and extracted twice using 100 mL of ethyl acetate. The collected organic layers were washed with Braine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (silica, petroleum ether, ethyl acetate) to obtain 4.00 g of the title compound. ESI-MS: 194 [M+H]+ Retention time (High-performance liquid chromatography): 0.75 minutes (Method M) 2-(5-chloro-4-methylisoquinoline-1-yl)propane-2-amine hydrochloride (Int-7.55) The title compound was prepared from 5-chloro-4-methylisoquinoline-1(2H)-one in a manner analogous to the intermediate compound Int-7.35, steps bg, see above. ESI-MS: 235 [M+H]+ Retention time (High-performance liquid chromatography): 0.78 minutes (Method A) 2-(5-fluoroisoquinolin-1-yl)propan-2-amine hydrochloride (Int-7.56) The title compound was prepared from the commercially available compound 1-chloro-5-fluoroisoquinoline in a manner analogous to the intermediate compound Int-7.35, steps cg, see above. ESI-MS: 205 [M+H]+ Retention time (High-performance liquid chromatography): 0.69 minutes (Method A) Preparing the final compounds Example 1: (2S,5R)-N-(2-(4-chloro-2-methoxyphenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: Tert-butyl (2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(4-chloro-2-methoxyphenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.1) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 88.9 mg, 0.18 mmol), 2-(4-chloro-2-methoxyphenyl)propane-2-amine hydrochloride (Int-7.1, 40.0 mg, 0.17 mmol), and N-methylmorpholine (0.14 mL, 1.27 mmol) in 4 mL dichloromethane was chilled in an ice bath, and propane phosphonic acid anhydride (50% in ethyl acetate, 0.19 mL, 0.31 mmol) was added. The mixture was allowed to warm to room temperature and stirred overnight. A saturated aqueous sodium bicarbonate solution and an equal volume of water were added, the layers were separated, and the aqueous layer was extracted twice using dichloromethane. The collected organic layers were dried over sodium sulfate, filtered, and the solvents were removed under reduced pressure to obtain the crude compound, which was used in the next step without further purification. ESI-MS: 703 [M+Na]+ Retention time (High-performance liquid chromatography): 1.30 minutes (Method E) Step b: (2S,5R)-N-(2-(4-chloro-2-methoxyphenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide (Example 1) To a mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl syl)oxy)methyl)-2-((2-(4-chloro-2-methoxyphenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.1, as obtained from the step above), 2 mL of methanol hydrochloride (4 M in dioxane, 0.42 mL, 1.70 mmol) was added, and the mixture was stirred at 50 °C overnight. Subsequently, the solvents were removed under reduced pressure, and the residue was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 60 °C). The product-containing fractions were lyophilized to obtain 22.7 mg of the title compound. ESI-MS: 343 [M+H]+ Retention time (High-performance liquid chromatography): 0.78 minutes (Method A) 1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 1.61 (s, 3 H), 1.64 (s, 3 H), 2.58 – 2.64 (m, 1 H), 2.68 (dd, J=12.4, 3.6 Hz, 1 H), 2.81 (dd, J=12.4, 7.5 Hz, 1 H), 3.45 (t, J=6.0 Hz, 2 H), 3.60 – 3.65 (m, 1 H), 3.73 (dd, J=11.2, 4.3 Hz, 1 H), 3.76 (dd, J=7.4, 3.5 Hz, 1 H), 3.81 (s, 3 H), 4.56 (t, J=5.4 Hz, 1 H), 6.93 (dd, J=8.4, 2.2 Hz, 1 H), 7.03 (d, J=2.0 Hz, 1 H), 7.22 (d, J=8.5 Hz, 1 H), 7.31 (s, 1 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 2: (2S,5R)-N-(2-(2-chloro-4-methylphenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide hydrochloride Step a: Tert-butyl (2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(2-chloro-4-methylphenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.2) The title compound was prepared from (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 119 mg, 0.24 mmol) and 2-(2-chloro-4-methylphenyl)propane-2-amine hydrochloride (Int-7.2, 50.0 mg, 0.23 mmol) in a manner analogous to the intermediate compound Int-10.1, see above, to obtain the crude title compound which was used in the next step without further purification. ESI-MS: 565 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.30 minutes (Method E) Step b: (2S,5R)-N-(2-(2-chloro-4-methylphenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide hydrochloride (Example 2) To a mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl syl)oxy)methyl)-2-((2-(2-chloro-4-methylphenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.2, as obtained from the step above) in methanol, hydrochloric acid (4 M in dioxane, 0.56 mL, 2.26 mmol) was added, and the mixture was stirred at 45 °C. After stirring overnight, the solvents were removed under reduced pressure, and the residue was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50 °C). The product-containing fractions were concentrated under reduced pressure and the remaining dioxane was dissolved. 0.1 mL of hydrochloric acid (4 M in dioxane) was added and the mixture was lyophilized to obtain 33.6 mg of the title compound in the form of the hydrochloride salt. ESI-MS: 327 [M+H]+ Retention time (High-performance liquid chromatography): 0.81 minutes (Method A) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.66 (s, 6 H), 2.25 (s, 3 H), 2.96 – 3.03 (m, 1 H), 3.06 – 3.12 (m, 1 H), 3.57 (s, 1 H), 3.62 – 3.77 (m, 2 H), 3.91 (d, J = 2.9 Hz, 2 H), 4.28 (dd, J = 9.1, 3.4 Hz, 1 H), 5.40 (br t, J = 5.0 Hz, 1 H), 7.09 (dd, J = 8.1, 1.1 Hz, 1 H), 7.16 (d, J = 1.1 Hz, 1 H), 7.35 (d, J = 8.1 Hz, 1 H), 8.06 (s, 1 H), 9.37 (br s, 2 H). Double divisor ratio: ≥ 95:5 Example 3: (2S,5R)-N-(2-(2-chloro-3-fluorophenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(2-chloro-3-fluorophenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.3) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 200 mg, 0.36 mmol), 2-(2-chloro-3-fluorophenyl)propane-2-amine hydrochloride (Int-7.3, 80.7 mg, 0.36 mmol) in 10 mL acetonitrile in an ice bath and N-methylmorpholine (0.16 mL, 1.44 mmol) and propane phosphonic acid anhydride (50% in ethyl acetate, 0.25 mL, 0.43 mmol) was added. After 45 minutes, 20 ml of 5% sodium bicarbonate solution and 60 ml of ethyl acetate were added. The layers were separated, the organic layer was dried over sodium sulfate, filtered, and the solvents were removed under low pressure to obtain the crude title compound, which was used in the next step without further purification. ESI-MS: 569 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.21 minutes (Method F) Step b: (2S,5R)-N-(2-(2-chloro-3-fluorophenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide (Example 3) To a mixture of tert-butyl(2S,5S)-5-(((tert-butyldiphenyl oxy)methyl)-2-((2-(2-chloro-3-fluorophenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.3, as obtained from the step above) in 10 mL of methanol, hydrochloric acid (4 M in dioxane, 1.73 mL, 6.92 mmol) was added, and the mixture was stirred at room temperature. After 4 hours, hydrochloric acid (4 M in dioxane, 1.73 mL, 6.93 mmol) and aqueous hydrochloric acid (1 M, 1.00 mL, 1.00 mmol) were added, and the mixture was stirred at room temperature. After stirring overnight, concentrated aqueous ammonia (≥ 25%) was added, and the mixture was washed with 30 mL of diethyl ether. The aqueous layer was filtered, and the residue was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 60 °C). The fractions containing the title compound were lyophilized, the residue was dissolved in dichloromethane, and the solvent was removed under reduced pressure. Diethyl ether was then added to the residue, and the solvent was removed under reduced pressure to obtain 40.0 mg of the compound. ESI-MS: 331 [M+H]+ Retention time (High-performance liquid chromatography): 0.80 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.68 (s, 3 H), 1.69 (s, 3 H), 2.61 (tt, J = 6.9, 3.7 Hz, 1 H), 2.68 (dd, J = 12.5, 3.5 Hz, 1 H), 2.83 (dd, J = 12.5, 7.8 Hz, 1 H), 3.45 (s, 1 H), 3.47 (s, 1 H), 3.62 (dd, J = 11.2, 3.3 Hz, 1 H), 3.75 (dd, J = 11.2, 4.0 Hz, 1 H), 3.80 (dd, J = 11.2, 3.3 Hz, 1 H), 4.56 (br s, 1 H), 7.22 – 7.36 (m, 3 H), 7.64 (s, 1 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 4: (2S,5R)-N-(2-(2-chloro-3,4-difluorophenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide hydrochloride Step a: Tert-butyl (2S tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(2-chloro-3,4-difluorophenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.4) The title compound was prepared from (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 152 mg, 0.31 mmol) and 2-(2-chloro-3,4-difluorophenyl)propane-2-amine hydrochloride (Int-7.4, 70.0 mg, 0.29 mmol) in a manner analogous to the intermediate compound Int-10.1, see above, and used in the next step without further purification. ESI-MS: 587 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.35 minutes (Method C) Step b: (2S,5R)-N-(2-(2-chloro-3,4-difluorophenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide hydrochloride (Example 4) To a mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl oxy)methyl)-2-((2-(2-chloro-3,4-difluorophenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.4, as obtained from the step above) in methanol, hydrochloric acid (4 M in dioxane, 0.84 mL, 3.35 mmol) was added, and the mixture was stirred at room temperature overnight, followed by heating for 1 day at 45 °C. The solvents were removed under reduced pressure, and the residue was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50 °C). The product-containing portions were freeze-dried. To the remaining material, dioxane and hydrochloric acid (4 molar in dioxane) were added, and the mixture was concentrated under reduced pressure to obtain 70.0 mg of the title compound. ESI-MS: 349 [M+H]+ Retention time (High-performance liquid chromatography): 0.82 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.68 (s, 3 H), 1.69 (s, 3 H), 3.00 – 3.07 (m, 1 H), 3.08 – 3.14 (m, 1 H), 3.62 – 3.77 (m, 2 H), 3.87 – 3.93 (m, 2 H), 4.31 (dd, J = 8.9, 3.6 Hz, 1 H), 5.39 (br s, 1 H), 7.32 – 7.46 (m, 2 H), 8.33 (s, 1 H), 8.76 (br s, 1 H), 9.93 (br s, 1 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 5: (2S,5R)-N-(2-(4-fluoro-2-methoxyphenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide trifluoroacetate Step a: Tert-butyl (2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(4-fluoro-2-methoxyphenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.5) The title compound was prepared from (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 119 mg, 0.24 mmol) and 2-(4-fluoro-2-methoxyphenyl)propane-2-amine hydrochloride (Int-7.5, 50.0 mg, 0.23 mmol) in a manner analogous to the intermediate compound Int-10.1, see above, and used in the next step without further purification. ESI-MS: 565 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.35 minutes (Method C) Step b: (2S,5R)-N-(2-(4-fluoro-2-methoxyphenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide (Example 5) To a mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl syl)oxy)methyl)-2-((2-(4-fluoro-2-methoxyphenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.5, as obtained from the step above) in 2 mL of methanol, hydrochloric acid (4 M in dioxane, 0.57 mmol, 2.27 mmol) was added, and the mixture was stirred at 50 °C. After stirring overnight, the solvents were removed under reduced pressure, and the residue was purified by preparative RP-HPLC (Waters SunFire C18, acetonitrile / water / trifluoroacetic acid, 60 °C). The product-containing fractions were lyophilized to obtain 40.3 mg of the title compound. ESI-MS: 327 [M+H]+ Retention time (High-performance liquid chromatography): 0.84 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.62 (s, 3 H), 1.64 (s, 3 H), 3.03 – 3.18 (m, 2 H), 3.34 (br s, 1 H), 3.63 – 3.73 (m, 2 H), 3.79 (s, 3 H), 3.81 – 3.90 (m, 2 H), 4.22 (dd, J=8.2, 3.7 Hz, 1 H), 4.62 – 5.50 (m, 1 H), 6.68 (td, J=8.4, 2.7 Hz, 1 H), 6.88 (dd, J=11.4, 2.5 Hz, 1 H), 7.23 (dd, J=8.7, 6.9 Hz, 1 H), 7.81 (s, 1 H), 8.61 (br s, 1 H), 9.39 (br s, 1 H). Double divisor ratio: ≥ 95:5 Example 6: (2S,5R)-N-(2-(2,4-difluoro-3-methylphenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide hydrochloride Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(2,4-difluoro-3-methylphenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.6) The title compound was prepared from (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 189 mg, 0.38 mmol) and 2-(2,4-difluoro-3-methylphenyl)propane-2-amine Hydrochloride (Int-7.6, 80.0 mg, 0.36 mmol) in a manner analogous to the intermediate compound Int-10.1, see above, and use in the next step without further purification. ESI-MS: 567 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.21 minutes (Method F) Step b: (2S,5R)-N-(2-(2,4-Difluoro-3-methylphenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide hydrochloride (Example 6) To a mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl oxy)methyl)-2-((2-(2,4-difluoro-3-methylphenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.6, as obtained from the step above) in 4 mL of methanol, hydrochloric acid (4 M in dioxane, 1.80 mL, 7.20 mmol) was added, and the mixture was stirred at 50 °C. After stirring overnight, the solvents were removed under reduced pressure, and the residue was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50 °C). The product-containing fractions were then concentrated under reduced pressure. Dioxane and hydrochloric acid (4 molar in dioxane) were added and the remaining material was lyophilized to obtain 84.6 mg of the title compound. ESI-MS: 329 [M+H]+ Retention time (High-performance liquid chromatography): 0.85 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.62 (s, 3 H), 1.63 (s, 3 H), 2.12 (br s, 3 H), 3.05 – 3.14 (m, 2 H), 3.57 (s, 1 H), 3.62 – 3.77 (m, 2 H), 3.84 – 3.94 (m, 2 H), 4.30 (dd, J=7.41, 4.75 Hz, 1 H), 5.38 (br s, 1 H), 6.95 (t, J=8.81 Hz, 1 H), 7.13 – 7.23 (m, 1 H), 8.18 (s, 1 H), 8.34 – 9.20 (m, 1 H), 9.35 – 10.66 (m, 1 H). Double divisor ratio: ≥ 95:5 Example 7: (2S,5R)-N-(2-(2-chloro-4,5-difluorophenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide hydrochloride Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(2-chloro-4,5-difluorophenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.7) The title compound was prepared from (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 200 mg, 0.40 mmol) and 2-(2-chloro-4,5-difluorophenyl)propane-2-amine hydrochloride (Int-7.7, 87.2 mg, 0.36 mmol) in a manner analogous to the intermediate compound Int-10.3, see above, and used in the next step without further purification. ESI-MS: 587 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.22 minutes (Method F) Step b: (2S,5R)-N-(2-(2-chloro-4,5-difluorophenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide hydrochloride (Example 7) The title compound was prepared from the ore tert-butyl(2S,5S)-5-(((tert-butyl diphenyl oxy)methyl)-2-((2-(2-chloro-4,5-difluorophenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.7, as obtained from the step above) and purified by a method corresponding to Example 3, see above. 35.0 mg was obtained. ESI-MS: 349 [M+H]+ Retention time (High-performance liquid chromatography): 0.83 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.65 (s, 3 H), 1.67 (s, 3 H), 2.61 (dq, J=6.9, 3.4 Hz, 1 H), 2.68 (dd, J=12.5, 3.5 Hz, 1 H), 2.83 (dd, J=12.6, 7.7 Hz, 1 H), 3.45 (br d, J=6.8 Hz, 2 H), 3.61 (dd, J=11.2, 3.2 Hz, 1 H), 3.74 (dd, J=11.2, 4.2 Hz, 1 H), 3.80 (dd, J=7.6, 3.4 Hz, 1 H), 4.55 (br s, 1 H), 7.45 – 7.61 (m, 2 H), 7.65 (s, 1 H). A signal from two Hs cannot be detected; it can be superimposed with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 8: (2S,5R)-N-(2-(4-fluoro-2-(trifluoromethyl)phenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide trifluoroacetate Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(4-fluoro-2-(trifluoromethyl)phenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.8) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl oxy)methyl)morpholine-2-carboxylic acid (Int-6, 136 mg, 0.27 mmol), 2-(4-fluoro-2-(trifluoromethyl)phenyl)propane-2-amine (Int-7.8, 100.0 mg, 0.23 mmol), and N-methylmorpholine (0.12 mL, 1.13 mmol) in dichloromethane was chilled in an ice bath, and propane phosphonic acid anhydride (50% in ethyl acetate, 0.27 mL, 0.45 mmol) was added. The mixture was allowed to warm to room temperature and stirred overnight. Saturated hydrated sodium bicarbonate and water were added, the layers were separated, and the aqueous layer was extracted twice using dichloromethane. The collected organic layers were dried over sodium sulfate, filtered, and the solvents were removed under reduced pressure to obtain the title compound, which was used in the next step without further purification. ESI-MS: 603 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.21 minutes (Method F) Step b: (2S,5R)-N-(2-(4-fluoro-2-(trifluoromethyl)phenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide trifluoroacetate (Example 8) To a mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl syl)oxy)methyl)-2-((2-(4-fluoro-2-(trifluoromethyl)phenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.8, as obtained from the step above) in 4 mL of methanol, hydrochloric acid (4 M, 1.13 mL, 4.52 mmol) and aqueous hydrochloric acid (4 M, 0.5 mL, 2.00 mmol) were added and the mixture was stirred at 50 °C. After stirring for 2 days, the solvents were removed under reduced pressure and the remaining material was purified by preparative RP-HPLC (Waters SunFire C18, acetonitrile / water / trifluoroacetic acid, 60°C) and the product-containing fractions were lyophilized to obtain 12.0 mg of the title compound. ESI-MS: 365 [M+H]+ Retention time (High-performance liquid chromatography): 0.84 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.65 (s, 3 H), 1.72 (s, 3 H), 2.94 – 3.04 (m, 1 H), 3.08 (br s, 1 H), 3.65 – 3.71 (m, 2 H), 3.78 – 3.85 (m, 1 H), 3.89 – 3.94 (m, 1 H), 4.16 (dd, J=8.8, 3.4 Hz, 1 H), 5.42 (br s, 1 H), 7.45 – 7.52 (m, 1 H), 7.55 (dd, J=10.0, 2.8 Hz, 1 H), 7.70 (dd, J=9.0, 5.7 Hz, 1 H), 8.30 (s, 1 H), 8.56 (br s, 1 H), 9.29 (br s, 1 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 9: (2S,5R)-N-(2-(2-fluoro-4-methylphenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide hydrochloride Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(2-fluoro-4-methylphenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.9) The title compound was prepared from (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 129 mg, 0.26 mmol) and 2-(2-fluoro-4-methylphenyl)propane-2-amine hydrochloride (Int-7.9, 50.0 mg, 0.25 mmol) in a manner analogous to the intermediate compound Int-10.1, see above, and used in the next step without further purification. ESI-MS: 671 [M+Na]+ Retention time (High-performance liquid chromatography): 1.36 minutes (Method C) Step b: (2S,5R)-N-(2-(2-fluoro-4-methylphenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide hydrochloride (Example 9) The title compound was prepared from the ore tert-butyl(2S,5S)-5-(((tert-butyl diphenyl syl)oxy)methyl)-2-((2-(2-fluoro-4-methylphenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.9, as obtained from the step above) and purified by a method corresponding to Example 4, see above. 50.7 mg was obtained. ESI-MS: 311 [M+H]+ Retention time (High-performance liquid chromatography): 0.83 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.62 (s, 6 H), 2.27 (s, 3 H), 3.09 (br s, 2 H), 3.60 – 3.75 (m, 2 H), 3.88 (d, J=3.0 Hz, 2 H), 4.23 – 4.30 (m, 1 H), 5.37 (br s, 1 H), 6.88 – 6.95 (m, 2 H), 7.15 – 7.21 (br s, 1 H), 8.09 (br s, 1 H), 9.14 (br s, 2 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 10: (2S,5R)-N-(2-(2-cyclopropyl-4-fluorophenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(2-cyclopropyl-4-fluorophenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.10) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl oxy)methyl)morpholine-2-carboxylic acid (Int-6, 110 mg, 0.22 mmol), 2-(2-cyclopropyl-4-fluorophenyl)propane-2-amine hydrochloride (Int-7.10, 45.0 mg, 0.20 mmol), and N-methylmorpholine (0.11 mL, 0.98 mmol) in dichloromethane was cooled in an ice-cold acetone bath, and propane phosphonic acid anhydride (50% in ethyl acetate, 0.23 mL, 0.39 mmol) was added. The mixture was allowed to warm to room temperature and stirred for 4 days. A saturated aqueous sodium bicarbonate solution and water were added, the layers were separated, and the aqueous layer was extracted twice using dichloromethane. The collected organic layers were dried over sodium sulfate, filtered, and the solvents were removed under reduced pressure to obtain the title compound, which was used in the next step without further purification. ESI-MS: 575 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.21 minutes (Method F) Step b: (2S,5R)-N-(2-(2-cyclopropyl-4-fluorophenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide (Example 10) To a mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl syl)oxy)methyl)-2-((2-(2-cyclopropyl-4-fluorophenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.10, as obtained from the step above) in 4 mL of methanol, hydrochloric acid (4 M, 0.98 mL, 3.91 mmol) and aqueous hydrochloric acid (4 M, 0.5 mL, 2.00 mmol) were added and the mixture was stirred at 50 °C. After stirring for 4 hours, the solvents were removed under reduced pressure and the remaining material was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 60°C) and the product-containing fractions were lyophilized to obtain 15.4 mg of the title compound. ESI-MS: 337 [M+H]+ Retention time (High-performance liquid chromatography): 0.86 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 0.62 – 0.72 (m, 1 H), 0.72 – 0.82 (m, 1 H), 0.89 – 1.01 (m, 2 H), 1.70 (s, 3 H), 1.70 (s, 3 H), 2.24 – 2.36 (m, 1 H), 2.36 – 2.46 (m, 1 H), 2.56 – 2.62 (m, 1 H), 2.65 – 2.72 (m, 1 H), 2.77 – 2.84 (m, 1 H), 3.43 (t, J=6.02 Hz, 2 H), 3.57 – 3.64 (m, 1 H), 3.67 – 3.73 (m, 1 H), 3.76 (dd, J=7.7, 3.5 Hz, 1 H), 4.53 (t, J=5.3 Hz, 1 H), 6.54 (dd, J=11.3, 2.9 Hz, 1 H), 6.82 – 6.90 (m, 1 H), 7.33 (dd, J=8.9, 6.3 Hz, 1 H), 7.59 (s, 1 H). Double divisor ratio: ≥ 95:5 Example 11: (2S,5R)-N-(2-(2-chloro-4-cyclopropylphenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide trifluoroacetate Step a: _ tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(2-chloro-4-cyclopropylphenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.11) The title compound was prepared from (2S,5S)-4-( tert-butoxycarbonyl)-5-(((tert-butyl diphenyl oxy)methyl)morpholine-2-carboxylic (Int-6, 159 mg, 0.32 mmol) and 2-(2-chloro-4-cyclopropylphenyl)propane-2-amine hydrochloride (Int-7.11, 70.0 mg, 0.28 mmol) in a manner analogous to the intermediate compound Int-10.10, see above, and use in the next step without further purification. ESI-MS: 591 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.27 minutes (Method F) Step b: (2S,5R)-N-(2-(2-chloro-4-cyclopropylphenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide trifluoroacetate (Example 11) The title compound was prepared from tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(2-chloro-4-cyclopropylphenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.11, as obtained from the step above) in a manner analogous to Example 10, see above, except that stirring was performed at 50 °C overnight instead of 4 hours. Purification was carried out using RP-HPLC (Waters SunFire C18, acetonitrile / water / trifluoroacetic acid, 60 °C), and the product-containing fractions were lyophilized to obtain 22.9 mg of the title compound. ESI-MS: 353 [M+H]+ Retention time (High-performance liquid chromatography): 0.92 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 0.63 – 0.70 (m, 2 H), 0.91 – 0.98 (m, 2 H), 1.66 (s, 6 H), 1.84 – 1.94 (m, 1 H), 3.00 – 3.17 (m, 2 H), 3.30 – 3.38 (m, 1 H), 3.62 – 3.73 (m, 2 H), 3.79 – 3.85 (m, 1 H), 3.85 – 3.93 (m, 1 H), 4.12 (br s, 1 H), 4.19 – 4.25 (m, 1 H), 6.96 (dd, J=8.2, 1.9 Hz, 1 H), 7.05 (d, J=1.9 Hz, 1 H), 7.34 (d, J=8.2 Hz, 1 H), 8.09 (s, 1 H), 8.57 (br s, 1 H), 9.33 (br s, 1 H). Double divisor ratio: ≥ 95:5 Example 12: (2S,5R)-N-(2-(2,4-difluorophenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide trifluoroacetate Step a: Tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(2,4-difluorophenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.12) The title compound was prepared from (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 121 mg, 0.24 mmol) and 2-(2,4-difluorophenyl)propane-2-amine hydrochloride (Int-7.12, 45.0 mg, 0.22 mmol) in a manner analogous to the intermediate compound Int-10.10, see above, except that it was stirred at 50 °C overnight and used in the next step without further purification. ESI-MS: 553 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.17 minutes (Method F) Step b: (2S,5R)-N-(2-(2,4-Difluorophenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide trifluoroacetate (Example 12) The title compound was prepared from tert-butyl(2S,5S)-5-(((tert-butyl diphenyl syl)oxy)methyl)-2-((2-(2,4-difluorophenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.12, as obtained from the step above) in a manner analogous to Example 10, see above, except that stirring was performed at 50 °C overnight instead of for 4 hours. Purification was carried out using RP-HPLC (Waters SunFire C18, acetonitrile / water / trifluoroacetic acid, 60 °C), and the product-containing fractions were lyophilized to obtain 55.3 mg of the title compound. ESI-MS: 315 [M+H]+ Retention time (High-performance liquid chromatography): 0.79 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.63 (s, 6 H), 3.05 – 3.19 (m, 2 H), 3.29 – 3.39 (m, 1 H), 3.62 – 3.74 (m, 2 H), 3.80 – 3.91 (m, 2 H), 4.24 (dd, J=7.5, 4.3 Hz, 1 H), 4.38 – 4.42 (m, 1 H), 6.99 (td, J=8.5, 2.3 Hz, 1 H), 7.11 (ddd, J=12.4, 9.4, 2.7 Hz, 1 H), 7.37 (td, J=9.25, 6.72 Hz, 1 H), 8.23 (s, 1 H), 8.60 (br s, 1 H), 9.46 (br s, 1 H). Double divisor ratio: ≥ 95:5 Example 13: (2S,5R)-N-(2-(2-chloro-4-fluorophenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(2-chloro-4-fluorophenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.13) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl oxy)methyl)morpholine-2-carboxylic acid (Int-6, 93.6 mg, 0.19 mmol), the commercially available compound 2-(2-chloro-4-fluorophenyl)propane-2-amine hydrochloride (Int-7.13, 40.0 mg, 0.18 mmol), and N-methylmorpholine (0.15 mL, 1.34 mmol) in 4 mL dichloromethane was chilled in an ice bath, and propane phosphonic acid anhydride (50% in ethyl acetate, 0.20 mL, 0.32 mmol) was added. The mixture was allowed to warm to room temperature and stirred overnight. A saturated aqueous sodium bicarbonate solution and an equal volume of water were added, the layers were separated, and the aqueous layer was extracted twice using dichloromethane. The collected organic layers were dried over sodium sulfate, filtered, and the solvents were removed under reduced pressure to obtain the crude compound, which was used in the next step without further purification. ESI-MS: 569 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.23 minutes (Method F) Step b: (2S,5R)-N-(2-(2-chloro-4-fluorophenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxymide (Example 13) To a mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl syl)oxy)methyl)-2-((2-(2-chloro-4-fluorophenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.13, as obtained from the step above) and 2 mL of methanol, hydrochloric acid (4 M in dioxane, 0.45 mL, 1.80 mmol) was added, and the mixture was stirred at 50 °C overnight. Subsequently, the solvents were removed under reduced pressure, and the residue was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 60 °C). The product-containing fractions were lyophilized to obtain 30.4 mg of the title compound. ESI-MS: 331 [M+H]+ Retention time (High-performance liquid chromatography): 0.86 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.66 (s, 3 H), 1.68 (s, 3 H), 2.30 (br s, 1 H), 2.56 – 2.64 (m, 1 H), 2.67 (dd, J=12.5, 3.5 Hz, 1 H), 2.82 (dd, J=12.4, 7.9 Hz, 1 H), 3.46 (dd, J=6.8, 5.5 Hz, 2 H), 3.61 (dd, J=11.2, 3.2 Hz, 1 H), 3.72 – 3.81 (m, 2 H), 4.54 (t, J=5.4 Hz, 1 H), 7.11 – 7.19 (m, 1 H), 7.29 (dd, J=8.7, 2.8 Hz, 1 H), 7.52 (dd, J=9.0, 6.3 Hz, 1 H), 7.55 (s, 1 H). Double divisor ratio: ≥ 95:5 Example 14: (2S,5R)-N-(2-(2-chlorophenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-(((2-(2-chlorophenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.14) The title compound was prepared from (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 127 mg, 0.26 mmol) and the commercially available compound 2-(2-chlorophenyl)propane-2-amine hydrochloride (Int-7.14, 50.0 mg, 0.24 mmol) in a manner analogous to the intermediate compound Int-10.1, see above, and used in the next step without further purification. ESI-MS: 551 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.35 minutes (Method C) Step b: (2S,5R)-N-(2-(2-chlorophenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide (Example 14) The title compound was prepared from tert-butyl(2S,5S)-5-(((tert-butyl diphenyl syl)oxy)methyl)-2-((2-(2-chlorophenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.14, as obtained from the step above) and purified by a method corresponding to Example 4, see above, except that the product-containing fractions were concentrated under reduced pressure instead of lyophilization. 59.2 mg was obtained. ESI-MS: 313 [M+H]+ Retention time (High-performance liquid chromatography): 0.81 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.69 (s, 6 H), 2.96 – 3.05 (m, 1 H), 3.06 – 3.13 (m, 1 H), 3.62 – 3.77 (m, 2 H), 3.91 (d, J=3.0 Hz, 2 H), 4.30 (dd, J=9.1, 3.4 Hz, 1 H), 5.39 (br s, 1 H), 7.19 – 7.36 (m, 3 H), 7.49 (dd, J=7.9, 1.7 Hz, 1 H), 8.12 (br s, 1 H), 9.40 (br s, 2 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 15: (2S,5R)-N-(2-(4-chloro-2-fluorophenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(4-chloro-2-fluorophenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.15) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholene-2-carboxylic acid (Int-6, 130 g, 260 mmol), the commercially available compound 2-(4-chloro-2-fluorophenyl)propane-2-amine hydrochloride (Int-7.15, 60.0 g, 268 mmol) and N-methylmorpholene (180 mL, 1.64 mol) was cooled in 750 mL dichloromethane at an internal temperature of 0 °C and propane phosphonic acid anhydride (50% in ethyl acetate, 280 mL, 458 mmol) was added slowly while the internal temperature was maintained between 0 °C and 5 °C. After stirring at 0°C for 1.5 hours, the reaction mixture was poured over 1000 mL of water, and most of the organic solvent was evaporated under reduced pressure. The remaining aqueous layer was extracted using 500 mL of tert-butylmethyl ether, and the layers were separated. The organic layer was washed using 800 mL of water, 1000 mL of 20% aqueous citric acid, and 500 mL of Bryn. Each of the aqueous layers was extracted twice using 500 mL of tert-butylmethyl ether.The collected organic layers were dried over magnesium sulfate, filtered and concentrated under low pressure to obtain the crude compound title which was used in the next step without further purification. ESI-MS: 569 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.24 minutes (Method F) Step b: (2S,5R)-N-(2-(4-chloro-2-fluorophenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide (Example 15) A mixture of tert-butyl(2S,5S)-5-(((tert-butyldiphenyl oxy)methyl)-2-((2-(4-chloro-2-fluorophenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.15, as obtained from the step above) and hydrochloric acid (4 M in dioxane, 500 mL, 2 M) was stirred at room temperature for 30 minutes. After the addition of 500 mL of methanol, the mixture was stirred at room temperature for 3 days. The solvents were removed under reduced pressure, the residue was shaken with 400 mL of water and 400 mL of heptane, and the layers were separated. The organic layer was extracted using 250 mL of 1 M aqueous hydrochloric acid, and the aqueous layers were washed with 350 mL of diethyl ether and collected. To the collected aqueous layers, 200 mL of concentrated aqueous ammonia (≥ 25%) was added, followed by extraction of the basal aqueous layer using dichloromethane (3 times, 400 mL each). The organic layers were collected, dried over magnesium sulfate, and concentrated under reduced pressure.To the remaining material, 100 mL of acetonitrile and approximately 5 mg of Example 15 crystal (published crystals, obtained as described below)* were added to initiate the formation of the crystalline solid. Acetonitrile was added until the reaction mixture was adequately stirred. The mixture was stirred and heated until reduction, followed by stirring at room temperature for 1 hour. The solvent was removed under reduced pressure, 160 mL of acetonitrile was added, and the mixture was stirred and heated until reduction. The mixture was stirred at room temperature for 2 hours and filtered. The solid was washed with acetonitrile and dried in a nitrogen-sterilized circulating oven at 40 °C to obtain 67.7 g of the title compound as a crystalline solid. The resulting material is suitable for single-crystal X-ray analysis; see below. ESI-MS: 331 [M+H]+ Retention time (High-performance liquid chromatography): 0.76 minutes (Method A) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.61 (s, 6 H), 2.58 – 2.65 (m, 1 H), 2.69 (dd, J=12.5, 3.5 Hz, 1 H), 2.86 (dd, J=12.4, 7.2 Hz, 1 H), 3.44 (d, J=6.8 Hz, 2 H), 3.59 – 3.65 (m, 1 H), 3.67 – 3.74 (m, 1 H), 3.82 (dd, J=7.2, 3.5 Hz, 1 H), 4.56 (br s, 1 H), 7.20 (dd, J=8.5, 2.0 Hz, 1 H), 7.29 (dd, J=12.3, 2.2 Hz, 1 H), 7.31 – 7.37 (m, 1 H), 7.63 (s, 1 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 *Published crystals can be obtained by purifying Example 15 ore by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 60°C), followed by drying the product-containing fractions and grinding the resulting solid using acetonitrile. The relative and absolute design of Example 15 was determined by single-crystal X-ray analysis. The data allowed the determination of the absolute design of Example 15 to be (2S, 5R) and the relative design of the 2-carboxymide and 5-hydroxymethyl substitution groups on morpholine to be ces, see Figure 1a. A suitable crystal was selected and fixed using Paratone N on an XtaLAB AFC11 (RCD3): a single-chiroquartile diffraction meter. The crystal was held at 100 K during data acquisition. Using Olex2 (Dolomanov, OV, Bourhis, LJ, Gildea, RJ, Howard, JAK & Puschmann, H. (2009), J. Appl. Cryst. 42, 339-341), the structure was solved using SHELXT (Sheldrick, GM (2015). Acta Cryst. A71, 3-8.) with intrinsic phasing and filtering using SHELXL (Sheldrick, GM (2015). Acta Cryst. C71, 3-8.). A correction package was applied using least-squares reduction. Crystal data and structure improvement for example 15. monoclinic crystal system P21 Vacuum Set a / angstrom 10.0781(2) b / angstrom 6.69060(10) c / angstrom 12.2443(3) α / ° 90 β / ° 108.788(2) γ / ° 90 Volume / Angstrom 3 781.62(3) Z 2 μ / mm-1 2.395 F(000) 350.0 Crystal size / mm3 0.5 × 0.1 × 0.02 Cu Kα radiation (λ = 1.54184) Data range aggregation 2Θ / ° 7.626 to 102.206 Index ranges: -10 ≤h ≤ 10, -6 ≤k ≤ 6, -12 ≤l ≤ 12 Collected reflections 4399 Independent reflections 1662 [Rint = 0.0103, Rsigma = 0.0113] Data / Constraints / Variables 1662 / 1 / 207 Product compatibility with F2 1.032 Final R indices [I>=2σ(I)] R1 = 0.0195, wR2 = 0.0522 Final R-values [all data] R1 = 0.0196, wR2 = 0.0523 The largest difference between the peak / hole / eangstrom -3 is 0.10 / -0.12 Flack variable 0.002(12) Example 16: (2S,5R)-N-(1-(4-chloro-2-fluorophenyl)cyclobutyl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((1-(4-chloro-2-fluorophenyl)cyclobutyl)carbamoyl)morpholine-4-carboxylate (Int-10.16) The title compound was prepared from (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 144 mg, 0.29 mmol) and the commercially available compound 1-(4-chloro-2-fluorophenyl)cyclobutane-1-amine hydrochloride (Int-7.16, 60.7 mg, 0.26 mmol) in a manner analogous to the intermediate compound Int-10.10, see above, and used in the next step without further purification. ESI-MS: 581 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.25 minutes (Method F) Step b: (2S,5R)-N-(1-(4-chloro-2-fluorophenyl)cyclobutyl)-5-(hydroxymethyl)morpholin-2-carboxymide (Example 16) The title compound was prepared from tert-butyl(2S,5S)-5-(((tert-butyl diphenyl syl)oxy)methyl)-2-((1-(4-chloro-2-fluorophenyl)cyclobutyl)carbamoyl)morpholine-4-carboxylate (Int-10.16, as obtained from the step above) and purified by a method corresponding to Example 10, see above, except that stirring at 50°C for 1 day followed by stirring at room temperature for 3 days was performed instead of stirring at 50°C for 4 hours. 44.2 mg was obtained. ESI-MS: 343 [M+H]+ Retention time (High-performance liquid chromatography): 0.86 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.69 – 1.81 (m, 1 H), 1.95 – 2.08 (m, 1 H), 2.20 (br s, 1 H), 2.56 – 2.63 (m, 1 H), 2.66 (dd, J=12.5, 3.6 Hz, 1 H), 2.85 (dd, J=12.4, 6.5 Hz, 1 H), 3.38 (t, J=5.8 Hz, 2 H), 3.60 (d, J=4.2 Hz, 2 H), 3.79 (dd, J=6.46, 3.55 Hz, 1 H), 4.53 (t, J=5.3 Hz, 1 H), 7.20(dd, J=8.4, 1.9 Hz, 1 H), 7.30 (dd, J=11.2, 2.2 Hz, 1 H), 7.46 (t, J=8.6 Hz, 1 H), 8.20 (s, 1 H). The four H signal is not detectable; it can be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 17: (2S,5R)-N-(2-(2-chloro-4-fluoro-3-methylphenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: Tert-butyl (2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(2-chloro-4-fluoro-3-methylphenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.17) r-SA">) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 130 mg, 0.26 mmol), 2-(2-chloro-4-fluoro-3-methylphenyl)propane-2-amine hydrochloride (Int-7.17, 136 mg, 0.29 mmol), and N,N-diisopropylethylamine (DIPEA) (199 μL, 151 mg, 1.17 mmol) in 5 mL of N,N-dimethylformamide was cooled in an ice bath. 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoro Borate (87.7 mg, 0.27 mmol) was added, and the mixture was allowed to warm to room temperature. After stirring overnight, the solvents were removed, and the residue was shaken using ethyl acetate and a 5% aqueous sodium bicarbonate solution. The layers were separated; the organic layer was washed with water, dried over sodium sulfate, filtered, and the solvents were removed under reduced pressure to obtain the title compound, which was used in the next step without further purification. ESI-MS: 583 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.23 minutes (Method F) Step b: (2S,5R)-N-(2-(2-chloro-4-fluoro-3-methylphenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide (Example 17) To a mixture of tert-butyl(2S,5S)-5-(((tert-butyldiphenyl oxy)methyl)-2-((2-(2-chloro-4-fluoro-3-methylphenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.17, as obtained from the step above) in 4 mL of methanol, hydrochloric acid (4 M in dioxane, 1.54 mL, 6.15 mmol) and aqueous hydrochloric acid (4 M, 0.5 mL, 2.00 mmol) were added, and the mixture was stirred at 50 °C. After stirring for 2 hours, hydrochloric acid (4 M in dioxane, 2.00 mL, 8.00 mmol) was added again, and the mixture was stirred at 50 °C overnight. The mixture was concentrated under reduced pressure, tetrahydrofuran was added, the mixture was filtered and the filtrate product was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 60°C) and the product-containing fractions were concentrated under reduced pressure to obtain 17.0 mg of the title compound. ESI-MS: 345 [M+H]+ Retention time (High-performance liquid chromatography): 0.86 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.68 (s, 3 H), 1.69 (s, 3 H), 2.23 (d, J=2.3 Hz, 3 H), 2.56 – 2.63 (m, 1 H), 2.67 (dd, J=12.5, 3.5 Hz, 1 H), 2.81 (dd, J=12.5, 7.9 Hz, 1 H), 3.43 – 3.49 (m, 2 H), 3.61 (dd, J=11.2, 3.2 Hz, 1 H), 3.71 – 3.81 (m, 2 H), 4.50 – 4.60 (m, 1 H), 7.12 (t, J=8.9 Hz, 1 H), 7.38 (dd, J=8.9, 6.2 Hz, 1 H), 7.55 (s, 1 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 18: (2S,5R)-N-(2-(2-chloro-5-fluorophenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(2-chloro-5-fluorophenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.18) The title compound was prepared from (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 130 mg, 0.26 mmol) and 2-(2-chloro-5-fluorophenyl)propane-2-amine hydrochloride (Int-7.18, 128 mg, 0.29 mmol) in a manner analogous to the intermediate compound Int-10.17, see above, except that the mixture was stirred for 3 days instead of overnight, and used in the next step without further purification. ESI-MS: 569 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.19 minutes (Method F) Step b: (2S,5R)-N-(2-(2-chloro-5-fluorophenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide (Example 18)To a mixture of tert-butyl(2S,5S)-5-(((tert-butyldiphenyl oxy)methyl)-2-((2-(2-chloro-5-fluorophenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.18, as obtained from the step above) in 4 mL of methanol, hydrochloric acid (4 M, 1.3 mL, 5.2 mmol) and aqueous hydrochloric acid (4 M, 0.5 mL, 2.0 mmol) were added and the mixture stirred at 50 °C. After 1 day, stirring was completed at room temperature for 6 days. The mixture was concentrated under reduced pressure, N,N-dimethylformamide was added, the mixture was filtered, and the filtrate was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 60°C). The product-containing fractions were concentrated under reduced pressure, diethyl ether was added, and the mixture was concentrated under reduced pressure.The remaining material was purified by supercritical fluid chromatography (Chiral®(R) Cellulose-SZ, supercritical carbon dioxide / isopropyl alcohol / ammonia, reverse pressure 150 bar, 40°C) and the product-containing fractions were concentrated under reduced pressure to obtain 33.3 mg of the title compound. ESI-MS: 331 [M+H]+ Retention time (High-performance liquid chromatography): 0.81 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.66 (s, 3 H), 1.68 (s, 3 H), 2.62 (br s, 1 H), 2.69 (dd, J=12.5, 3.0 Hz, 1 H), 2.84 (dd, J=12.6, 7.7 Hz, 1 H), 3.42 – 3.50 (m, 2 H), 3.62 (dd, J=11.2, 3.2 Hz, 1 H), 3.75 (dd, J=11.2, 4.0 Hz, 1 H), 3.78 – 3.83 (m, 1 H), 4.57 (br s, 1 H), 7.06 – 7.14 (m, 1 H), 7.27 (dd, J=11.0, 3.0 Hz, 1 H), 7.37 (dd, J=8.8, 5.6 Hz, 1 H), 7.64 (s, 1 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 19: (2S,5R)-N-(2-(3-chloro-2,4-difluorophenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide hydrochloride Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(3-chloro-2,4-difluorophenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.19) To a mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 180 mg, 85% purity by 1H-NMR, 0.31 mmol), 2-(3-chloro-2,4-difluorophenyl)propane-2-amine hydrochloride (Int-7.19, 69.3 mg, 0.34 mmol) in 5 mL N,N-dimethylformamide, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (108 mg, 0.34 mmol) and N,N-diisopropylethylamine (213 µL, 1.23 mL) were added. The mixture was stirred at room temperature overnight. 2-(3-chloro-2,4-difluorophenyl)propane-2-amine hydrochloride (Int-7.19, 25.0 mg, 0.10 mmol) was added, and the mixture was stirred at room temperature for 8 hours. The solvents were removed under reduced pressure, and the residue was shaken using ethyl acetate and 5% aqueous sodium bicarbonate. The layers were separated; the organic layer was washed with water and 5% aqueous sodium bicarbonate solution added to facilitate separation.The organic layer was dried over sodium sulfate, filtered, and the solvents were removed under reduced pressure to obtain the title compound, which was used in the next step without further purification. ESI-MS: 587 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.11 minutes (Method F) Step b: (2S,5R)-N-(2-(3-chloro-2,4-difluorophenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide hydrochloride (Example 19) A mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl oxy)methyl)-2-((2-(3-chloro-2,4-difluorophenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.19, as obtained from the step above) and 8 mL dichloromethane was cooled in an ice bath. Hydrochloric acid (4 M, 1.55 mL, 6.20 mmol) and 2 mL methanol were added, and the mixture was stirred at room temperature for 3 days. Aqueous hydrochloric acid (4 M, 1.00 mL, 4.00 mmol) was added, and the mixture was stirred at 40 °C for 3 hours and at room temperature overnight. Aqueous hydrochloric acid (4 M, 2.00 mL, 8.00 mmol) was added, and the mixture was stirred at 50 °C for 2 days. The solvents were removed under reduced pressure, tetrahydrofuran was added, the mixture was filtered, and the filtrate was purified by preparative RP-HPLC (Waters SunFire C18, acetonitrile / water / trifluoroacetic acid, 60 °C). The product-containing fractions were then lyophilized. To the residue, dioxane and hydrochloric acid (4 M in dioxane, 1 mmol) were added.The mixture was concentrated under reduced pressure (00 ml). This was repeated twice to obtain 24.9 mg of the target compound. ESI-MS: 349 [M+H]+ Retention time (High-performance liquid chromatography): 0.78 minutes (Method A) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.63 (s, 6 H), 2.58 – 2.65 (m, 1 H), 2.65 – 2.72 (m, 1 H), 2.82 – 2.90 (m, 1 H), 3.43 (dd, J=6.5, 5.4 Hz, 2 H), 3.59 – 3.65 (m, 1 H), 3.66 – 3.74 (m, 1 H), 3.83 (dd, J=7.0, 3.5 Hz, 1 H), 4.55 (t, J=5.3 Hz, 1 H), 7.22 (td, J=8.8, 1.7 Hz, 1 H), 7.36 (td, J=9.1, 6.4 Hz, 1 H), 7.73 (s, 1 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 21: (2S,5R)-N-(2-(3,4-difluoro-2-methylphenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(3,4-difluoro-2-methylphenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.21) The title compound was prepared from (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 130 mg, 0.26 mmol) and 2-(3,4-difluoro-2-methylphenyl)propane-2-amine hydrochloride (Int-7.21, 63.4 mg, 0.29 mmol) in a manner analogous to the intermediate compound Int-10.17, see above, except that the mixture was stirred for 5 days instead of overnight, and used in the next step without further purification. ESI-MS: 567 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.15 minutes (Method F) Step b: (2S,5R)-N-(2-(3,4-Difluoro-2-methylphenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide (Example 21) إلى خليط من خام تيرت- بيوتيل (2S، 5S)-5-(((تيرت- بيوتيل داي فينيل سليل) أوكسي) ميثيل)-2-((2-(3، 4- داي فلورو -2- ميثيل فينيل) بروبان -2-يل) كربامويل) مورفولين -4- كربوكسيلات (Int-10.21، كما تم الحصول عليه من الخطوة المذكورة أعلاه) و4 مل ميثانول تمت إضافة حمض هيدروكلوريك (4 مولار في دايوكسان، 1.43 مل، 5.70 مللي مول) وتقليب الخليط طوال الليل عند درجة حرارة الغرفة. تمت إضافة حمض هيدروكلوريك (4 مولار في دايوكسان، 2.00 مل، 8.00 مللي مول) وحمض هيدروكلوريك مائي (4 مولار، 0.5 مل، 2.00 مللي مول) وتم تقليب الخليط عند 50 درجة مئوية. بعد 4.5 ساعة، تمت إضافة حمض هيدروكلوريك (4 مولار في دايوكسان، 2.00 مل، 8.00 مللي مول) وتم تقليب الخليط عند 50 درجة مئوية طوال الليل. تم تركيز الخليط تحت ضغط منخفض، تمت إضافة تترا هيدرو فيوران، تم ترشيح الخليط وتمت تنقية ناتج الترشيح بواسطة RP-HPLCتحضيري (Waters XBridge C18، أسيتونيتريل / ماء / أمونيا، 60 درجة مئوية). تم تجفيد الأجزاء المحتوية على المنتج للحصول على 41.0 مجم من مركب العنوان. ESI-MS: 329 [M+H]+ Retention time (High-performance liquid chromatography): 0.82 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.61 (s, 6 H), 2.31 (d, J=3.4 Hz, 3 H), 2.57 – 2.64 (m, 1 H), 2.68 (dd, J=12.5, 3.5 Hz, 1 H), 2.84 (dd, J=12.5, 7.4 Hz, 1 H), 3.44 (br d, J=6.0 Hz, 2 H), 3.59 – 3.65 (m, 1 H), 3.67 – 3.73 (m, 1 H), 3.81 (dd, J=7.3, 3.5 Hz, 1 H), 4.56 (br s, 1 H), 7.09 – 7.18 (m, 2 H), 7.70 (s, 1 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 22: (2S,5R)-N-(2-(3,5-dichloro-2-fluorophenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(3,5-dichloro-2-fluorophenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.22) To a mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 100 mg, 0.20 mmol), 2-(3,5-dichloro-2-fluorophenyl)propane-2-amine hydrochloride (Int-7.22, 50.0 mg, 0.19 mmol) and triethylamine (150 µL, 1.08 mmol) in 2 mL, N,N-dimethylformamide 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (70 mg, 0.22 mmol) was added and the mixture was stirred at room temperature for 2 hours. Water and dichloromethane were added, the layers were separated, and the organic layer was concentrated under low pressure to obtain the title compound, which was used in the next step without further purification. ESI-MS: 725 [M+Na]+ Retention time (High-performance liquid chromatography): 1.32 minutes (Method E) Step b: (2S,5R)-N-(2-(3,5-Dichloro-2-fluorophenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide (Example 22) A mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl syl)oxy)methyl)-2-((2-(3,5-dichloro-2-fluorophenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.22, as obtained from the step above), hydrochloric acid (4 M in dioxane, 3.00 mL, 12.0 mmol) and aqueous hydrochloric acid (4 M, 1.00 mL, 4.00 mmol) was stirred overnight at room temperature, followed by heating at 40 °C for 2 hours. The mixture was concentrated under reduced pressure and purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50 °C). The product-containing portions were freeze-dried to obtain 46.0 mg of the title compound. ESI-MS: 365 [M+H]+ Retention time (High-performance liquid chromatography): 0.81 minutes (Method A) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.62 (s, 3 H), 1.63 (s, 3 H), 2.23 – 2.41 (br m, 1 H), 2.59 – 2.66 (m Hz, 1 H), 2.69 (dd, J=12.4, 3.6 Hz, 1 H), 2.88 (dd, J=12.4, 6.8 Hz, 1 H), 3.43 (br d, J=5.5 Hz, 2 H), 3.58 – 3.65 (m, 1 H), 3.66 – 3.71 (m, 1 H), 3.85 (dd, J=6.8, 3.6 Hz, 1 H), 4.55 (br s, 1H), 7.31 (dd, J=6.5, 2.6 Hz, 1 H), 7.65 (dd, J=5.9, 2.6 Hz, 1 H), 7.81 (s, 1 H). Double divisor ratio: ≥ 95:5 Example 23: (2S,5R)-N-(2-(4-chloro-2,3-difluorophenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(4-chloro-2,3-difluorophenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.23) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 203 mg, 0.41 mmol) and 2-(4-chloro-2,3-difluorophenyl)propane-2-amine hydrochloride (Int-7.23, 130 mg, 0.41 mmol) was stirred in 5 mL of N,N-dimethylformamide in an ice bath. 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (144 mg, 0.45 mmol) and N,N-diisopropylethylamine (284 µL, 1.63 mmol) were added, and the mixture was allowed to warm to room temperature and stirred for 2 days. A saturated aqueous potassium carbonate solution was prepared, and equal volumes of water and ethyl acetate were added to separate the layers. The aqueous layer was extracted twice using ethyl acetate, and the collected organic layers were washed with water. The organic layer was concentrated under reduced pressure to obtain the title compound, which was used in the next step without further purification. Step b: (2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-N-(2-(4-chloro-2,3-difluorophenyl)propan-2-yl)morpholine-2-carboxamide (2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-N-(2-(4-chloro-2,3-difluorophenyl)propan-2-yl)morpholine-2-carboxamide (Int-11.23) To a mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl oxy)methyl)-2-((2-(4-chloro-2,3-difluorophenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.23, as obtained in the step above) in 5 mL of dichloromethane, trifluoroacetic acid (1 mL, 13.1 mmol) was added, and the mixture was stirred at room temperature overnight. The mixture was concentrated under reduced pressure, dichloromethane was added, and 5% aqueous sodium bicarbonate solution was added until pH was alkaline. The layers were separated, the organic layer was dried over sodium sulfate, and the mixture was filtered and concentrated under reduced pressure to obtain the title compound, which was used in the next step without further purification. ESI-MS: 587 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.27 minutes (Method C) Step c: (2S,5R)-N-(2-(4-chloro-2,3-difluorophenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide (Example 23) A mixture of (2S,5S)-5-(((tert-butyldiphenyl syl)oxy)methyl)-N-(2-(4-chloro-2,3-difluorophenyl)propane-2-yl)morpholine-2-carboxymide (Int-11.23, as obtained from the step above) was treated in 5 mL of tetrahydrofuran using tetrabutylammonium fluoride (1.0 M in tetrahydrofuran, 0.61 mL, 0.61 mmol) and stirred overnight at room temperature. Dichloromethane and 5% aqueous sodium bicarbonate solution were added, and the plates were separated. The aqueous layer was extracted three times using dichloromethane. The collected organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The remaining material was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50°C), and the product-containing fractions were concentrated under reduced pressure to obtain 30.0 mg of the title compound. ESI-MS: 349 [M+H]+ Retention time (High-performance liquid chromatography): 0.86 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.62 (s, 6 H), 2.21 – 2.31 (m, 1 H), 2.57 – 2.65 (m, 1 H), 2.65 – 2.72 (m, 1 H), 2.87 (dd, J=12.4, 7.0 Hz, 1 H), 3.39 – 3.46 (m, 2 H), 3.59 – 3.65 (m, 1 H), 3.66 – 3.72 (m, 1 H), 3.83 (dd, J=7.0, 3.6 Hz, 1 H), 4.54 (t, J=5.3 Hz, 1 H), 7.14 – 7.22 (m, 1 H), 7.34 (ddd, J=8.8, 7.0, 1.8 Hz, 1 H), 7.77 (s, 1 H). Double divisor ratio: ≥ 95:5 Example 24: (2S,5R)-N-(2-(4,5-dichloro-2-fluorophenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(4,5-dichloro-2-fluorophenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.24) To a mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholin-2-carboxylic acid (Int-6, 180 mg, 0.34 mmol), 2-(4,5-dichloro-2-fluorophenyl)propane-2-amine hydrochloride (Int-7.24, 170.0 mg, 0.66 mmol) and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (232 mg, 0.72 mmol) in 2 mL, N,N-dimethylformamide and N,N-diisopropylethylamine (0.46 mL, 2.63 mmol) were added and the mixture was stirred at room temperature for 2 hours. The reaction mixture was shaken using 25 mL of saturated aqueous sodium bicarbonate solution, 25 mL of water, and ethyl acetate. The layers were separated, and the aqueous layer was extracted twice using ethyl acetate. The collected organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound, which was then used in the next step without further purification. ESI-MS: 603 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.26 minutes (Method F) Step b: (2S,5R)-N-(2-(4,5-Dichloro-2-fluorophenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide (Example 24) To a mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl syl)oxy)methyl)-2-((2-(4,5-dichloro-2-fluorophenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.24, as obtained from the step above) and 5 mL dichloromethane, hydrochloric acid (4 M in dioxane, 2.77 mL, 11.1 mmol) was added, and the mixture was stirred overnight. Subsequently, hydrochloric acid (4 M in dioxane, 2.77 mL, 11.1 mmol) and 0.5 mL methanol were added, and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure and purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50 °C). The product-containing portions were freeze-dried to obtain 57.0 mg of the title compound. ESI-MS: 365 [M+H]+ Retention time (High-performance liquid chromatography): 0.90 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.61 (s, 3 H), 1.62 (s, 3 H), 2.58 – 2.66 (m, 1 H), 2.67 – 2.73 (m, 1 H), 2.88 (dd, J=12.4, 6.8 Hz, 1 H), 3.40 – 3.46 (m, 2 H), 3.59 – 3.64 (m, 1 H), 3.66 – 3.72 (m, 1 H), 3.84 (dd, J=6.8, 3.6 Hz, 1 H), 4.55 (br t, J=5.2 Hz, 1 H), 7.49 (d, J=8.0 Hz, 1 H), 7.57 (d, J=11.7 Hz, 1 H), 7.75 (s, 1 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 25: (2S,5R)-5-(hydroxymethyl)-N-(2-(naphthalen-1-yl)propan-2-yl)morpholine-2-carboxamide Step a: Tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(naphthalen-1-yl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.25) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenylsilyl)oxy)methyl)morpholin-2-carboxylic acid (Int-6, 100 mg, 0.20 mmol), the commercially available compound 2-(naphthalene-1-yl)propane-2-amine hydrochloride (Int-7.25, 45 mg, 0.20 mmol) and triethylamine (0.15 mL, 1.08 mmol) and 2 mL N,N-dimethylformamide was stirred at room temperature. 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (70 mg, 0.22 mmol) was added and the mixture was stirred at room temperature for 1.5 hours. Water and dichloromethane were added, the layers were separated, and the organic layer was concentrated under low pressure to obtain the title compound, which was used in the next step without further purification. ESI-MS: 667 [M+H]+ Retention time (High-performance liquid chromatography): 1.30 minutes (Method E) Step b: (2S,5R)-5-(hydroxymethyl)-N-(2-(naphthalene-1-yl)propane-2-yl)morpholene-2-carboxylamide (Example 25) A mixture of tert-butyl(2S,5S)-5-(((tert-butyldiphenyl methyl)oxy)methyl)-2-((2-(naphthalene-1-yl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.25, as obtained from the step above) and hydrochloric acid (4 M in dioxane, 3.00 mL, 12.0 mmol) was stirred at room temperature for 30 minutes. Then, 1 mL of methanol was added, and the mixture was stirred at room temperature for 5 days. The mixture was concentrated under reduced pressure and purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50°C). The product-containing fractions were lyophilized to obtain 50.0 mg of the title compound. ESI-MS: 329 [M+H]+ Retention time (High-performance liquid chromatography): 0.78 minutes (Method A) 1H-NMR (400 MHz, DMSO-d6) δ ppm 1.81 (s, 3 H), 1.82 (s, 3 H), 2.53 – 2.61 (m, 2 H), 2.67 (d, J=7.6 Hz, 1 H), 3.44 (t, J=6.0 Hz, 2 H), 3.56 – 3.64 (m, 1 H), 3.68 – 3.76 (m, 2 H), 4.53 (s, 1 H), 7.40 – 7.49 (m, 3 H), 7.54 (dd, J=7.4, 1.0 Hz, 1 H), 7.79 (d, J=8.0 Hz, 1 H), 7.87 – 7.94 (m, 2 H), 8.45 – 8.54 (m, 1 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 26: (2S,5R)-N-(2-(2,3-dichlorophenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide hydrochloride Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(2,3-dichlorophenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.26) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenylsilyl)oxy)methyl)morpholin-2-carboxylic acid (Int-6, 180 mg, 0.34 mmol), the commercially available compound 2-(2,3-dichlorophenyl)propane-2-amine hydrochloride (Int-7.26, 82.3 mg, 0.34 mmol), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (121 mg, 0.38 mmol), and 5 mL N,N-dimethylformamide was treated with N,N-diisopropylethylamine (0.24 mL, 1.37 mmol). After stirring at room temperature for 2 hours, the mixture was poured over 50 mL of 5% aqueous sodium bicarbonate solution. The resulting solid was filtered, washed with water, 15 mL of dioxane was added, and the mixture was dried to obtain the title compound, which was used in the next step without further purification. ESI-MS: 585 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.23 minutes (Method F) Step b: (2S,5R)-N-(2-(2,3-Dichlorophenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide hydrochloride (Example 26)To a mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl syl)oxy)methyl)-2-((2-(2-chloro-3-fluorophenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.26, as obtained from the step above) in 6 mL of dichloromethane, hydrochloric acid (4 M in dioxane, 0.42 mmol, 1.68 mmol) and 50 µL of water were added, and the mixture was stirred at room temperature. After 3 days, 3 mL of methanol and aqueous hydrochloric acid (4 M in dioxane, 2.50 mL, 10 mmol) were added, and the mixture was stirred at room temperature for 2 days. The mixture was concentrated under reduced pressure. To the residue, 5 mL of methanol and concentrated aqueous ammonia (≥ 25%) were added until a basic pH was obtained. The mixture was filtered, purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 60°C), and the fractions containing the title compound were lyophilized. To the residue, 4 mL of dichloromethane was added, along with hydrochloric acid (4 M in dioxane, 0.40 mL, 1.60 mmol), and the solvents were removed under reduced pressure to obtain 106 mg of the title compound. ESI-MS: 347 [M+H]+ Retention time (High-performance liquid chromatography): 0.85 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.69 (s, 3 H), 1.70 (br s, 3 H), 2.98 – 3.15 (m, 2 H), 3.61 – 3.77 (m, 2 H), 3.89 (d, J=2.91 Hz, 2 H), 4.24 – 4.31 (m, 1 H), 5.33 – 5.47 (m, 1 H), 7.28 – 7.36 (m, 1 H), 7.45 – 7.57 (m, 2 H), 8.30 (s, 1 H), 8.69 (br s, 1 H), 9.78 (br s, 1 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 27: (2S,5R)-N-(2-(3,5-dichlorophenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(3,5-dichlorophenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.27) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholin-2-carboxylic acid (Int-6, 130 mg, 0.26 mmol), the commercially available compound 2-(3,5-dichlorophenyl)propane-2-amine (Int-7.27, 48 μL, 0.29 mmol) and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (87.7 mg, 0.27 mmol) and 5 mL N,N-dimethylformamide was cooled in an ice bath, followed by the addition of N,N-diisopropylethylamine (0.15 mL, 1.17 mmol). After stirring at room temperature overnight, the mixture was concentrated and then shaken using ethyl acetate and a 5% aqueous sodium bicarbonate solution. The organic layer was washed with water, dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound, which was used in the next step without further purification. ESI-MS: 585 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.22 minutes (Method F) Step b: (2S,5R)-N-(2-(3,5-Dichlorophenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide hydrochloride (Example 27) The title compound was prepared from the crude tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(3,5-dichlorophenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.27, as obtained from the step above) and purified by a method corresponding to Example 1, see above, except that 1.31 mL of hydrochloric acid was used (4 M in dioxane, 5.24 mmol). 38.0 mg of the title compound was obtained. ESI-MS: 347 [M+H]+ Retention time (High-performance liquid chromatography): 0.88 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.56 (s, 6 H), 2.60 – 2.68 (m, 1 H), 2.71 (dd, J=12.4, 3.4 Hz, 1 H), 2.92 (dd, J=12.4, 6.7 Hz, 1 H), 3.44 (br t, J=5.8 Hz, 2 H), 3.60 – 3.66 (m, 1 H), 3.67 – 3.72 (m, 1 H), 3.86 (dd, J=6.7, 3.6 Hz, 1 H), 4.55 (br t, J=5.2, 1 H), 7.33 (d, J=1.8 Hz, 2 H), 7.40 (t, J=1.8 (Hz, 1 H), 7.75 (s, 1 H). A signal from two Hs cannot be detected; it can be superimposed with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 28: (2S,5R)-N-(2-(3,4-dichlorophenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide hydrochloride Step a: Tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(3,4-dichlorophenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.28) The title compound Int-10.28 is prepared from (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenylsilyl)oxy)methyl)morpholin-2-carboxylic acid (Int-6, 180 mg, 0.34 mmol) and the commercially available compound 2-(3,4-dichlorophenyl)propane-2-amine hydrochloride (Int-7.28, 170 mg, 0.71 mmol) in a manner analogous to the intermediate compound Int-10.24, see above, and used in the next step without further purification. ESI-MS: 585 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.25 minutes (Method F) Step b: (2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-N-(2-(3,4-dichlorophenyl)propan-2-yl)morpholine-2-carboxamide (2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-N-(2-(3,4-dichlorophenyl)propan-2-yl)morpholine-2-carboxamide (Int-11.28) To a mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl syl)oxy)methyl)-2-((2-(3,4-dichlorophenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.28, as obtained from the step above) and 3 mL dichloromethane, trifluoroacetic acid (0.56 mL, 7.22 mmol) was added, and the mixture was stirred at room temperature overnight. A saturated aqueous sodium bicarbonate solution and an equal volume of water were added until a basic pH was obtained. Dichloromethane was then added, and the layers were separated. The aqueous layer was extracted twice using dichloromethane. The collected organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound, which was used in the next step without further purification. ESI-MS: 585 [M+H]+ Retention time (High-performance liquid chromatography): 1.08 minutes (Method F) Step c: (2S,5R)-N-(2-(3,4-Dichlorophenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide hydrochloride (Example 28) The title compound was prepared from the crude (2S,5S)-5-(((tert-butyldiphenyl syl)oxy)methyl)-N-(2-(3,4-dichlorophenyl)propane-2-yl)morpholene-2-carboxymide (Int-11.28, as obtained from the step above) and purified in a manner corresponding to Example 23, see above, except that after purification 1 mL of dichloromethane and 0.30 mL of hydrochloric acid (4 M in dioxane, 1.2 mmol) were added and the mixture was concentrated under reduced pressure to obtain 55.0 mg of the title compound as the hydrochloride salt. ESI-MS: 347 [M+H]+ Retention time (High-performance liquid chromatography): 0.88 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.56 (s, 3 H), 1.57 (s, 3 H), 3.06 – 3.15 (m, 2 H), 3.62 – 3.77 (m, 2 H), 3.84 – 3.93 (m, 2 H), 4.30 (br t, J=6.0 Hz, 1 H), 5.37 (br t, J=5.1 Hz, 1 H), 7.32 (dd, J=8.5, 2.3 Hz, 1 H), 7.50 – 7.57 (m, 2 H), 8.28 (s, 1 H), 9.12 (br s, 2 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 29: (2S,5R)-N-(2-(3-chloro-2-fluorophenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide hydrochloride Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(3-chloro-2-fluorophenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.29) To a mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholin-2-carboxylic acid (Int-6, 180 mg, 0.34 mmol), the commercially available compound 2-(3-chloro-2-fluorophenyl)propane-2-amine hydrochloride (Int-7.29, 76.7 mg, 0.34 mmol) and N,N-diisopropylethylamine (0.24 mL, 1.37 mmol) in 5 mL, N,N-dimethylformamide 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (121 mg, 0.38 mmol) was added. After stirring at room temperature for 2 hours, the mixture was poured over 50 mL of 5% aqueous sodium bicarbonate solution. The mixture was extracted using 70 mL of ethyl acetate, the organic layer was washed twice with 30 mL of 5% aqueous sodium bicarbonate solution each time, dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound, which was used in the next step without further purification. ESI-MS: 569 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.21 minutes (Method F) Step b: (2S,5R)-N-(2-(3-chloro-2-fluorophenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide hydrochloride (Example 29) To a mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl syl)oxy)methyl)-2-((2-(3-chloro-2-fluorophenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.29, as prepared in the step above) in 6 mL dichloromethane, hydrochloric acid (4 M in dioxane, 0.42 mL, 1.68 mmol) was added. After stirring for 2 hours at room temperature, 50 µL of water and hydrochloric acid (4 M in dioxane, 2.50 mL, 10 mmol) were added. The mixture was stirred for 3 days at room temperature, then 3 mL of methanol and aqueous hydrochloric acid (4 M, 5.00 mL, 20.0 mmol) were added, and the mixture was stirred for 2 days. The mixture was concentrated under reduced pressure, and 5 mL of methanol and concentrated aqueous ammonia (≥ 25%) were added to the residue until a basic pH was obtained. The mixture was filtered, purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 60 °C), and the fractions containing the title compound were lyophilized. To the remaining material, 4 mL of dichloromethane and hydrochloric acid (4 M in dioxane, 0.40 mL, 1.6 mmol) were added and the solvents were removed under reduced pressure to obtain 108 mg of the title compound. ESI-MS: 331 [M+H]+ Retention time (High-performance liquid chromatography): 0.84 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.64 (s, 3 H), 1.65 (s, 3 H), 3.03 – 3.16 (m, 2 H), 3.62 – 3.80 (m, 2 H), 3.86 – 3.96 (m, 2 H), 4.33 (dd, J=8.1, 4.1 Hz, 1 H), 5.40 (br s, 1 H), 7.11 – 7.19 (m, 1 H), 7.32 (td, J=7.7, 1.3 Hz, 1 H), 7.41 – 7.47 (m, 1 H), 8.32 (s, 1 H), 8.51 – 10.38 (br m, 2 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 30: (2S,5R)-N-(2-(4-fluoro-2-methylphenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide L-(+)-tartrate Step a: Tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(4-fluoro-2-methylphenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.30) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 290 mg, 80% purity by 1H-NMR, 0.46 mmol), the commercially available compound 2-(4-fluoro-2-methylphenyl)propane-2-amine hydrochloride (Int-7.30, 95.0 mg, 0.46 mmol), and triethylamine (300 µL, 2.15 mmol) was stirred in 5 mL of N,N-dimethylformamide in an ice bath, and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (160 mg, 0.50 mmol). Addition: After stirring at room temperature overnight, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (80 mg, 0.25 mmol) was added, and the mixture was stirred for 1 hour at room temperature. After the addition of water and acetonitrile, the mixture was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50°C). The product-containing fractions were lyophilized to obtain the title compound. ESI-MS: 649 [M+H]+ Retention time (High-performance liquid chromatography): 1.36 minutes (Method C) Step b: (2S,5R)-N-(2-(4-fluoro-2-methylphenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide L-(+)-tartrate (Example 30) A mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl oxy)methyl)-2-((2-(4-fluoro-2-methylphenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.30, as obtained from the step above), hydrochloric acid (4 M in dioxane, 5.00 mL, 20.0 mmol) and aqueous hydrochloric acid (4 M, 2.50 mL, 10.0 mmol) was stirred overnight at room temperature. The mixture was concentrated under reduced pressure, methanol was added, followed by the addition of concentrated aqueous ammonia (≥ 25%) until a basic pH was obtained. The remaining material was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50°C) and the product-containing fractions were lyophilized. Four milliliters of tetrahydrofuran and L-(+)-tartrate (28.0 mg, 0.19 mmol) were added, and the mixture was stirred overnight. The resulting solid was filtered, washed with tetrahydrofuran, and dried at 50°C under vacuum to obtain 65.0 mg of the title compound as the L-(+)-tartrate salt. ESI-MS: 311 [M+H]+ Retention time (High-performance liquid chromatography): 0.75 minutes (Method A) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.61 (s, 6 H), 2.38 (s, 3 H), 2.81 – 2.97 (m, 3 H), 3.49 – 3.58 (m, 2 H), 3.67 – 3.73 (m, 1 H), 3.74 – 3.81 (m, 1 H), 3.98 (dd, J=7.7, 3.6 Hz, 1 H), 4.11 (s, 2 H), 4.31 (br s, 6 H), 6.88 – 6.95 (m, 2 H), 7.28 – 7.36 (m, 1 H), 7.80 (s, 1 H). Double divisor ratio: ≥ 95:5 Example 31: (2S,5R)-N-(2-(4-chloro-2-methylphenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(4-chloro-2-methylphenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.31) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 290 mg, 80% purity by 1H-NMR, 0.46 mmol), the commercially available compound 2-(4-chloro-2-methylphenyl)propane-2-amine hydrochloride (Int-7.31, 100 mg, 0.45 mmol) and triethylamine (300 µL, 2.15 mmol) was stirred in 5 mL N,N-dimethylformamide in an ice bath and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (160 mg, 0.50 mmol) was added. After stirring at room temperature overnight, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (80 mg, 0.25 mmol) was added, and the mixture was stirred for 1 hour at room temperature. After the addition of water and acetonitrile, the mixture was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50°C). The product-containing fractions were lyophilized to obtain 170 mg of the title compound. ESI-MS: 665 [M+H]+ Retention time (High-performance liquid chromatography): 1.38 minutes (Method C) Step b: (2S,5R)-N-(2-(4-chloro-2-methylphenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide (Example 31) A mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl oxy)methyl)-2-((2-(4-chloro-2-methylphenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.31, 170 mg, 0.26 mmol) and hydrochloric acid (4 M in dioxane, 5.00 mL, 20.0 mmol) was stirred for 45 minutes. Aqueous hydrochloric acid (4 M, 2.50 mL, 10.0 mmol) was then added, and the mixture was stirred overnight at room temperature. The mixture was concentrated under reduced pressure, and methanol was added, followed by the addition of concentrated aqueous ammonia (≥ 25%) until a basic pH was obtained. The remaining material was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50°C) and the product-containing fractions were lyophilized to obtain 52.0 mg of the title compound. ESI-MS: 327 [M+H]+ Retention time (High-performance liquid chromatography): 0.79 minutes (Method A) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.59 (s, 3 H), 1.60 (s, 3 H), 2.37 (s, 3 H), 2.60 (tt, J=6.9, 3.6 Hz, 1 H), 2.68 (dd, J=12.6, 3.4 Hz, 1 H), 2.82 (dd, J=12.6, 7.6 Hz, 1 H), 3.41 – 3.47 (m, 2 H), 3.58 – 3.64 (m, 1 H), 3.68 – 3.75 (m, 1 H), 3.80 (dd, J=7.5, 3.5 Hz, 1 H), 4.54 (br s, 1 H), 7.10 – 7.19 (m, 2 H), 7.30 (d, J=8.4 Hz, 1 H), 7.58 (s, 1 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 32: (2S,5R)-N-(2-(4-fluoro-2-methylbenzofuran-7-yl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide hydrochloride Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(4-fluorobenzofuran-7-yl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.32) The title compound Int-10.32 is prepared from (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenylsilyl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 180 mg, 0.36 mmol), 2-(4-fluoro-2-methylbenzofuran-7-yl)propane-2-amine hydrochloride (Int-7.32, 114 mg, as obtained from the synthesis described above) in a manner analogous to the intermediate compound Int-10.19, see above, and used in the next step without further purification. ESI-MS: 589 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.24 minutes (Method F) Step b: (2S,5R)-N-(2-(4-fluoro-2-methylbenzofuran-7-yl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxymide hydrochloride (Example 32) To a mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl syl)oxy)methyl)-2-((2-(4-fluorobenzofuran-7-yl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.32, as obtained from the step above) and 4 mL dichloromethane, hydrochloric acid (4 M in dioxane, 1.80 mL, 7.2 mmol), several drops of methanol, and several drops of water were added. After stirring overnight, the mixture was concentrated under reduced pressure, methanol was added, and the mixture was filtered. Purification was performed by preparative RP-HPLC (Waters SunFire C18, acetonitrile / water / trifluoroacetic acid, 50 °C), and the fractions containing the title compound were lyophilized. To a mixture of the residue and 2 mL of dichloromethane, hydrochloric acid in diethyl ether was added, and the mixture was concentrated under reduced pressure. The resulting residue was purified by supercritical fluid chromatography (Chiralpak(R) IG, supercritical carbon dioxide / methanol / ammonia, reverse pressure 150 bar, 40 °C), and the product-containing fractions were concentrated under reduced pressure to obtain 22.0 mg of the title compound. ESI-MS: 351 [M+H]+ Retention time (High-performance liquid chromatography): 0.88 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.72 (s, 3 H), 1.73 (s, 3 H), 2.46 (d, J=0.8 Hz, 3 H), 2.80 – 2.96 (m, 3 H), 3.54 (br t, J=5.3 Hz, 2 H), 3.70 – 3.76 (m, 1 H), 3.76 – 3.82 (m, 1 H), 4.01 (dd, J=7.4, 3.5 Hz, 1 H), 4.89 (br s, 1 H), 6.20 (br s, 1 H), 6.65 (d, J=1.0 Hz, 1 H), 6.93 (t, J=9.0 Hz, 1 H), 7.08 (dd, J=8.5, 5.3 Hz, 1 H), 7.83 (s, 1 H). Double divisor ratio: ≥ 95:5 Example 33: (2S,5R)-N-(2-(4-bromo-2-fluorophenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: Tert-butyl (2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(4-bromo-2-fluorophenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.33) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholin-2-carboxylic acid (Int-6, 300 mg, 0.60 mmol), the commercially available compound 2-(4-bromo-2-fluorophenyl)propane-2-amine hydrochloride (Int-7.33, 170 mg, 0.63 mmol) and triethylamine (0.40 mL, 2.87 mmol) and 3 mL of N,N-dimethylformamide were added in an ice bath, along with 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (210 mg, 0.65 mmol). The mixture was stirred in an ice bath for 2 hours. Methanol was added and the mixture was purified by preparative RP-HPLC (Waters XBridge, acetonitrile / water / ammonia, 50°C). The product-containing fractions were lyophilized to obtain the title compound. ESI-MS: 713 [M+H]+ Retention time (High-performance liquid chromatography): 1.38 minutes (Method C) Step b: (2S,5R)-N-(2-(4-bromo-2-fluorophenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide (Example 33) To a mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl oxy)methyl)-2-((2-(4-bromo-2-fluorophenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.33, 100 mg, 0.14 mmol) in methanol hydrochloride (4 M in dioxane, 2.00 mL, 8.00 mmol) and the mixture was stirred at room temperature. After stirring for 3 days, the mixture was concentrated under reduced pressure. The residue was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50 °C), and the product-containing fractions were lyophilized to obtain 41.0 mg of the title compound. ESI-MS: 375 [M+H]+ Retention time (High-performance liquid chromatography): 0.77 minutes (Method A) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.61 (s, 6 H), 2.58 – 2.65 (m, 1 H), 2.69 (dd, J=12.6, 3.6 Hz, 1 H), 2.86 (dd, J=12.5, 7.2 Hz, 1 H), 3.44 (br d, J=6.6 Hz, 2 H), 3.58 – 3.65 (m, 1 H), 3.67 – 3.74 (m, 1 H), 3.81 (dd, J=7.2, 3.5 Hz, 1 H), 4.55 (br s, 1 H), 7.24 – 7.35 (m, 2 H), 7.40 (dd, J=12.0, 2.0 (Hz, 1 H), 7.63 (s, 1 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 34: (2S,5R)-N-(2-(4-ethynyl-2-fluorophenyl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: Tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(2-fluoro-4-((trimethylsilyl)ethynyl)phenyl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.34) In an argon atmosphere, a mixture of tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(4-bromo-2-fluorophenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.33, 70.0 mg, 0.10 mmol), ethinyltrimethylsilane (50.0 µL, 0.35 mmol), copper(I) iodide (5.00 mg, 0.03 mmol), [1,1'-bis(biphenylfospheno)ferrocene]dichloropalladium(II) (8.00 mg, 0.01 mmol), and triethylamine (50.0 µL, 0.36 mmol) was heated in 1 mL of N,N-dimethylformamide. Microwaved at 80°C. After 1 hour, acetonitrile was added, followed by acetic acid until an acidic pH was achieved. The mixture was filtered, purified by preparative RP-HPLC (Waters SunFire C18, acetonitrile / water / trifluoroacetic acid, 50°C), and the product-containing fractions were concentrated under reduced pressure to obtain 70.0 mg of the target compound. ESI-MS: 631 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.33 minutes (Method F) Step b: (2S,5R)-N-(2-(4-ethinyl-2-fluorophenyl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide (Example 34) A mixture of tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(2-fluoro-4-((trimethylsilyl)ethinyl)phenyl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.34, 70.0 mg, 0.10 mmol) and hydrochloric acid (4 M in dioxane, 3.00 mL, 1.70 mmol) was stirred for 1 hour, and aqueous hydrochloric acid (4 M, 1.00 mL, 4.00 mmol) was added. The mixture was stirred at room temperature overnight. The mixture was concentrated under reduced pressure, methanol was added, followed by the addition of concentrated aqueous ammonia (≥ 25%) until a basic pH was obtained. The mixture was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50°C) and the product-containing fractions were lyophilized to obtain 18.0 mg of the title compound. ESI-MS: 321 [M+H]+ Retention time (High-performance liquid chromatography): 0.76 minutes (Method A) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.62 (s, 6 H), 2.33 (br s, 1 H), 2.57 – 2.65 (m, 1 H), 2.69 (dd, J=12.5, 3.5 Hz, 1 H), 2.86 (dd, J=12.5, 7.2 Hz, 1 H), 3.44 (br d, J=6.7 Hz, 2 H), 3.58 – 3.65 (m, 1 H), 3.67 – 3.75 (m, 1 H), 3.82 (dd, J=7.2, 3.5 Hz, 1 H), 4.24 (s, 1 H), 4.55 (br s, 1 H), 7.18 – 7.26 (m, 2 H), 7.29 – 7.36 (m, 1 H), 7.63 (s, 1 H). Double divisor ratio: ≥ 95:5 Example 35: (2S,5R)-N-(2-(4-chloroisoquinolin-1-yl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(4-chloroisoquinolin-1-yl)propan-2-yl)carbamoyl)morpholine-4-carboxylate A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenylsilyl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 1.19 g, 2.26 mmol), 2-(4-chloroisoquinoline-1-yl)propane-2-amine hydrochloride (Int-7.35, 580 mg, 2.26 mmol), N,N-diisopropylethylamine (1.57 mL, 9.02 mmol) and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (796 mg, 2.48 mmol) was stirred in 15 mL of N,N-dimethylformamide at room temperature for 2.5 hours. The reaction mixture was poured onto 150 mL of aqueous sodium bicarbonate solution (5%) and stirred for several minutes. The resulting solid was filtered, washed with water, and air-dried to obtain 1.20 g of the desired product, which was used in the next step without further purification. ESI-MS: 702 [M+H]+ Retention time (High-performance liquid chromatography): 1.24 minutes (Method F) Step b: A">(2S,5R)-N-(2-(4-chloroisoquinoline-1-yl)propane-2-yl)-5-(hydroxymethyl)morpholin-2-carboxymide (Example 35) A mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl oxy)methyl)-2-((2-(4-chloroisoquinoline-1-yl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.35, 1.20 g, 1.71 mmol), 40 mL dichloromethane, and hydrochloric acid (4 M in dioxane, 12.8 mL, 51.2 mmol) was stirred for 3 days at ambient temperature, followed by the addition of 20 mL of methanol. The mixture was stirred at ambient temperature overnight. The mixture was concentrated under reduced pressure, ethyl acetate was added, followed by the addition of concentrated aqueous ammonia (≥ 25%) until pH was alkaline. The mixture was first purified by flash chromatography (silica, dichloromethane / ethanol / aqueous ammonia), concentrated, and then purified twice by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 60°C). The product-containing fractions were lyophilized to obtain 464 mg of the title compound. ESI-MS: 364 [M+H]+ Retention time (High-performance liquid chromatography): 0.87 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.78 (s, 6 H), 2.5–2.56 (m, 1 H, partially overlaid with solvent residue signal), 2.56–2.63 (m, 1 H), 2.67 (dd, J=12.6, 7.4 Hz, 1 H), 3.45 (br d, J=6.3 Hz, 2 H), 3.59–3.66 (m, 1 H), 3.67–3.78 (m, 2 H), 4.55 (br s, 1 H), 7.69 (virt. t, d, J=7.4 Hz, 1 H), 7.89 (virt. t, J=7.6 Hz, 1 H), 8.20 (d, J=8.6 Hz, 1 H), 8.45 (s, 1 H), 8.53 (s, 1 H), 8.75 (d, J=8.6 Hz, 1 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 36: (2S,5R)-N-(2-(4-fluoroisoquinolin-1-yl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(4-fluoroisoquinolin-1-yl)propan-2-yl)carbamoyl)morpholine-4-carboxylate A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenylsilyl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 5.19 g, 8.31 mmol), 2-(4-fluoroisoquinoline-1-yl)propane-2-amine hydrochloride (Int-7.36, 2.00 g, 8.31 mmol), N,N-diisopropylethylamine (5.79 mL, 33.2 mmol) and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (2.93 g, 9.14 mmol) was stirred in 40 mL of N,N-dimethylformamide at room temperature for 2 hours. The reaction mixture was poured onto 150 mL of aqueous sodium bicarbonate solution (5%) and stirred for several minutes. 250 mL of ethyl acetate was added, the layers were separated, the organic layer was washed with water, dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound, which was used in the next step without further purification. ESI-MS: 686 [M+H]+ Retention time (High-performance liquid chromatography): 1.20 minutes (Method F) Step b: (2S,5R)-N-(2-(4-fluoroisoquinoline-1-yl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxymide fumarate (Example 36) A mixture of tert-butyl(2S,5S)-5-(((tert-butyldiphenyl oxy)methyl)-2-((2-(4-fluoroisoquinoline-1-yl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.36, as obtained in the previous step), 120 mL dichloromethane, hydrochloric acid (4 M in dioxane, 41.5 mL, 166 mmol), several drops of water, and several mL of methanol was stirred overnight at room temperature. Hydrochloric acid (4 M in dioxane, 10.0 mL, 40 mmol) was added again, and the mixture was stirred for 5 days at room temperature. The mixture was concentrated under reduced pressure, methanol was added, followed by the addition of triethylamine until a basic pH was obtained. The mixture was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 60°C). The product-containing fractions were concentrated under reduced pressure, followed by the addition of ethyl acetate, sodium sulfate drying, filtration, reduced-pressure concentration, and grinding with diisopropyl ether to obtain 1.79 g of the title compound. ESI-MS: 348 [M+H]+ Retention time (High-performance liquid chromatography): 0.82 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.77 (s, 6 H), 2.52 – 2.53 (m, 2 H), 2.68 (dd, J=12.6, 7.4 Hz, 1 H), 3.42 – 3.48 (m, 2 H), 3.60 – 3.66 (m, 1 H), 3.70 – 3.77 (m, 2 H), 4.55 (br t, J=4.7 Hz, 1 H), 7.68 (d, J=8.6 Hz, 7.0 Hz, 1.1 Hz, 1 H), 7.85 (virt. t, J=7.4 Hz, 1 H), 8.10 (d, J=8.2 Hz, 1 H), 8.37 (d, J=1.1 Hz, 1 H), 8.68 – 8.74 (m, 1 H), 8.75 (d, J=8.6 Hz, 1 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 37: (2S,5R)-N-(2-(4-fluoro-7-methylisoquinolin-1-yl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(4-fluoro-7-methyl-isoquinolin-1-yl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.37) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 1.20 g, 2.40 mmol), 2-(4-fluoro-7-methylisoquinoline-1-yl)propane-2-amine hydrochloride (Int-7.37, 612 mg, 2.41 mmol), triethylamine (1.34 mL, 9.61 mmol), and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (848 mg, 2.64 mmol) was stirred in 10 mL N,N-dimethylformamide and 15 mL acetonitrile at room temperature overnight, followed by heating to 60°C. The reaction mixture was incubated for 3 hours. A 5% aqueous sodium bicarbonate solution was added, and the mixture was extracted three times using ethyl acetate. The collected organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound, which was used in the next step without further purification. ESI-MS: 700 [M+H]+ Retention time (High-performance liquid chromatography): 1.30 minutes (Method E) Step b: (2S,5R)-N-(2-(4-fluoro-7-methylisoquinoline-1-yl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxymide (Example 37) A mixture of tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(4-fluoro-7-methylisoquinoline-1-yl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.37, as obtained in the previous step) was stirred in 5 mL of methanol and hydrochloric acid (4 M in dioxane, 12.0 mL, 48.0 mmol) at room temperature overnight. The mixture was concentrated under reduced pressure, methanol was added, followed by triethylamine, until a basic pH was obtained. The mixture was filtered, diluted with tetrahydrofuran, and purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 60 °C). The product-containing portions were freeze-dried to obtain 333 mg of the title compound. ESI-MS: 362 [M+H]+ Retention time (High-performance liquid chromatography): 0.76 minutes (Method A) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.76 (s, 3 H), 1.77 (s, 3 H), 2.29 H (br s, 1 H), 2.55 (s, 3 H), 2.56 – 2.63 (m, 1 H), 2.66 (dd, J=12.5, 7.7 Hz, 1 H), 3.43 – 3.49 (m, 2 H), 3.60 – 3.67 (m, 1 H), 3.70 – 3.77 (m, 2 H), 4.53 (br t, J=4.9 Hz, 1 H), 7.66 – 7.72 (m, 1 H), 7.99 (d, J=8.5 Hz, 1 H), 8.29 (d, J=1.1 Hz, 1 H), 8.41 (s, 1 H), 8.75 (d, J=8.5 Hz, 1 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 38: (2S,5R)-N-(2-(4,7-difluoroisoquinolin-1-yl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(4,7-difluoroisoquinolin-1-yl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.38) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 180 mg, 90% purity by 1H-NMR, 0.32 mmol) and 5 mL acetonitrile was cooled in an ice bath. 2-(4,7-difluoroisoquinoline-1-yl)propane-2-amine hydrochloride (Int-7.38, 87.8 mg, 0.34 mmol), triethylamine (0.18 mL, 1.30 mmol), and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (115 mg, 0.36 mmol) were added and the mixture stirred at room temperature. The room was incubated overnight. The reaction mixture was poured onto a saturated aqueous sodium bicarbonate solution and an equal volume of water, and the resulting mixture was extracted twice using dichloromethane. The collected organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound, which was used in the next step without further purification. ESI-MS: 704 [M+H]+ Retention time (High-performance liquid chromatography): 1.18 minutes (Method F) Step b: (2S,5R)-N-(2-(4,7-Difluoroisoquinoline-1-yl)propane-2-yl)-5-(hydroxymethyl)morpholin-2-carboxymide (Example 38) A mixture of tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(4,7-difluoroisoquinoline-1-yl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.38, as obtained in the previous step), 4 mL methanol, hydrochloric acid (4 M in dioxane, 1.62 mL, 6.48 mmol), and aqueous hydrochloric acid (4 M, 0.50 mL, 2.00 mmol) was stirred at 50 °C overnight. The mixture was concentrated under reduced pressure, and methanol was added. The mixture was filtered, diluted with methanol, and purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 60 °C). The product-containing portions were freeze-dried to obtain 60.4 mg of the title compound. ESI-MS: 366 [M+H]+ Retention time (High-performance liquid chromatography): 0.82 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.73 (s, 3 H), 1.74 (s, 3 H), 2.21 H (br s, 1 H), 2.48 – 2.51 (m, 1 H), 2.57 – 2.63 (m, 1 H), 2.68 (dd, J=12.4, 7.4 Hz, 1 H), 3.39 – 3.51 (m, 2 H), 3.59 – 3.67 (m, 1 H), 3.69 – 3.77 (m, 2 H), 4.51 (t, J=5.3 Hz, 1 H), 7.74 – 7.82 (m, 1 H), 8.18 (dd, J=9.2 Hz, 5.9 Hz, 1 H), 8.37 (d, J=1.1 Hz, 1 H), 8.39 – 8.47 (m, 2 H). Double divisor ratio: ≥ 95:5 Example 39: (2S,5R)-N-(2-(4,6-difluoroisoquinolin-1-yl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide hydrochloride: Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(4,6-difluoro-isoquinolin-1-yl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.39) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl oxy)methyl)morpholine-2-carboxylic acid (Int-6, 122 mg, 0.24 mmol), 2-(4,6-difluoroisoquinoline-1-yl)propane-2-amine hydrochloride (Int-7.38, 60.0 mg, 0.23 mmol), and N-methylmorpholine (0.19 mL, 1.74 mmol) was stirred in 4 mL dichloromethane over an ice bath, and propane phosphonic acid anhydride (50% in ethyl acetate, 0.26 mL, 0.42 mmol) was added. The mixture was allowed to warm to room temperature and stirred overnight. Next, an aqueous sodium bicarbonate solution and an equal volume of water were added, the layers were separated, and the aqueous layer was extracted twice using dichloromethane. The collected organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound, which was used in the next step without further purification. ESI-MS: 704 [M +H]+ Retention time (High-performance liquid chromatography): 1.35 minutes (Method C) Step b: (2S,5R)-N-(2-(4,6-Difluoroisoquinoline-1-yl)propane-2-yl)-5-(hydroxymethyl)-morpholine-2-carboxylamide hydrochloride (Example 39) A mixture of tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(4,6-difluoroisoquinoline-1-yl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.39, as obtained from the previous step) was stirred in 2 mL of methanol and hydrochloric acid (4 M in dioxane, 0.59 mL, 2.34 mmol) at 45 °C overnight. The mixture was concentrated under reduced pressure, and methanol, tetrahydrofuran, and triethylamine were added. The mixture was then purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50 °C). The product-containing portions were lyophilized, before dioxane and hydrochloric acid (4 M in dioxane, 0.10 mL, 0.40 mmol) were added and the mixture was lyophilized to obtain 65.0 mg of the title compound. ESI-MS: 366 [M+H]+ Retention time (High-performance liquid chromatography): 0.83 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.77 (s, 6 H), 2.81 -2.91 (m, 1 H), 2.93 – 3.01 (m, 1 H), 3.28 (br s, 1 H), 3.60 – 3.67 (m, 1 H), 3.67 – 3.74 (m, 1 H), 3.79 – 3.86 (m, 1 H), 3.87 – 3.94 (m, 1 H), 4.22 (br s, 1 H) 4.28 (dd, J=8.9 Hz, 3.4 Hz, 1 H), 7.57 – 7.65 (m, 1 H), 7.83 (dd, J= 9.3 Hz, 2.7 Hz, 1 H), 8.43 (s, 1 H), 8.57 – 8.67 (m, 1 H), 8.80 (ddd, J=9.5 Hz, 5.4 Hz, 2.0 Hz, 1 H), 8.97 (s, 1 H), 10.0 (br s, 1 H). Double divisor ratio: ≥ 95:5 Example 40: (2S,5R)-5-(hydroxymethyl)-N-(2-(isoquinolin-1-yl)propan-2-yl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(isoquinolin-1-yl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.40) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 168 mg, 0.27 mmol), 2-(isoquinoline-1-yl)propane-2-amine (Int-7.40, 50.0 mg, 0.27 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (112 mg, 0.30 mmol) and N,N-diisopropylethylamine (0.14 mL, 0.81 mmol) was stirred into 4 mL of N,N-dimethylformamide at ambient temperature overnight. A saturated aqueous sodium bicarbonate solution and water were added, and the mixture was stirred for 15 minutes. The resulting solids were separated by filtration, washing with water, and drying under reduced pressure to obtain the title compound, which was used in the next step without further purification. ESI-MS: 668 [M+H]+ Retention time (High-performance liquid chromatography): 1.35 minutes (Method C) Step b: (2S,5R)-5-(hydroxymethyl)-N-(2-(isoquinoline-1-yl)propane-2-yl)morpholin-2-carboxylamide (Example 40) A mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl oxy)methyl)-2-((2-(isoquinoline-1-yl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.40, as obtained in the previous step) was stirred in 4 mL of dichloromethane and hydrochloric acid (4 M in dioxane, 0.97 mL, 3.89 mmol) at room temperature overnight. The mixture was concentrated under reduced pressure, and methanol, tetrahydrofuran, and water were added. The mixture was then purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50 °C). The product-containing fractions were lyophilized to obtain 26.0 mg of the title compound. ESI-MS: 330 [M+H]+ Retention time (High-performance liquid chromatography): 0.78 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.81 (s, 3 H), 1.81 (s, 3 H), 2.55 -2.64 (m, 2 H), 2.72 (dd, J=12.5 Hz, 7.4 Hz, 1 H), 3.45 (s, 1 H), 3.46 (s, 1 H), 3.61 – 3.67 (m, 1 H), 3.71 – 3.79 (m, 2 H), 4.54 (br s, 1 H), 7.54 – 7.61 (m, 1 H), 7.66 – 7.74 (m, 2 H), 7.95 (d, J=8.0 Hz, 1 H), 8.39 (d, J=5.6 Hz, 1 H), 8.56 (s, 1 H), 8.62 (d, J=8.7 Hz, 1 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 41: (2S,5R)-N-(2-(4-fluoro-3-methylisoquinolin-1-yl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(4-fluoro-3-methylisoquinolin-1-yl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.41) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 180 mg, 0.34 mmol), 2-(4-fluoro-3-methylisoquinoline-1-yl)propane-2-amine hydrochloride (Int-7.41, 91.5 mg, 0.36 mmol), N,N-diisopropylethylamine (0.24 mL, 1.37 mmol) and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (121 mg, 0.38 mmol) was stirred in 4 mL of N,N-dimethylformamide at room temperature for 2 hours. A 5% aqueous sodium bicarbonate solution and ethyl acetate were added to the reaction mixture, and the mixture was stirred for several minutes. The layers were separated, and the organic layer was washed with water, dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound, which was used in the next step without further purification. ESI-MS: 700 [M+H]+ Retention time (High-performance liquid chromatography): 1.27 minutes (Method F) Step b: (2S,5R)-N-(2-(4-fluoro-3-methylisoquinoline-1-yl)propane-2-yl)-5-(hydroxymethyl)morpholin-2-carboxymide (Example 41) A mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl oxy)methyl)-2-((2-(4-fluoro-3-methylisoquinoline-1-yl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.41, as obtained in the previous step), 7 mL dichloromethane, hydrochloric acid (4 M in dioxane, 1.71 mL, 6.84 mmol), several drops of water, and methanol was stirred overnight at room temperature. The mixture was concentrated under reduced pressure, methanol was added, and the mixture was filtered and purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 60 °C). The product-containing fractions were lyophilized to obtain 57.5 mg of the title compound. ESI-MS: 362 [M+H]+ Retention time (High-performance liquid chromatography): 0.92 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.78 (s, 3 H), 1.79 (s, 3 H), 2.54 -2.64 (m, 5 H), 2.72 (dd, J=12.5 Hz, 7.3 Hz, 1 H), 3.46 (d, J=6.8 Hz, 2 H), 3.62 – 3.67 (m, 1 H), 3.71 – 3.79 (m, 2 H), 4.55 (br s, 1 H), 7.56 – 7.63 (m, 1 H), 7.76 – 7.83 (m, 2 H), 8.03 (d, J=8.2 Hz, 1 H), 8.56 (d, J=5.6 Hz, 1 H), 8.60 – 8.66 (m, 1 H). Double divisor ratio: ≥ 95:5 Example 42: (2S,5R)-N-(2-(3-methylisoquinolin-1-yl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(3-methylisoquinolin-1-yl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.42) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 125 mg, 0.25 mmol), 2-(3-methylisoquinoline-1-yl)propane-2-amine (Int-7.42, synthesis described in IAN 2016 / 075240, 40.0 mg, 0.20 mmol), triethylamine (0.13 mL, 0.90 mmol), and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (80.2 mg, 0.25 mmol) was stirred in 2 mL of N,N-dimethylformamide at room temperature throughout At night, a 5% aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted using ethyl acetate. The organic layer was washed with water and brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound, which was used in the next step without further purification. ESI-MS: 682 [M+H]+ Retention time (High-performance liquid chromatography): 1.32 minutes (Method A) Step b: (2S,5R)-N-(2-(3-methylisoquinoline-1-yl)propane-2-yl)-5-(hydroxymethyl)morpholin-2-carboxymide (Example 42) A mixture of tert-butyl(2S,5S)-5-(((tert-butyldiphenyl oxy)methyl)-2-((2-(3-methylisoquinoline-1-yl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.42, as obtained in the previous step), 2 mL of methanol, and hydrochloric acid (4 M in dioxane, 0.51 mL, 2.05 mmol) was stirred at room temperature overnight. The mixture was concentrated under reduced pressure, methanol and triethylamine were added, and the mixture was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 60 °C). The product-containing fractions were lyophilized to obtain 34.2 mg of the title compound. ESI-MS: 344 [M+H]+ Retention time (High-performance liquid chromatography): 0.61 minutes (Method A) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.82 (s, 3 H), 1.83 (s, 3 H), 2.58 (d, J=0.6 Hz, 3 H), 2.59 – 2.66 (m, 2 H), 2.78 (dd, J=12.4 Hz, 7.2 Hz, 1 H), 3.42 – 3.46 (m, 2 H), 3.63 – 3.69 (m, 1 H), 3.71 – 3.82 (m, 2 H), 4.54 (t, J=5.1 Hz, 1 H), 7.45 – 7.55 (m, 2 H), 7.62 – 7.68 (m, 1 H), 7.85 (d, J=8.0 Hz, 1 H), 8.54 (d, J=8.5 Hz, 1 H), 8.82 (s, 1 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 43: (2S,5R)-N-(2-(3,5-dichloropyridin-2-yl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(3,5-dichloropyridin-2-yl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.43) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenylsilyl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 218 mg, 0.44 mmol), 2-(3,5-dichloropyridine-2-yl)propane-2-amine (Int-7.43, 105 mg, 0.51 mmol), N,N-diisopropylethylamine (0.30 mL, 1.74 mmol) and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (154 mg, 0.48 mmol) was stirred into 5 mL of N,N-dimethylformamide at room temperature overnight. A saturated aqueous potassium carbonate solution and an equal volume of water were added to the reaction mixture. The mixture was extracted twice using ethyl acetate, and the collected organic layers were washed with water and concentrated under reduced pressure to obtain the title compound, which was used in the next step without further purification. Step b: (2S,5R)-N-(2-(3,5-Dichloropyridine-2-yl)propane-2-yl)-5-(hydroxymethyl)morpholin-2-carboxymide (Example 43) A mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl oxy)methyl)-2-((2-(3,5-dichloropyridine-2-yl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.43, as obtained in the previous step) and hydrochloric acid (4 M in dioxane, 5 mL, 20.0 mmol) was stirred overnight at room temperature. Hydrochloric acid (4 M in dioxane, 2.5 mL, 10.0 mmol) was added again, and the mixture was stirred for another 3 days at the same temperature. The mixture was concentrated under reduced pressure and purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50 °C). The product-containing fractions were concentrated under low pressure to obtain 70.0 mg of the title compound. ESI-MS: 348 [M+H]+ Retention time (High-performance liquid chromatography): 0.83 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.64 (s, 3 H), 1.64 (s, 3 H), 2.07 (s, 1 H), 2.57 – 2.65 (m, 1 H), 2.69 (dd, J=12.5 Hz, 3.5 Hz, 1 H), 2.86 (dd, J=12.6 Hz, 7.6 Hz, 1 H), 3.45 (br dd, J=6.1 Hz, 4.8 Hz, 2 H), 3.62 (dd, J=11.2 Hz, 3.2 Hz, 1 H), 3.74 (dd, J=11.2 Hz, 4.2 Hz, 1 H), 3.82 (dd, J=7.5 Hz, 3.5 Hz, 1 H) 4.54 (br t, J=4.8 Hz, 1 H), 7.88 (s, 1 H), 8.05 (d, J=2.2 Hz, 1 H), 8.53 (d, J=2.2 Hz, 1 H). Double divisor ratio: ≥ 95:5 Example 44: (2S,5R)-N-(2-(3-chloro-5-fluoropyridin-2-yl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(3-chloro-5-fluoropyridin-2-yl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.44) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 112 mg, 0.22 mmol), 2-(3-chloro-5-fluoropyridine-2-yl)propane-2-amine (Int-7.38, 45 mg, 0.20 mmol), and N-methylmorpholine (0.11 mL, 1.00 mmol) in 5 mL acetonitrile was cooled in an ice / acetone bath. Propane phosphonic acid anhydride (50% in ethyl acetate, 0.24 mL, 0.40 mmol) was added, and the mixture was allowed to warm to room temperature and stirred overnight. To the reaction mixture, a saturated aqueous sodium bicarbonate solution and an equal volume of water were added, and the resulting mixture was extracted twice using dichloromethane. The collected organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound, which was used in the next step without further purification. ESI-MS: 570 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.18 minutes (Method F) Step b: (2S,5R)-N-(2-(4,7-Difluoroisoquinoline-1-yl)propane-2-yl)-5-(hydroxymethyl)morpholin-2-carboxymide (Example 44) A mixture of tert-butyl(2S,5S)-5-(((tert-butyldiphenyl oxy)methyl)-2-((2-(3-chloro-5-fluoropyridine-2-yl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.44, as obtained in the previous step), 4 mL methanol, hydrochloric acid (4 M in dioxane, 1.00 mL, 4.00 mmol), and aqueous hydrochloric acid (4 M, 0.50 mL, 2.00 mmol) was stirred at 50 °C overnight. Aqueous hydrochloric acid (4 M, 0.50 mL, 2.00 mmol) was added again, and the mixture was stirred at 50 °C for 2 hours. The mixture was concentrated under reduced pressure, and methanol was added, followed by aqueous ammonium hydroxide solution, until a basic pH was achieved. The mixture was filtered and purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 60°C). The product-containing fractions were lyophilized to obtain 60.4 mg of the title compound. ESI-MS: 332 [M+H]+ Retention time (High-performance liquid chromatography): 0.76 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.65 (s, 3 H), 1.65 (s, 3 H), 2.27 (br s, 1 H), 2.57 – 2.65 (m, 1 H), 2.69 (dd, J=12.6 Hz, 3.6 Hz, 1 H), 2.86 (dd, J=12.5 Hz, 7.6 Hz, 1 H), 3.45 (br dd, J=6.6 Hz, 5.5 Hz, 2 H), 3.62 (dd, J=11.2 Hz, 3.3 Hz, 1 H), 3.75 (dd, J=11.2 Hz, 4.2 Hz, 1 H), 3.82 (dd, J=7.5 Hz, 3.5 Hz, 1 H) 4.55 (t, J=5.3 Hz, 1 H), 7.87 (s, 1 H), 7.93 (dd, J=8.5 Hz, 2.5 Hz, 1 H), 8.51 (dd, J=2.6 Hz, 0.7 Hz, 1 H). Double divisor ratio: ≥ 95:5 Example 45: (2S,5R)-N-(2-(3,5-dichloro-4-methylpyridin-2-yl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(3,5-dichloro-4-methylpyridin-2-yl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.45) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenylsilyl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 342 mg, 0.68 mmol), 2-(3,5-dichloro-4-methylpyridin-2-yl)propane-2-amine (Int-7.45, 120 mg, 0.55 mmol), N,N-diisopropylethylamine (0.43 mL, 2.46 mmol) and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (220 mg, 0.68 mmol) was stirred into 4 mL of N,N-dimethylformamide at room temperature overnight. The mixture was concentrated under reduced pressure, a 5% aqueous sodium bicarbonate solution was added, and the mixture was extracted using ethyl acetate. The organic layer was washed with water and brine, then dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound, which was used in the next step without further purification. ESI-MS: 600 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.26 minutes (Method F) Step b: (2S,5R)-N-(2-(3,5-Dichloro-4-methylpyridine-2-yl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxymide (Example 45) A mixture of tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(3,5-dichloro-4-methylpyridin-2-yl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.45, as obtained in the previous step), 2 mL of methanol, and hydrochloric acid (4 M in dioxane, 1.37 mL, 5.48 mmol) was stirred at room temperature overnight. Hydrochloric acid (4 M in dioxane, 1.5 mL, 6 mmol) was added, and the mixture was stirred at 50 °C for 7 hours. The mixture was concentrated under reduced pressure, tetrahydrofuran, methanol, and triethylamine were added, and the mixture was filtered and purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50°C). The product-containing fractions were concentrated under reduced pressure to obtain 52.0 mg of the title compound. ESI-MS: 362 [M+H]+ Retention time (High-performance liquid chromatography): 0.87 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.65 (s, 6 H), 2.43 (s, 3 H), 2.57 – 2.64 (m, 1 H), 2.68 (dd, J=12.6 Hz, 3.6 Hz, 1 H), 2.84 (dd, J=12.6 Hz, 7.6 Hz, 1 H), 3.41 – 3.49 (m, 2 H), 3.62 (dd, J=11.2 Hz, 3.3 Hz, 1 H), 3.74 (dd, J=11.2 Hz, 4.2 Hz, 1 H), 3.81 (dd, J=7.6 Hz, 3.6 Hz, 1 H), 4.55 (br t, J=5.3 Hz, 1 H), 7.89 (s, 1 H), 8.49 (s, 1 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 46: (2S,5R)-N-(2-(3-chloro-5-fluoro-4-methylpyridin-2-yl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(3-chloro-5-fluoro-4-methylpyridin-2-yl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.46) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 247 mg, 0.49 mmol), 2-(3-chloro-5-fluoro-4-methylpyridin-2-yl)propane-2-amine (Int-7.46, 80.0 mg, 0.39 mmol), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (158 mg, 0.49 mmol) and triethylamine (0.25 mL, 1.78 mmol) was stirred in 2 mL N,N-dimethylformamide at room temperature overnight. The mixture was concentrated under reduced pressure, a 5% aqueous sodium bicarbonate solution was added, and the mixture was extracted three times using ethyl acetate. The collected organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound, which was used in the next step without further purification. ESI-MS: 584 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.23 minutes (Method F) Step b: (2S,5R)-N-(2-(3-chloro-5-fluoro-4-methylpyridine-2-yl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide (Example 46) A mixture of tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(3-chloro-5-fluoro-4-methylpyridin-2-yl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.46, as obtained in the previous step), 1 mL of methanol, and hydrochloric acid (4 M in dioxane, 5 mL, 20 mmol) was stirred at room temperature overnight. The mixture was concentrated under reduced pressure, methanol and three drops of triethylamine were added, and the mixture was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50 °C). The product-containing fractions were concentrated under reduced pressure to obtain 21.0 mg of the title compound. ESI-MS: 346 [M+H]+ Retention time (High-performance liquid chromatography): 0.82 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.66 (s, 3 H), 1.66 (s, 3 H), 2.29 (d, J=2.2 Hz, 3 H), 2.60 – 2.67 (m, 1 H), 2.71 (dd, J=12.6 Hz, 3.6 Hz, 1 H), 2.82 – 2.90 (m, 1 H), 3.46 (br dd, J=6.3 Hz, 4.8 Hz, 2 H), 3.63 (dd, J=11.2 Hz, 3.2 Hz, 1 H), 3.75 (dd, J=11.3 Hz, 4.1 Hz, 1 H), 3.82 (dd, J=7.7 Hz, 3.5 Hz, 1 H), 4.58 (br t, J=4.6 Hz, 1 H), 7.92 (s, 1 H), 8.43 (s, 1 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 47: (2S,5R)-N-(2-(5-chloro-3-fluoro-4-methylpyridin-2-yl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(5-chloro-3-fluoro-4-methylpyridin-2-yl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.47) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl oxy)methyl)morpholine-2-carboxylic acid (Int-6, 230 mg, 0.46 mmol), 2-(5-chloro-3-fluoro-4-methylpyridin-2-yl)propane-2-amine (Int-7.47, 100 mg, 0.42 mmol), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (154 mg, 0.48 mmol) and triethylamine (0.26 mL, 1.88 mmol) was stirred in 3 mL N,N-dimethylformamide at room temperature overnight. An additional amount of 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (50 mg, 0.16 mmol) and triethylamine (0.10 mL, 0.72 mmol) was added, and the mixture was stirred for another 3.5 hours. The mixture was concentrated under reduced pressure in a bicarbonate solution. Sodium hydroxide (5%) was added, and the mixture was extracted using ethyl acetate. The organic layer was washed with water and brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound, which was used in the next step without further purification. ESI-MS: 584 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.26 minutes (Method F) Step b: (2S,5R)-N-(2-(5-chloro-3-fluoro-4-methylpyridine-2-yl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxymide (Example 47) A mixture of tert-butyl(2S,5S)-5-(((tert-butyldiphenyl oxy)methyl)-2-((2-(5-chloro-3-fluoro-4-methylpyridin-2-yl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.47, as obtained in the previous step), 2 mL methanol, and hydrochloric acid (4 M in dioxane, 1.04 mL, 4.18 mmol) was stirred at room temperature overnight. The mixture was concentrated under reduced pressure, methanol and triethylamine were added, and the mixture was filtered and purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50 °C). The product-containing fractions were concentrated under reduced pressure to obtain 110 mg of the title compound. ESI-MS: 346 [M+H]+ Retention time (High-performance liquid chromatography): 0.84 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.63 (s, 6 H), 2.26 (br s, 1 H), 2.29 (d, J=2.3 Hz, 3 H), 2.58 – 2.68 (m, 1 H), 2.72 (dd, J=12.6 Hz, 3.6 Hz, 1 H), 2.87 (dd, J=12.7 Hz, 7.1 Hz, 1 H), 3.43 (dd, J=6.5 Hz, 5.6 Hz, 2 H), 3.60 – 3.66 (m, 1 H), 3.68 – 3.75 (m, 1 H), 3.83 (dd, J=7.1 Hz, 3.6 Hz, 1 H), 4.55 (t, J=5.4 Hz, 1 H), 8.09 (s, 1 H), 8.40 (s, 1 H). Double divisor ratio: ≥ 95:5 Example 48: (2S,5R)-N-(2-(3,5-difluoro-4-methylpyridin-2-yl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(3,5-difluoro-4-methylpyridin-2-yl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.48) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenylsilyl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 148 mg, 0.30 mmol), 2-(3,5-difluoro-4-methylpyridin-2-yl)propane-2-amine (Int-7.48, 50 mg, 0.27 mmol), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (99.2 mg, 0.31 mmol) and triethylamine (0.17 mL, 1.21 mmol) was stirred in 2 mL N,N-dimethylformamide at room temperature overnight. The mixture was concentrated under reduced pressure, a 5% aqueous sodium bicarbonate solution was added, and the mixture was extracted twice using ethyl acetate. The collected organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound, which was used in the next step without further purification. ESI-MS: 568 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.20 minutes (Method F) Step b: (2S,5R)-N-(2-(3,5-Difluoro-4-methylpyridine-2-yl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide (Example 48) A mixture of tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(3,5-difluoro-4-methylpyridin-2-yl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.48, as obtained in the previous step), 1 mL of methanol, and hydrochloric acid (4 M in dioxane, 5.00 mL, 20.0 mmol) was stirred at room temperature overnight. The mixture was concentrated under reduced pressure, methanol and three drops of triethylamine were added, and the mixture was filtered and purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50 °C). The product-containing fractions were lyophilized to obtain 38.8 mg of the title compound. ESI-MS: 330 [M+H]+ Retention time (High-performance liquid chromatography): 0.79 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.63 (s, 6 H), 2.21 (br s, 3 H), 2.34 (br s, 1 H), 2.57 – 2.65 (m, 1 H), 2.73 (dd, J=12.6 Hz, 3.6 Hz, 1 H), 2.87 (dd, J=12.5 Hz, 7.2 Hz, 1 H), 3.43 (br d, J=6.6 Hz, 2 H), 3.61 – 3.66 (m, 1 H), 3.69 – 3.75 (m, 1 H), 3.83 (dd, J=7.2 Hz, 3.5 Hz, 1 H), 4.55 (br t, J=4.6 Hz, 1 H), 8.15 (s, 1 H), 8.35 (s, 1 H). Double divisor ratio: ≥ 95:5 Example 49 (2S,5R)-N-(2-(3,5-dichloro-6-methylpyridin-2-yl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(3,5-dichloro-6-methylpyridin-2-yl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.49) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 159 mg, 0.32 mmol), 2-(3,5-dichloro-6-methylpyridin-2-yl)propane-2-amine (Int-7.49, 70 mg, 0.32 mmol), and 5 mL N,N-dimethylformamide was cooled in an ice bath under stirring. N,N-diisopropylethylamine (0.22 mL, 1.28 mmol) and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (113 mg, 0.35 mmol) were added, and the mixture was allowed to warm. The reaction mixture was brought to room temperature. It was stirred for 1.5 days, then ethyl acetate, a saturated aqueous potassium carbonate solution, and an equal volume of water were added. The layers were separated, and the aqueous layer was extracted twice using ethyl acetate twice. The collected organic layers were washed with water and concentrated under reduced pressure to obtain the title compound, which was used in the next step without further purification. Step b: (2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-N-(2-(3,5-dichloro-6-methylpyridin-2-yl)propan-2-yl)morpholine-2-carboxamide (2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-N-(2-(3,5-dichloro-6-methylpyridin-2-yl)propan-2-yl)morpholine-2-carboxamide (Int-11.49) A mixture of tert-butyl(2S,5S)-5-(((tert-butyl diphenyl oxy)methyl)-2-((2-(3,5-dichloro-6-methylpyridine-2-yl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.49, as obtained in the previous step), 5 mL dichloromethane, and 1 mL trifluoroacetic acid was stirred overnight. A 5% aqueous sodium bicarbonate solution was added, the layers were separated, the organic layer was dried over sodium sulfate, and the mixture was filtered and concentrated under reduced pressure to obtain the title compound, which was used in the next step without further purification. ESI-MS: 600 [M+H]+ Retention time (High-performance liquid chromatography): 1.34 minutes (Method C) Step c: (2S,5R)-N-(2-(3,5-Dichloro-6-methylpyridine-2-yl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxylamide (Example 49) A mixture of (2S,5S)-5-(((tert-butyldiphenyl syl)oxy)methyl)-N-(2-(3,5-dichloro-6-methylpyridin-2-yl)propane-2-yl)morpholene-2-carboxymide (Int-11.49, as obtained in the previous step) and 5 mL of tetrahydrofuran was treated with tetrabutylammonium fluoride (1.0 M in tetrahydrofuran, 0.48 mL, 0.48 mmol) and stirred overnight at room temperature. Dichloromethane and 5% aqueous sodium bicarbonate solution were added, the layers were separated, and the aqueous layer was extracted three times with dichloromethane. The collected organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The remaining material was purified by preparative RP-HPLC (Waters Xbridge C18, acetonitrile / water / ammonia, 60°C) and the product-containing fractions were concentrated under reduced pressure to obtain 10.4 mg of the title compound. ESI-MS: 362 [M+H]+ Retention time (High-performance liquid chromatography): 0.92 minutes (Method C) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.64 (s, 3H), 1.65 (s, 3H), 2.52 (3H, partially overlaid with solvent residue signal), 2.58–2.65 (m, 1H), 2.71 (dd, J=12.5 Hz, 3.5 Hz, 1H), 2.87 (dd, J=12.5 Hz, 7.5 Hz, 1H), 3.42–3.48 (m, 2H), 3.60–3.66 (m, 1H), 3.72–3.77 (m, 1H), 3.82 (dd, J=7.5 Hz, 3.4 Hz, 1H), 4.54 (m, 1H), 7.97 (s, 1 H), 8.00 (s, 1 H). If no single H signal is detected, it could be overlaid with a solvent residue signal or a water signal. Double divisor ratio: ≥ 95:5 Example 50: (2S,5R)-N-(2-(7-fluoro-1-methyl-1H-indazol-3-yl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide hydrochloride Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(7-fluoro-1H-indazol-3-yl)propan-2-yl)carbamoyl)morpholine-4-carboxylate(Int-10.50a) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 183 mg, 0.37 mmol), 2-(7-fluoro-1H-indazol-3-yl)propane-2-amine hydrochloride (Int-7.50, prepared according to the synthesis described in INR 2016 / 075240, 80.0 mg, 0.35 mmol) and N-methylmorpholine (0.29 mL, 2.61 mmol) in 4 mL dichloromethane in an ice bath and propane phosphonic acid anhydride (50% in ethyl acetate, 0.38 mL, 0.63 mmol) was added. The mixture was allowed to warm to room temperature and stirred overnight. Then, an aqueous sodium bicarbonate solution and an equal volume of water were added, the layers were separated, and the aqueous layer was extracted twice using dichloromethane. The collected organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. Tetrahydrofuran was added, the mixture was filtered, and purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50°C). The fractions containing the title compound were concentrated under reduced pressure to obtain 135.0 mg of the compound. ESI-MS: 575 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.35 minutes (Method A) Step b: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(7-fluoro-1-methyl-1H-indazol-3-yl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.50b) To a mixture of tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(7-fluoro-1H-indazol-3-yl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.50a, 50.0 mg, 0.07 mmol), 2 mL N,N-dimethylformamide, and cesium carbonate (29.0 mg, 0.09 mmol), methyl iodide (2 M in tert-butyl methyl ether, 37.0 µL, 0.07 mmol) was added. The resulting mixture was stirred at room temperature for 3.5 hours. Methyl iodide (2 M in tert-butyl methyl ether, 10.0 µL, 0.02 mmol) was added again, and the mixture was stirred for 2.5 hours. Water and brine were added, and the mixture was extracted using dichloromethane. The organic layer was washed three times with water, washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain 47.0 mg of the title compound, which was used in the next step without further purification. ESI-MS: 689 [M+H]+ Retention time (High-performance liquid chromatography): 1.28 minutes (Method E) Step c: (2S,5R)-N-(2-(7-fluoro-1-methyl-1H-indazol-3-yl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxymide hydrochloride (Example 50) To a mixture of tert-butyl(2S,5S)-5-(((tert-butyldiphenyl oxy)methyl)-2-((2-(7-fluoro-1-methyl-1H-indazol-3-yl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.50b, as obtained from the step above), 2 mL of methanolic hydrochloric acid (4 M in dioxane, 0.15 mL, 0.60 mmol) was added, and the mixture was stirred at 50 °C overnight. Hydrochloric acid (4 M in dioxane, 0.15 mL, 0.60 mmol) was added again, and the mixture was stirred at 50 °C overnight and at room temperature for four days. Subsequently, the solvents were removed under reduced pressure, and the residual material was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 60 °C). The product-containing fractions were then concentrated under reduced pressure. To the residual material, dioxane and hydrochloric acid (4 M in dioxane, 0.05 mL, 0.20 mmol) were added, and the mixture was concentrated under reduced pressure to obtain 18.3 mg of the title compound. ESI-MS: 351 [M+H]+ Retention time (High-performance liquid chromatography): 0.75 minutes (Method A) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.72 (s, 3 H), 1.72 (s, 3 H), 2.94 – 3.01 (m, 1 H), 3.04 – 3.10 (m, 1 H), 3.52 – 3.61 (m, 1 H), 3.61 – 3.73 (m, 2 H), 3.88 (virt. d, J=3.3 Hz, 2 H), 4.11 (d, J=1.0 Hz, 3 H), 4.29 (dd, J=8.7 Hz, 3.5 Hz, 1 H), 5.37 (br s, 1 H), 6.99 – 7.06 (m, 1 H), 7.14 – 7.21 (m, 1 H), 7.65 (d, J=8.1 Hz, 1 H), 8.46 (s, 1 H), 8.63 (br s, 1 H), 9.64 (br s, 1 H). Double divisor ratio: ≥ 95:5 Example 51: (2S,5R)-N-(2-(7-chloro-1-methyl-1H-indazol-3-yl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide hydrochloride Step a: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(7-chloro-1H-indazol-3-yl)propan-2-yl)carbamoyl)morpholine-4-carboxylate(Int-10.51a) A mixture of (2S,5S)-4-(tert-butoxycarbonyl)-5-(((tert-butyldiphenyl syl)oxy)methyl)morpholine-2-carboxylic acid (Int-6, 125 mg, 0.25 mmol), 2-(7-chloro-1H-indazol-3-yl)propane-2-amine hydrochloride (Int-7.51, prepared according to the synthesis described in INR 2016 / 075240, 50.0 mg, 0.24 mmol) and N-methylmorpholine (0.20 mL, 1.79 mmol) in 4 mL dichloromethane in an ice bath and propane phosphonic acid anhydride (50% in ethyl acetate, 0.26 mL, 0.43 mmol) was added. The mixture was allowed to warm to room temperature and stirred overnight. Then, an aqueous sodium bicarbonate solution and an equal volume of water were added, the layers were separated, and the aqueous layer was extracted twice using dichloromethane. The collected organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. Tetrahydrofuran was added, the mixture was filtered, and purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 50°C). The fractions containing the title compound were concentrated under reduced pressure to obtain 75%.0 mg of the compound. ESI-MS: 591 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.37 minutes (Method A) Step b: tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(7-chloro-1-methyl-1H-indazol-3-yl)propan-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.51b) To a mixture of tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(7-chloro-1H-indazol-3-yl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.50a, 75.0 mg, 0.11 mmol), 2 mL N,N-dimethylformamide, and cesium carbonate (42.4 mg, 0.13 mmol), methyl iodide (2 M in tert-butyl methyl ether, 59.7 µL, 0.12 mmol) was added. The resulting mixture was stirred at room temperature overnight. Water and brine were added, and the mixture was extracted using ethyl acetate. The organic layer is washed three times with water and brine, dried over sodium sulfate, filtered and concentrated under low pressure to obtain 62.0 mg of the title compound which is used in the next step without further purification. ESI-MS: 605 [M−Boc+H]+ Retention time (High-performance liquid chromatography): 1.32 minutes (Method E) Step c: (2S,5R)-N-(2-(7-chloro-1-methyl-1H-indazol-3-yl)propane-2-yl)-5-(hydroxymethyl)morpholene-2-carboxymide hydrochloride (Example 51) To a mixture of tert-butyl(2S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-((2-(7-chloro-1-methyl-1H-indazol-3-yl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.51b, as obtained from the step above) and 2 mL of methanol hydrochloride (4 M in dioxane, 0.40 mL, 1.60 mmol) was added, and the mixture was stirred overnight at 50 °C and at room temperature for four days. Afterward, the solvents were removed under reduced pressure. Tetrahydrofuran, methanol, and triethylamine were added, and the residue was purified by preparative RP-HPLC (Waters XBridge C18, acetonitrile / water / ammonia, 60°C). The product-containing fractions were concentrated under reduced pressure. Dioxane and hydrochloric acid (4 M in dioxane, 0.05 mL, 0.20 mmol) were added to the residue, and the mixture was lyophilized to obtain 29.1 mg of the title compound. ESI-MS: 367 [M+H]+ Retention time (High-performance liquid chromatography): 0.70 minutes (Method A) 1H-NMR (400 MHz, DMSO-d6), δ (ppm) = 1.71 (s, 3 H), 1.72 (s, 3 H), 2.92 – 3.02 (m, 1 H), 3.03 – 3.09 (m, 1 H), 3.54 – 3.62 (m, 3 H), 3.83 – 3.92 (m, 2 H), 4.26 (s, 3 H), 4.26 – 4.32 (m, 1 H), 5.37 (br s, 1 H), 6.99 – 7.08 (m, 1 H), 7.42 (dd, J=7.4 Hz, 0.7 Hz, 1 H), 7.83 (d, J=8.2 Hz, 0.7 Hz, 1 H), 8.49 (s, 1 H), 8.64 (br s, 1 H), 9.70 (br s, 1 H). Double divisor ratio: ≥ 95:5 Example 52: (2S, 5 (2S,5R)-N-(2-(7-fluoro-1-methyl-1H-indazol-3-yl)propan-2-yl)-5-(hydroxymethyl)morpholine-2-carboxamide hydrochloride To a mixture of tert-butyl(2S,5S)-5-(((tert-butyldiphenyl oxy)methyl)-2-((2-(7-fluoro-1H-indazol-3-yl)propane-2-yl)carbamoyl)morpholine-4-carboxylate (Int-10.50a, 85 mg, 0.126 mmol), 2 mL of methanolic hydrochloride (4 M in dioxane, 0.32 mL, 1.26 mmol) was added, and the mixture was stirred overnight at 45 °C. Hydrochloric acid (4 M in dioxane, 0.30 mL, 1.20 mmol) was then added again, and the mixture was stirred overnight at 45 °C. The solvents were then removed under reduced pressure. Tetrahydrofuran, methanol, and triethylamine were added, and the residue was pu...
Claims
1. A compound with the formula (I)(I) where R5 is methyl; R6 is -C1-4-alkyl or -C3-6-cycloalkyl; or R5 and R6 together with the carbon atom to which they are bonded form C3-6-cycloalkyl; A is a phenyl ring, which can be substituted using 1 to 3 substitution groups, chosen independently from a group consisting of -halogen, -CF3, -C1-4-alkyl, -C3-6-cycloalkyl, -C2-4-alkynyl and -O-C1-4-alkyl; Or A is a heteroaryl with 6–10 atoms, where it can be a substitution using 1 to 3 substitution groups, independently chosen from a group consisting of -halogen, -CF3, -C1-4-alkyl, and -O-C1-4-alkyl; or a salt thereof.
2. A compound according to the protection element 1, where R5 and R6 are methyl; or a salt thereof. 3.A compound according to protection element 1, where A is a phenyl ring, which can be substituted using 1 to 3 substitution groups, independently chosen from a group consisting of -halogen, -CF3, -C1-4-alkyl, -C3-6-cycloalkyl, -C2-4-alkynyl, and -O-C1-4-alkyl; where R5 is methyl; where R6 is methyl; or a salt thereof.
4. A compound according to protection element 1, where the compound has the formula (Ia)(Ia), where R1 is chosen from a group consisting of -H, -halogen, -CF3, -C1-4-alkyl, -C3-6-cycloalkyl, and -O-C1-4-alkyl; R2 is chosen from a group consisting of -H, -halogen, and -C1-4-alkyl; R3 is chosen from a group consisting of -H, -halogen, -C1-4-alkyl, -C3-6-cycloalkyl, and -C2-4-alkynyl; R4 is chosen from a group consisting of -H, -halogen, and -C1-4-alkyl; R5 is methyl; R6 is methyl; or a salt thereof. 5.A compound according to protection element 1, according to formula (I)(I), where A is chosen from a set consisting of , , , and where it can have substitutions using 1 to 3 substitution groups, chosen independently from a set consisting of -halogen, -CF3, -C1-4-alkyl, and -O-C1-4-alkyl; where R5 is methyl; where R6 is methyl; or a salt thereof.
6. A compound according to protection element 1, where A is chosen from a set consisting of , , , and; where R1 is chosen from a set consisting of -H, -halogen, -CF3, -C1-4-alkyl, and -O-C1-4-alkyl; R2, R3, R4, R7, R8, and R9 are independently selected from a group consisting of -H, -halogen, and -C1-4-alkyl; R5 is methyl; R6 is methyl; R10 is -H or -C1-4-alkyl; or a salt thereof.
7. A compound according to protection element 1, where the compound is selected from a group consisting of, ...
10. The compound, according to protection factor 1, in its free salt form.
11. The compound, according to protection factor 1, or a salt thereof that is pharmacologically acceptable for use as a medicine.
12. The compound, according to protection factor 1, or a salt thereof that is pharmacologically acceptable for use in the treatment of a disease or condition associated with or modulated by the activity of somatostatin receptor 4 (SSTR4).
13. The compound, according to protection factor 1, or a salt thereof that is pharmacologically acceptable for use in the treatment of a selected disease, disorder, or condition from the group consisting of pain or pain-related conditions, inflammation-related conditions, neurological conditions, and psychiatric conditions, such as psychosis spectrum disorders, schizophrenia (positive and negative symptoms and cognitive impairment associated with schizophrenia), psychosis, learning and memory impairment, and dementia, such as Alzheimer's disease.The compound, according to protection factor 1 or a pharmaceutically acceptable salt thereof, is indicated for use in the treatment of a selected disease or condition from the group comprising acute pain, visceral pain, neuropathic pain, inflammatory pain, receptor-mediated pain, inflammatory changes associated with diseases of the airways and lungs, mild cognitive impairment, cognitive impairment associated with psychosis spectrum disorders, cognitive impairment associated with neurodegenerative disorders, cognitive impairment associated with seizure disorders and epilepsy, and the treatment of positive symptoms in psychiatric disorders.
14. A pharmaceutical formulation containing the compound, according to protection factor 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 15.A medicinal combination that includes, in addition to a compound according to protection factor 1, or a pharmaceutically acceptable salt thereof as additional active ingredients, a selected substance from the group consisting of anti-inflammatory drugs, cholinergic therapies, beta-amyloid-targeted therapies, tautau-related therapy, neuroprotective therapies, analgesic drugs, anti-migraine drugs, antidepressants, mood stabilizers, typical and atypical antipsychotics, anxiolytics, antiepileptic drugs, sleeping agents, cognitive enhancers, stimulants, additional psychoactive drugs, chemotherapeutic drugs, and selections of Treatment used for metabolic disorders.
